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Introduction
Introduction
Post-translational modification of proteins, such 
as phosphorylation, methylation, acetylation 
or ubiquitination, plays a critical role in many 
cellular processes due to its ability to rapidly and 
reversibly change the behavior of the modified 
protein. Ubiquitination is unusual in that the 
modifier is not a small functional group but a 76 
amino acid polypeptide. Ubiquitin modification 
of target proteins has many functions, it can 
target for degradation by chain formation linked 
through lysine 4, but it also plays a role in DNA 
repair, signal transduction, endocytosis and other 
processes by modifying targets with a single 
ubiquitin or differentially linked chains (reviewed 
in 1-3).
Besides ubiquitin there are a number of ubiquitin 
like proteins (UBLs) that resemble ubiquitin both 
in fold (Figure 1b) and modification mechanism 
(Figure 2) but have distinct functional roles 
(reviewed in 4-7). SUMO is one of these UBLs and, 
although it only shares 18% sequence identity 
with ubiquitin, the three dimensional structure 
is conserved between the two (Figure 1). The 
biological functions of SUMO modification are 
highly diverse as it has been shown to be involved 
in nuclear transport, DNA repair, regulation of 
transcription, signal transduction and many other 
processes9-15.
There are four SUMO isoforms in mammalian 
cells that share between 40 and 97% sequence 
identity (Figure 1a) and only partially overlap 
in target specificity. SUMO 2 and 3 are almost 
identical (97%) and differ in cellular localization 
and distribution from SUMO1. Whereas most 
SUMO1 is conjugated to targets there is a large 
pool of free SUMO2 and SUMO3 in cells that gets 
conjugated upon various stress signals16-18. Both 
SUMO1 and SUMO2/3 form chains on targets in 
vitro but so far only SUMO 2/3 chains have been 
found in vivo19,20. 
Figure 1: SUMO and ubiquitin are 
structurally similar. (A) Sequence 
alignment of the four SUMO isoforms 
and ubiquitin with secondary structure 
elements of SUMO1 on top. Identical 
residues are shaded dark grey, 
conserved residues are shaded light 
grey. (B) Cartoon representation of the 
three-dimensional structures of SUMO1 
and ubiquitin. C-terminus (C) and N-
terminus (N) are indicated.
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SUMO1 MSDQEAKPSTEDLGDKKEG-EYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTPKELG 81
SUMO2 MAD-E-KPK-E--GVKTENNDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLE 77
SUMO3 MSE-E-KPK-E--GVKTEN-DHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLE 76
SUMO4 MAN-E-KPT-EE--VKTENNNHINLKVAGQDGSVVQFKIKRQTPLSKLMKAYCEPRGLSMKQIRFRFGGQPISGTDKPAQLE 77
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SUMO and disease
Since the SUMO pathway is involved in many 
cellular processes it is not surprising that it has 
been implicated in diseases as well. A role for 
SUMO in cancer, neurodegenerative diseases and 
viral infection is suggested although the exact 
functional mechanisms are not known.
Cancer
A growing number of oncogenes and tumor 
suppressor genes, including PML, MDM-2, c-Myb, 
c-Jun, p53 and Rb are targets for sumoylation21-27. 
Moreover, SUMO plays a role in many processes 
involved in cancer like DNA replication and repair, 
NFκB and MAP kinase signaling, and cell cycle 
control. One would expect that the regulatory 
role of SUMO modification of these proteins can 
influence the role of these proteins in cancer. The 
fact that the SUMO machinery may be involved 
in cancer is supported by the fact that both the 
SUMO E3 ligase Pias3 and the SUMO-conjugating 
enzyme Ubc9 are upregulated in a number of 
human malignancies2-30. Recently, a link between 
SUMO and cancer metastasis was found when it 
was shown that the expression of the metastasis 
repressor gene KAI1 was affected by sumoylation. 
The β-catenin-reptin chromatin remodeling 
complex is responsible for this downregulation 
of the KAI1 promoter and this is mediated by 
reptin sumoylation leading to enhanced HDAC1 
interaction31,32.
Neurodegenerative diseases
Several studies have implicated sumoylation in 
the pathology of neurodegenerative diseases 
like Parkinson’s, Alzheimer and Huntington’s. 
These disorders all involve the accumulation 
or aggregation of abnormal proteins and in 
many cases show a malfunction in proteasomal 
degradation. Huntington’s disease is characterized 
by the accumulation of a pathogenic mutated 
form of the Huntingtin protein (Htt) and appears 
to have increased toxicity when sumoylated33. Tau 
and α-synuclein are other examples of proteins 
that aggregate in neurodegenerative diseases 
and both are SUMO modified in vitro suggesting 
a role for SUMO in regulating these proteins34. 
The Parkin gene encodes for a ubiquitin E3 ligase 
and is mutated in a juvenile form of Parkinson’s. 
There are two aspects that link this protein to the 
SUMO pathway, the first is that Parkin targets the 
SUMO E3 RanBP2 for proteasomal degradation, 
and the second is that Parkin interacts with SUMO 
and this affects its intracellular localization and 
ligase activity. The last link between SUMO an 
neurodegenerative diseases came from a study 
on amyloid β (Aβ), the peptide that causes 
neurotoxicity in Alzheimer’s disease. Here it was 
shown that overexpression of SUMO3 dramatically 
reduces Aβ production while overexpression of a 
SUMO3 mutant that is not able to form chains 
increased Aβ production. Although this study 
does not show that Aβ or its precursor amyloid 
precursor protein (APP) is modified with SUMO3, 
it does indicate a role for SUMO3 chain formation 
in Aβ production in Alzheimer’s disease35.
Viral infection
Several viral proteins can either be covalently 
modified by SUMO themselves, or, can alter 
the sumoylation status of host proteins36. The 
first is true for the bovine papillomavirus E1 
protein. Upon SUMO modification this protein is 
transported to the nucleus where it plays a role 
in viral replication. Mutation of the sumoylation 
site prevents nuclear targeting and causes a loss 
of replication capacity of the virus 37. Altered 
host cell sumoylation is caused by the Gam1 
protein from an avian adenovirus, this protein 
inactivates the human SUMO E1 activating 
enzyme causing an overall inhibition of protein 
sumoylation3. Also, it was shown that both the 
herpes simplex virus (HSV) ICP0 protein and the 
cytomegalovirus (CMV) IE1 protein can abrogate 
the SUMO modification of PML and Sp100 causing 
a disruption of nuclear body formation 39.
The mechanism of ubiquitin(-like) 
modification
In sumoylation as well as ubiquitination, the C-
terminus of the modifier is ligated to a lysine on 
the target protein using a highly regulated three 
step enzymatic cascade (Figure 2). The enzymes 
involved are in many cases related but not 
identical between ubiquitination and ubiquitin-
like modification. The first, ATP-dependent step, 
is catalyzed by an E1 or activating enzyme, 
and involves the formation of an intermediate 
adenylate followed by the formation of a thioester 
bond between the C-terminus of the modifier and 
the catalytic cysteine of the E1 enzyme. Then, the 
modifier is transferred to an E2 or conjugating 
enzyme again forming a thioester bond with an 
active cysteine of the enzyme. In the last step, 
an E3 enzyme promotes the ligation of the 
modifier to an ε-amino group of a substrate lysine 
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residue through an isopeptide bond. The removal 
of the modifier from a substrate is a single step 
reaction catalyzed by specialized proteases called 
deconjugating enzymes.
In mammalian cells there is only one E1 enzyme 
for ubiquitin conjugation, Uba1, and also a single 
E1 for SUMO, the heterodimer Aos1-Uba240,41. In 
contrast to ubiquitination where there are roughly 
30 E2 enzymes identified42, sumoylation uses a 
single E2 enzyme, Ubc9, which is essential in both 
yeast and mammals43-46. Ubiquitin modification 
requires an E3 enzyme belonging to one of 
three different classes, the HECT, RING or U-
box proteins. SUMO modification can take place 
without the help of an E3 since Ubc9 interacts 
directly with many targets (see below). However, 
there are factors that enhance SUMO modification, 
three different types of these SUMO E3 ligases 
have been identified: the Siz/Pias SP-RING family 
47-51, the nucleoporin RanBP2/Nup3552,53 and Pc2 
(polycomb group protein 2)54,55. SP-RING SUMO 
ligases resemble the RING ubiquitin ligases and 
are thought to function similarly by bringing the 
E2 and target together. The RanBP2 E3 ligase has 
no similarity to any other E3 ligase, it does not 
directly interact with the target but functions by 
positioning the Ubc9-SUMO thioester for efficient 
SUMO transfer to the target53,56. The E3 function 
of Pc2 involves two domains of the protein, one 
that directly recruits both Ubc9 and the target, 
and one that comprises the E3 ligase activity55. 
Deconjugating enzymes perform two functions, 
they process the nascent modifier to its mature 
form, and they cleave the isopeptide bond 
between modifier and target. A large number 
of deubiquitinating enzymes (DUBs) have been 
identified belonging to two different classes, 
the ubiquitin C-terminal hydrolases (UCH) 
or the ubiquitin-specific proteases (USP)57,5. 
In mammalian cells the presence of 6 SUMO 
deconjugating enzymes or SUMO isopeptidases 
has been predicted, of these, 4 have been shown 
to possess SUMO isopeptidase activity, Senp1, 2, 
3 and 6. SUMO deconjugating enzymes are highly 
target specific due to their catalytic properties as 
well as their variable physical location59,60.
SUMO consensus sequence
The SUMO E2 enzyme, Ubc9, differs from ubiquitin 
E2 conjugating enzymes in that it directly 
interacts with a specific site on many targets. This 
site consists of a hydrophobic residue, followed by 
the SUMO acceptor lysine, any amino acid, and a 
glutamic or aspartic acid, creating the traditional 
consensus site for SUMO modification: ΨKxE/
D61. The consensus site is usually found on an 
unstructured region of a protein and the details of 
the interaction are shown in the crystal structure 
of RanGAP1 in complex with Ubc962. The presence 
of a consensus site is not a strict requirement 
for sumoylation of a target since several 
proteins have been found to be modified on non-
consensus sites10,63. Possibly, there are additional 
consensus sequences that are not identified yet. 
Ubiquitin and SUMO binding motifs
Although many SUMO targets have been identified, 
the direct consequence of both ubiquitination and 
sumoylation is in many cases still not precisely 
known. One popular view is that ubiquitination 
causes a signal by changing the interaction surface 
of a protein. This newly created surface can in 
its turn be recognized by a downstream receptor 
protein carrying a ubiquitin binding domain (UBD) 
probably combined with a target-specific binding 
domain. Many UBDs have been identified recently, 
like the UIM, UBA, CUE, GAT and NZF domains, 
and each of them seems to have a preference 
for either mono-ubiquitin or poly-ubiquitin chains 
linked through specific lysines64,65. One obvious 
example of receptor proteins carrying a UBD are 
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Figure 2: Schematic view of the multistep process of SUMO modification showing the transfer of SUMO (S) from the 
E1 to the E2, and with the help of an E3 to the target. The chemistry of the created bonds is shown in close-ups.
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the proteasomal receptors that are responsible 
for targeting of poly-ubiquitinated proteins to the 
destruction machinery66-68.
In analogy with ubiquitin, also for SUMO an 
interaction motif (SIM) has been found. Several 
groups have identified a similar sequence 69-72 and 
the consensus appears to be a hydrophobic stretch 
(V/I)(V/I)X(V/I/L) flanked by acidic residues or 
possible phosphorylation sites. Structural studies 
of SUMO bound to a SIM have revealed that the 
hydrophobic residues form a beta strand that is 
added to SUMOs beta-sheet56,72. Interestingly, 
this binding motif was identified in SUMO targets 
but also in enzymes of the SUMO cascade like the 
SUMO E1 and several SUMO E3s 56,70,71,73.
Structural information in the SUMO pathway
Structural and biochemical studies in the SUMO 
pathway have revealed many aspects of the 
mechanism of SUMO modification. The structure of 
the SUMO E1 heterodimer Aos1-Uba2 in complex 
with SUMO and ATP shows that the enzyme needs 
to undergo multiple conformational changes 
to facilitate the three phases of its mission; 
adenylating, thioester formation and thioester 
transfer to the E274. The ubiquitin-like domain (Ubl) 
of the E1 plays an important role in the recruitment 
of the E2 as is also shown for the E1 enzyme of 
another ubiquitin like molecule, Nedd875. The 
crystal structure of the SUMO E2, Ubc9 is very 
similar to ubiquitin E2s showing the characteristic 
150 amino acid E2 α/β fold76,77. The specificity of 
Ubc9 for SUMO instead of ubiquitin seems to be 
predominantly caused by the discrimination in E1 
interaction due to a different surface charge76. 
Another important piece of structural information 
came with the Ubc9-RanGAP1 structure showing 
how Ubc9 recognizes a target by interacting with 
the ΨKxE/D consensus site sequence located on a 
loop-region in RanGAP162. This structure was the 
basis for the structure determination of a larger 
complex comprising SUMO modified RanGAP1, 
the catalytic fragment of the RanBP2 E3 ligase 
and Ubc956. This structure, together with the 
biochemical work that is presented in chapter 2 
of this thesis, has shown how the SUMO E3 ligase 
RanBP2 most probably works, by positioning 
the SUMO E2-thioester in an optimal orientation 
to enhance conjugation53,56. Even though this 
structure has provided many pieces of valuable 
information, it does not show a true E2-E3-SUMO-
target intermediate complex since RanGAP1 is 
already SUMO modified and it is not a target for 
the E3 RanBP2. A structure of a bonafide RanBP2 
substrate in complex with the Ubc9~SUMO 
thioester intermediate and RanBP2 would be 
needed to fully confirm this mechanism.
The structures of several SUMO modified targets 
have shown that there is a large variation in the 
degree of interaction between the target and the 
modifier. NMR studies on both SUMO modified 
RanGAP1 and Ets-1 have shown that, besides 
the covalent bond that links the modifier to the 
substrate, there is virtually no interaction between 
the two7,79. However, in case of SUMO-modified 
TDG the target and modifier interact extensively 
and this is, to a lesser extent, also true for both 
E2-25K and Ubc9 (0 and chapter 3 and 4 of this 
thesis).
Consequence of SUMO modification
While hundreds of SUMO targets have been 
identified so far, only for a limited number the 
biochemical consequence of modification has 
been studied in detail. This is the case for mono-
sumoylation, for poly-sumoylation even less is 
known about the functional consequence. In 
chapter 5 we describe details on the regulation of 
SUMO chain formation.  
While ubiquitination mostly functions as an adapter 
creating a new binding interface, sumoylation 
seems to have more diverse consequences. These 
can be roughly separated in four categories: SUMO 
can affect enzymatic activity, it can change protein 
localization, it can modulate the interaction with 
other proteins, or it can stabilize proteins. Only 
few targets for each category have been studied 
in detail and these are discussed here.
Affecting enzymatic activity or protein function
Thymine DNA glycosylase (TDG) is an enzyme that 
recognizes irregular base pairs between a guanine 
and a uracil or thymine (G•U or G•T), excises the 
mismatched base and creates an abasic site that 
can then be processed by downstream enzymes. 
TDG has been shown to be a target for SUMO 
modification in vivo and also interacts with SUMO 
non-covalently through a sequence resembling 
a SIM1. SUMO modification is required for the 
release of TDG from the DNA after excision of the 
mismatched base and thus enhances the turnover 
rate of the enzyme1,2. The crystal structure of 
SUMO modified TDG confirmed that sumoylation 
causes a conformational change in the protein 
that interferes with DNA binding0. For the release 
of DNA both non-covalent and covalent interaction 
12
Chapter 1
with SUMO are necessary. Here, the function of 
sumoylation is to release the abasic site in order 
for base excision repair to proceed.
E2-25K is a ubiquitin conjugating enzyme that 
can be regulated by SUMO modification. As is 
described in chapter 3, SUMO does not influence 
the active site of E2-25K directly but it prevents 
interaction with the ubiquitin activating enzyme 
thereby inhibiting thioester formation of E2-
25K63. Another, very abundantly, modified protein 
is the plasma membrane potassium leak channel 
K2P13. Despite expression of this protein in heart, 
brain and kidney, it had never been shown to be 
active as a K+ channel, until it was found that it is 
fully sumoylated. Mutation of the target lysine, or 
overexpression of a SUMO-deconjugating enzyme, 
turned this protein into a functional pH-sensitive 
potassium channel. How SUMO alters the physical 
properties of this protein is not clear yet.
Localization
The Ran-GTPase activating protein RanGAP1 is 
the most abundantly SUMO modified protein in 
mammalian cells and, upon sumoylation, binds 
to RanBP2, a protein that forms the cytoplasmic 
filaments of nuclear pore complexes (NPC) and 
has SUMO E3 ligase activity12,4,5. The fact that the 
SUMO isopeptidase Senp2 localizes to the nuclear 
site of the NPC, suggests a role for sumoylation 
in nuclear–cytoplasmic transport which is further 
supported by the fact that several SUMO targets 
depend on a nuclear localization signal to get 
sumoylated 12,86. During mitosis, when nuclear 
pore complexes disassemble, sumoylated 
RanGAP1 remains associated with RanBP2 and 
enriches at kinetochores and mitotic spindles 
where it is responsible for stable microtubule-
kinetochore association7,.
The PML protein was first identified as part of 
the oncogenic PML-RARalpha chimera in acute 
promyelocytic leukemia (APL). PML is the main 
component of nuclear structures called PML 
nuclear bodies (NBs), which seem to function 
in regulation of transcription, genome stability, 
response to viral infection, apoptosis, and tumor 
suppression. PML itself is a target for sumoylation 
and its SUMO modification is a prerequisite for 
its localization to the NBs where it subsequently 
recruits other sumoylated and non-sumoylated 
proteins like Sp100, Daxx, p53, BLM and 
others25,9,90. Recently it was shown that PML 
contains a SUMO interaction motif and a model 
was suggested where sumoylated PML creates a 
network of noncovalent and covalent interactions 
between SUMOs and SIMs on PML but also on 
other proteins in the NBs91,92. PML seems to play 
an active role in the formation of this network and 
its recently confirmed SUMO E3 ligase activity 
may play a crucial role in this process93.
Modulating binding interfaces
Proliferating cell nuclear antigen (PCNA) is an 
essential processivity factor that loads DNA 
polymerases onto the DNA and associates with 
many other proteins involved in replication-
associated events. PCNA can be modified with 
ubiquitin and, at least in yeast, also with SUMO, 
and this leads to the recruitment of specific factors. 
When the DNA is damaged, PCNA ubiquitination 
facilitates the bypass of replication-blocking 
lesions either in a mutagenic way by promoting 
the association of error-prone polymerases, or in 
an error-free way by using the undamaged sister 
chromatid10,14. PCNA can be modified with SUMO 
independent of DNA damage and this recruits the 
Srs2 helicase in order to inhibit recombination. 
Here, SUMO modification causes a direct 
interaction between SUMO modified PCNA and 
Srs2 to prevent unwanted recombination during 
replication 94,95.
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Figure 2: Sumoylation of a target protein (T) can have several consequences. (A) It can affect the activity of the 
protein, (B) it can change the location of a protein, (C) it can modulate the interaction with other proteins, or (D) it can 
prevent ubiquitination of a protein.
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The SUMO-conjugating enzyme, Ubc9, can also 
be sumoylated and functions as a modulator of 
target selection as is described in chapter 4 of this 
thesis. While modification of some targets is not 
affected by Ubc9 sumoylation, others are strongly 
impaired or enhanced in modification. The 
enhancement of Sp100 sumoylation by SUMO-
modified Ubc9 is due to enhanced interaction 
mediated by a SUMO interaction motif present 
in Sp100. Therefore, SUMO modification of the 
target Ubc9 likely serves to recruit a subclass of 
SUMO targets.
Several transcription factors like p73α, p53, LEF1, 
c-Jun and c-Myb, p300, Elk-1 are targets for SUMO 
modification9,11,21,50,70. In most cases sumoylation 
has a repressive effect on transcription but there 
are also cases where the SUMO can stimulate 
gene expression9,96-98. In many of these cases 
the functional role of sumoylation is not known. 
However, there are a few examples where 
SUMO modification promotes the interaction 
with co-repressors like HDACs. Sumoylation 
of the transcription factor Elk-1 stimulates the 
association with HDAC2 thereby repressing 
expression from an Elk-1 regulated promoter99. 
Also, SUMO modification of the repression domain 
of the co-activator p300 was shown to promote 
binding to HDAC69 and mutation of the SUMO-
site resulted in an increased p300-mediated 
transcriptional activity. However, the role of 
HDACs in SUMO-mediated repression seems to be 
more complicated since HDACs can both regulate 
sumoylation of targets and are also SUMO targets 
themselves100,101. Moreover, it is likely that 
there are also other proteins that contribute to 
SUMO-dependent inhibition of transcription and 
regulation.
Stabilization
Protein stabilization was one of the first functions 
found for SUMO modification. It was based on 
the fact that in some cases SUMO and ubiquitin 
compete for the same lysine and thus, SUMO can 
prevent the proteasomal degradation of targets. 
This mechanism has be proposed for several 
targets but in most of these cases it is not as 
simple as pure competition102. The best known 
example is IκBα, the inhibitory protein that 
retains the transcriptional activator NF-κB in the 
cytoplasm. Even though in this case ubiquitination 
and sumoylation take place on the same residue, 
several other regulatory events are needed for 
either modification and only a very small fraction 
of IκBα seems to be modified in the cell. Another 
example is MDM2, the ubiquitin E3 ligase for 
p53. This protein can be both ubiquitinated or 
sumoylated but it is not clear whether this takes 
place on the same residue. However, sumoylation 
of MDM2 seems to inhibit its self-ubiquitination 
and prevents degradation103.
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Post-translational modification with the ubiquitin-related protein SUMO1 requires the E1 
enzyme Aos1-Uba2 and the E2 enzyme Ubc9. Distinct E3 ligases strongly enhance modification 
of specific targets. The SUMO E3 ligase RanBP2 (also known as Nup358) has no obvious 
similarity to RING- or HECT-type enzymes. Here we show that RanBP2’s 30-kD catalytic 
fragment is a largely unstructured protein. Despite two distinct but partially overlapping 79-
residue catalytic domains, one of which is sufficient for maximal activity, RanBP2 binds to 
Ubc9 in a 1:1 stoichiometry. Identification of nine RanBP2 and three Ubc9 side chains that are 
important for RanBP2-dependent SUMOylation indicates largely hydrophobic interactions. 
These properties distinguish RanBP2 from all other known E3 ligases, and we speculate that 
RanBP2 exerts its catalytic effect by altering Ubc9’s properties rather than by mediating 
APC (Anaphase promoting complex) or SCF (Skp 
cullin F-box protein)12,14,15. 
In principle, modification with SUMO can be 
carried out just by Aos1-Uba2 and Ubc9. This 
is because target recognition is accomplished 
(at least in part) by Ubc9, which can bind to 
the SUMO acceptor site (ΨKXE/D; Ψ is a bulky 
hydrophobic residue and X is any residue) present 
in most known SUMO targets1,2. However, for 
most targets, transfer efficiency in the presence 
of E1 and E2 enzymes is very poor, and can be 
strongly stimulated through SUMO E3 ligases. 
The Siz/PIAS family of SUMO E3 ligases shares 
a conserved domain with similarity to ubiquitin 
RING-finger proteins. This ‘SP-RING’ (Siz/PIAS-
RING) is required for their function as SUMO 
E3 ligases (reviewed in ref. 16). The polycomb 
protein Pc2 has recently been described as an E3 
ligase for the transcriptional corepressors CtBP1 
and CtBP217, but its mode of action is currently 
unclear. Finally, we have shown previously 
that the nuclear pore complex protein RanBP2 
(Nup35) catalytically enhances SUMOylation 
of the nuclear body component Sp100 and the 
histone deacetylase HDAC4, but not of the 
tumor suppressor p53 in vitro1,19. RanBP2 is 
a multidomain protein with interaction sites for 
proteins including nuclear transport receptors, 
target interactions. 
Introduction
Post-translational modification with ubiquitin-
related proteins of the SUMO family is an important 
mechanism for regulating protein function. The 
consequences of SUMOylation range from changes 
in protein interactions or activity to changes in 
subcellular localization or stability1–5. The basic 
principle of conjugation resembles ubiquitination6–
9. Activation of the SUMO C terminus requires ATP 
and leads to thioester bond formation with the 
E1 activating enzyme heterodimer Aos1-Uba2. 
In consecutive steps SUMO is transferred to the 
single E2-conjugating enzyme Ubc9, and then 
forms an isopeptide bond with the ε-amino group 
of a lysine in the acceptor protein. 
Ubiquitination always depends on a third class of 
enzymes, the E3 ligases. These proteins recognize 
both a specific E2 enzyme and the acceptor 
protein. Two different classes of ubiquitin E3 
ligases can be distinguished: HECT E3s such as 
E6-AP form an ubiquitin thioester intermediate 
before transferring ubiquitin to the target, while 
RING-finger E3s and the structurally related U-
box proteins serve as adaptors between the E2-
Ubiquitin thioester and the target7,10–13. RING-finger 
E3s exist in two flavors, single-subunit proteins 
such as Mdm2, and multi-subunit complexes like 
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Escherichia coli, enriched on GST-sepharose, and 
cleaved on the column by thrombin. This resulted 
in near-homogenous fragments (Fig. 1b). 
AutoSUMOylation  
We first tested the deletion fragments for 
automodification, as we had previously observed 
extensive SUMO chain formation on BP2∆FG at high 
concentrations1.  We incubated 1.5 µM fragments 
with recombinant Aos1-Uba2 and Ubc9, SUMO1 
and ATP (Fig. 1c). Efficient chain formation was 
observed only for the longest fragment, BP2∆FG 
. IR1+2 gives rise to several discrete modified 
species, consistent with the addition of up to four 
SUMO1 moieties per fragment. A similar pattern, 
albeit at much reduced levels, was also observed 
with IR1+M. Very faint modification of IR1 with 
several SUMO1 residues and a very low level of 
a monoSUMOylated M-L species were detectable 
only at very long exposure (data not shown). 
Consistent with extensive chain forming activity 
only for the largest fragment, a lysine residue 
in the N-terminal flanking region (Lys2592) was 
identified by mass spectrometry as the major 
SUMO acceptor site (P.K. and T.K.S., unpublished 
data). 
The IR1+M fragment has full activity 
The catalytic activity of the RanBP2 fragments 
was next tested in Sp100 modification. In a pilot 
experiment, equal amounts (20 ng) of BP2∆FG, 
the GTPase Ran, Ubc9, and SUMOylated GTPase-
activating protein RanGAP120–24. Its E3 activity 
resides in a 33-kDa fragment without substantial 
homology to any other protein1. This suggested 
that the mechanisms by which E3 ligases function 
are more diverse than previously anticipated. 
To address the question of how RanBP2 functions 
in SUMOylation, we set out to further dissect its 
catalytic domain. The data presented here are 
consistent with the model that RanBP2 enhances 
SUMOylation at least in part by altering Ubc9’s 
catalytic properties, rather than as a HECT type 
enzyme or a simple adaptor. RanBP2 is thus the 
first clear example for an E3 ligase that is neither 
a HECT enzyme nor a RING-finger (related) 
protein. 
Results
We previously mapped the SUMO E3 activity of 
the 358-kDa RanBP2 to a 33-kDa, 286-residue 
fragment termed BP2∆FG1. This fragment 
contains two ~50-residue internal repeats (IR1 
and IR2) separated by a 25-residue middle 
domain (M)20,21,25. To understand the catalytic 
mechanism of BP2∆FG, we wanted to map its 
Ubc9-binding site, identify a minimal catalytic 
domain, and test for automodification. We 
generated deletion fragments (Fig. 1a), each of 
which was expressed as a GST-fusion protein in 
Figure 1 Auto-modification and 
E3 ligase activity of RanBP2 
deletion fragments. (a) Schematic 
representation of selected RanBP2 
fragments. BP2∆FG, the SUMO E3 
ligase domain described previously, 
consists of two internal repeats (IR1 
and IR2) separated by the 25-residue 
M domain, and N- and C-terminal 
flanking regions. BP2∆FG: residues 
2553–2838; IR1+2: residues 2633–
2761; IR1+M: residues 2633– 2711; 
IR1: residues 2633–2685; M-L: 
residues 2661–2735. (b) Selected 
recombinant RanBP2 fragments 
separated on a 5–20% (w/v) SDS 
gel and stained by Coomassie blue. 
(c) AutoSUMOylation of RanBP2. 
Indicated RanBP2 fragments (1.5 µM 
each) were applied as substrates in an 
in vitro SUMOylation assay using 10 
ng Ubc9 (2 nM), 150 ng Aos1-Uba2 
(68 nM), 1.7 µg SUMO1 (7.5 µM) and 
ATP, and incubated for 30 minutes at 
30°C. Analysis was by immunoblotting 
using anti-SUMO1. (d) RanBP2 catalysis of Sp100 SUMOylation. 250 ng (196 nM) GST-Sp100 was tested for modification 
in the absence or presence of RanBP2 fragments (20 ng each; 31 nM BP2∆FG, 67 nM IR1+2, 158 nM IR1, 109 nM IR1+M, 
115 nM M-L) and 10 ng Ubc9 (28 nM), 150 ng Aos1-Uba2 (68 nM), 0.5 µg SUMO1 (2.2µM) and ATP. After incubation for 
30 minutes at 30°C samples were analyzed by immunoblotting with anti-GST. Arrowhead indicates SUMOylated form.
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IR1+2, IR1+M, IR1 and M-L were added to 
basic Sp100 SUMOylation reactions with limiting 
concentrations of Ubc9. Notably, reduction of 
the RanBP2 fragment from 286 residues to the 
79 residue IR1+M fragment did not reduce its 
catalytic activity, indicating that flanking regions 
and IR2 are dispensable for activity.  Further 
deletion of 26 residues severely impaired activity, 
but the resulting IR1 clearly had residual activity 
when compared to reactions in its absence (Fig. 
1d, lanes 7 and ). The M-L fragment, which 
contains about half of IR1 and half of the related 
IR2 fragment, and is thus comparable in length 
and amino acid composition to the highly active 
IR1+M fragment, was completely inactive. A 29-
residue fragment containing just the M domain 
was also inactive (see below). Taken together, 
these findings suggest that IR1+M represents a 
catalytic core domain.
IR1 is sufficient for Ubc9 binding
Previously, we showed that BP2∆FG coelutes with 
Ubc9 in gel filtration1, and that GST-IR1+2 binds 
to Ubc9 in pull-down experiments25. Considering 
that IR1 had some E3 ligase activity, we wanted 
to test its ability to stably interact with Ubc9. We 
applied untagged IR1 and a preincubated mixture 
of IR1 and Ubc9 to gel filtration on Superdex 75 in 
a physiological buffer. The highly active IR1+2 and 
the inactive M-L fragments were also included in 
this analysis (Fig. 2a). As evidenced by a change 
in elution volume, Ubc9 comigrated with IR1+2, 
IR1 and the catalytically inactive M-L fragment. 
Notably, the 29-residue M domain did not stably 
interact with Ubc9 in gel filtration experiments or 
pull-down assays25 (data not shown). These data 
suggest that IR1 (or the C-terminal half of IR1 
that is also present in M-L) binds stably to Ubc9 
under conditions comparable to those used in 
enzyme assays. We next applied a more stringent 
assay to compare IR1, IR1+M and IR1+2 binding. 
This involved Ubc9 pull-down on immobilized 
GST fragments in the presence of 0.1%  (v/v) 
Triton X100 and extensive washing of the beads 
after binding (Fig. 2b). Under those conditions, 
comparable amounts of Ubc9 bound to both GST-
IR1+2 and GST-IR1+M, whereas binding to GST-
IR1 was substantially reduced. Taken together, 
these data suggest that the observed difference 
in activity for IR1 and IR1+M may be due to 
differences in Ubc9 binding. 
Figure 2 Ubc9 interacts with IR1 
and more stably with IR1+M. (a) 
Indicated proteins (50 µg each at final 
concentrations of 14 µM for Ubc9, 17 
µM for IR1+2, 40 µM for IR1, and 29 
µM of M-L) were incubated for 1 h 
on ice and applied to gel filtration on 
Superdex 75. Fractions were analyzed 
by SDS-PAGE. (b) IR1+M binds 
Ubc9 more stably than IR1. Bacterial 
lysate containing recombinant Ubc9 
was incubated with immobilized GST-
IR1+2, GST-IR1+M and GST-IR1 in 
PBS plus 0.1% (v/v) TritonX100 for 
30 min at room temperature. After 
extensive washing, bound samples 
were analyzed by 5–20% (w/v) SDS-
PAGE.
Figure 3 IR1+M catalyzes Sp100 
SUMOylation efficiently. (a) 
Concentration dependence of different 
RanBP2 fragments. GST-Sp100 (250 
ng; 196 nM) GST-Sp100 was tested for 
modification in the absence or presence 
of increasing concentrations of RanBP2 
fragments. After 30 min samples 
were analyzed by immunoblotting 
with antibodies against GST. (b) 
RanBP2 fragments (20 ng each: 31 nM 
BP2∆FG, 67 nM IR1+2, 109 nM IR1+M, 
15 nM IR1) were compared for E3 
activity on GST-Sp100 in a time course 
experiment. Thick and thin arrows 
indicate mono- and diSUMOylated 
forms of Sp100, respectively. 
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The M domain strongly enhances RanBP2’s 
activity
The experiment described above suggested 
that the M domain enhances IR1’s intrinsic 
E3 ligase activity by increasing its affinity for 
Ubc9. This model predicts that IR1 and IR1+M 
differ substantially in their dose-response 
curves. We therefore analyzed the concentration 
dependence for each of the fragments (Fig. 3a). 
As shown previously, BP2∆FG worked at very low 
concentrations (10 nM), but lost efficiency at 
high concentrations. This is probably due to its 
competing reaction, the SUMO chain formation 
(see Fig. 1c). Indeed, IR1+2, which does not form 
chains efficiently, enhanced Sp100 modification 
even at the highest concentrations used. Notably, 
there was a marked difference in dose dependence 
between IR1 and IR1+M. Whereas IR1+M had full 
activity at approximately equimolar concentration 
to Ubc9, IR1 had to be used at substantially 
higher concentration (~ 1 µM) to modify Sp100 
efficiently. All fragments stimulated Sp100 
SUMOylation in a time-dependent manner (Fig. 
3b). In this experiment, fragments were used 
at the same amounts (20 ng) to compensate 
for the different concentration requirements. 
Taken together, Ubc9-binding and activity assays 
are consistent with the interpretation that the 
catalytically inactive 25-residue M domain 
contributes to binding and serves to target the 
catalytic domain (IR1) to Ubc9.
IR1+M has reduced target specificity 
We previously showed that BP2∆FG exerts 
target specificity1. The mechanism of this 
was however unclear, as we could not detect 
BP2∆FG-target interactions.  We were therefore 
interested in testing the target specificity of the 
shorter fragments. First, we tested BP2∆FG, 
IR1+2 and IR1 for E3 activity on four different 
SUMO substrates, Sp100, HDAC4, p53 and Lef-
1. Sp100 and HDAC4 are efficiently modified in 
vitro in the presence of BP2∆FG1,19, p53 is an 
in vitro substrate for the E3 ligases PIAS1 and 
PIASxβ26,27, and Lef1 modification has been shown 
to be stimulated by PIASy2. All substrates were 
subjected to in vitro SUMOylation in the absence 
and presence of different RanBP2 fragments, or 
for comparison with PIAS1 (Fig. 4a). The inactive 
M-L fragment was included as a negative control.
Consistent with our previous findings, BP2∆FG 
stimulated SUMOylation of Sp100 strongly, in 
fact much better than did PIAS1 (compare lanes 
3 and 7). HDAC4 and Lef1 modification was 
enhanced by both PIAS1 and BP2∆FG. IR1+2 
and IR1 modified Sp100, HDAC4 and Lef1 to 
the extent expected from the analysis above 
(IR1+2 functioned with high efficiency, IR1 was 
much less active). As expected, PIAS1 strongly 
enhanced p53 SUMOylation, whereas BP2∆FG was 
inactive. In contrast, IR1+2 and especially IR1 
stimulated SUMOylation of p53 to some extent. 
This effect was even clearer when we repeated 
the experiment with IR1+M (Fig. 4b). Whereas 
IR1+2 had only a minimal effect on p53, IR1+M 
clearly enhanced p53 SUMOylation. To exclude 
that IR1+M activated modification nonspecifically, 
we also tested IR1+2 and IR1+M on an Sp100 
Figure 4 Shorter 
RanBP2 fragments 
have reduced target 
specificity. (a) 
Indicated SUMO 
substrates (250 ng 
each of 196 nM GST-
Sp100, 127 nM GST-
HDAC4, 27 nM His-
Lef1 or 166 nM GST-
p53) were tested 
for modification in 
the absence and 
presence of RanBP2 
fragments (20 ng 
each; 31 nM BP2∆FG, 
67 nM IR1+2, 
15 nM IR1, 115 
nM M-L) or PIAS1 
(1 µg). Samples 
were analyzed by 
immunoblotting with 
anti-GST or anti-
His. (b) Substrate 
specificity of IR1+M 
(40 nM) and IR1+2 
Figure 5 Cysteine 
mutants of IR1 
have residual 
ligase activity. 
(a) In vitro 
SUMOylation of 
GST-Sp100 in 
the presence of 
wild-type (WT) or 
mutant IR1 in a 
time-dependent 
manner. Analysis 
was done by 
immunoblotting 
with antibodies 
against GST. (b) 
In vitro SUMOylation of GST-Sp100 in the presence of WT 
or mutant IR1 in a concentration-dependent manner (IR1 
at 15 nM, 790 nM, or 151 nM).
(40 nM) was tested on GST-Sp100 WT (wild type), GST-
Sp100K297R and GST-p53 (250 ng each; 196 nM for 
Sp100 and 166 nM for p53).
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mutant (K297R) that lacked its major SUMOylation 
site. Notably, both fragments failed to stimulate 
modification of Sp100 K297R, demonstrating that 
their activity still depended on the presence of a 
genuine SUMO acceptor site. In conclusion, the 
79-residue IR1+M fragment retains specificity for 
genuine SUMO acceptor sites, but lacks the target 
specificity observed for larger RanBP2 fragments. 
One interpretation of these finding is that IR2 and 
flanking regions in the larger fragments restrict 
modification to specific targets.
RanBP2 is not a HECT-related E3 ligase
Our previous analysis of the BP2∆FG fragment 
included mutagenesis of two conserved cysteines1. 
The mutated fragment was catalytically active, but 
still contained 5 cysteines. Here we have mapped 
minimal ligase activity to the 52-residue fragment 
IR1, which contains a single cysteine. This allowed 
us to confirm whether RanBP2 requires a cysteine 
for its function. We generated two distinct 
mutants (C2659S and C2659A) and tested them 
in a time course for Sp100 modification (Fig. 5a). 
Both mutants were reduced in activity, but clearly 
stimulated Sp100 SUMOylation. Reduced activity 
could be partially compensated for by increased 
amounts of the mutants (Fig. 5b). Consequently, 
the single cysteine in IR1 is important but not 
absolutely essential for function, and RanBP2 is 
not a HECT-related E3 ligase.
 Mapping of Ubc9 interaction sites in IR1
To further dissect RanBP2s E3 ligase activity, 
we wanted to identify single residues required 
for function of the minimal fragment IR1. As 
IR1 is markedly similar to IR2, we focused on 
residues identical in both fragments. Of those, we 
converted 15 to alanine or serine in single point 
mutants (indicated by dots in Fig. 6a). Each 
mutant was purified as a GST-fusion protein, 
cleaved with thrombin, and tested for SUMO E3 
activity on Sp100. In the first set of experiments, 
IR1 fragments were used at 20 ng (15 nM) 
per reaction (Fig. 6b). Whereas some mutants 
including P2640A, K2645A, K2652A and P2655A 
behaved like WT IR1, others showed severely 
reduced or apparently abolished E3 activity. 
To discriminate between mutants with reduced 
activity and those that where completely inactive, 
we next assayed for concentration dependence. 
Increasing the concentration of T2656A almost 
fully restored its function, and increasing the 
concentration of the mutants P2654A, C2659S, 
D2676A and F2677A partially restored their 
function (Fig. 6c). A probable interpretation 
is that these mutants have reduced affinity for 
– or a greater koff from - Ubc9. In contrast, the 
mutants L2651A, L2653A, F2657A and F2658A 
remained catalytically inactive irrespective of the 
amount used. These mutants may be completely 
unable to interact with Ubc9, or they may bind 
Figure 6 RanBP2 mutants 
defective for activity and 
Ubc9 binding. (a) Amino 
acid comparison of IR1, 
IR2 and IR1+M. Identical 
amino acids between IR1 
and IR2 are in bold. Fifteen 
mutants in IR1 and seven in 
the IR1+M fragment were 
generated by individually 
changing  indicated amino 
acids (dots) to alanine or 
serine (Cys2659). (b) GST-
Sp100 SUMOylation in the 
absence or presence of 20 
ng (15 nM) wild-type (WT) 
or mutant IR. Samples were 
analyzed by immunoblotting 
with antibodies against GST. 
(c) Sp100 SUMOylation was 
tested in the presence of three 
different concentrations of the 
indicated IR1 mutants (at 15 
nM, 790 nM, and 1.5 µM). 
(d) His-Ubc9 immobilized on 
Ni2+ beads was incubated for 
1 h with an approximately 
three-fold molar excess of WT 
or mutant IR1, and analyzed for binding by SDS-PAGE. Empty beads served as a control. Shown are total input and total 
bound fractions. (e) Sp100 SUMOylation was tested in the presence of three different concentrations of the indicated 
IR1+M mutants (10 nM, 80 nM and 640 nM).
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Ubc9 but be unable to contribute to subsequent 
catalytic events. We tested this in pull-down 
experiments under low stringency conditions (Fig. 
6d): wild-type IR1 binding was detected, but 
none of the four mutants bound Ubc9. Notably, 
circular dichroism (CD) spectra of wild-type 
and mutant IR1 fragments are very similar and 
reflect a largely unstructured conformation (data 
not shown, but see below). We next introduced 
several mutations in the M part of the IR1+M 
fragment, and analyzed the mutants for activity 
as we did for IR1. Of seven randomly selected 
mutants in hydrophobic and hydrophilic residues, 
6 had no detectable effect. One mutant, Y2689A, 
showed a substantial reduction in activity towards 
Sp100 at low concentrations, but was functional 
at elevated levels (Fig. 6e). In summary, of 22 
single point mutants analyzed, 9 were defective 
in function. Defects in five of these mutants 
could be compensated for by using increased 
concentrations, and four hydrophobic mutants 
were inactive at all concentrations tested. These 
inactive mutants also did not bind to Ubc9 in pull-
down assays. 
Ubc9 mutants in RanBP2-dependent 
SUMOylation
Notably, most of the critical residues that we 
identified in IR1 and M are bulky hydrophobic or 
aromatic residues. This suggested that RanBP2-
Ubc9 interaction is mediated at least in part by 
hydrophobic interactions. We therefore generated 
six Ubc9 mutants in which surface-exposed 
hydrophobic residues were changed to alanine, 
and tested them for Sp100 modification in the 
presence of three different concentrations of 
IR1+M or IR1, respectively (Fig. 7a,b). Although 
all six stimulated Sp100 SUMOylation in the 
presence of IR1+M, mutants I4A, V25A and L57A 
were clearly reduced in activity. This effect was 
even more pronounced with the less efficient E3 
ligase fragment IR1 (Fig. 7a). Notably, these 
mutants behaved exactly like wild-type Ubc9 in 
E3 ligase-independent SUMOylation of Sp100 and 
RanGAP1 (data not shown). Taken together, these 
findings implicate the Ubc9 residues Ile4, Val25 
and Leu57 in RanBP2-Ubc9 interaction.
One additional mutant (N85Q) was included 
in this analysis, because Asn5 in Ubc9 and 
the corresponding asparagine in ubiquitin 
E2 conjugating enzymes has recently been 
described as essential for E2 and E2-RING E3 
mediated isopeptide bond formation. Notably, 
mutating Ubc9 asparagine 5 to glutamine did 
not impair thioester bond formation
29
 (see also 
Supplementary Fig. 1 online), and HECT E3-
dependent isopeptide bond formation was not 
affected in the ubiquitin E2 mutant UbcH5A 
N77Q
29
. From our finding that RanBP2 does not 
function as a HECT-type E3 ligase, we expected 
that it may require Asn85 for catalysis. Indeed, 
similar to the RING-type E3 ligase PIASxα in 
Figure 7 Ubc9 mutants 
defective in RanBP2-
dependent modification. 
(a) Indicated wild-
type (WT) and mutant 
Ubc9 proteins (56 
nM) were tested on 
Sp100 modification in 
the presence of three 
concentrations of IR1+M 
and IR1. For this analysis, 
mutants were generated 
in His-Ubc9, and the tag 
was removed by thrombin. 
(b) Ubc9 structure37 with 
mutations and the active 
cysteine indicated. Mutant 
residues with clear effects 
on IR1-dependent Sp100 
SUMOylation are indicated 
in black. 
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29
, the RanBP2 fragments 
IR1 or IR1+M could not overcome the defect 
conferred by the N85Q mutation in Ubc9 in Sp100 
SUMOylation (Fig. 7a  and Supplementary 
Fig. 1 online). Notably, N85Q is not completely 
inactive for isopeptide bond formation. Although 
Ubc9 N85Q was inactive in Sp100 modification 
even at high concentrations, it was still functional 
in RanGAP1 SUMOylation, albeit with reduced 
efficiency (Supplementary Fig. 1 online).
Two overlapping catalytic domains in 
BP2∆FG
Until this point we had focused on the IR1 
fragment. Its similarity with IR2 suggested that 
IR2 might be catalytically active as well. However, 
the M fragment, which strongly stimulates IR1 
activity in the context of the IR1+M fragment, 
exists only once in RanBP2, and is C-terminal of 
IR1 but N-terminal of IR2. We therefore tested 
both IR2 and the M+IR2 fragment for E3 ligase 
Figure 8 IR1+M and M+IR2 
are both highly active in 
Sp100 SUMOylation. (a) IR2 
and M+IR2 catalyze Sp100 
SUMOylation. Indicated 
fragments were tested on 
GST-Sp100 modification as 
described in Figure 3a. A longer 
exposure of IR2-dependent 
reactions is also included to 
reveal its weak but detectable 
activity. (b) IR2 and M+IR2 do 
not stably interact with Ubc9. 
His-Ubc9 immobilized on Ni2+ 
beads was incubated for 1 h 
with IR1, IR2 and M+IR2, and 
analyzed for binding by SDS-
PAGE. Empty beads served 
as a control. Shown are total 
input and total bound fractions. 
(c) M+IR2 does not co-elute 
with Ubc9: 50 µg of Ubc9 (14 
µM) and M+IR2 (4 µM) was 
incubated for 1 h on ice and 
applied to gel filtration on 
Superdex 75. Fractions were 
analyzed by SDS-PAGE.
Figure 9 The largely 
unstructured BP2∆FG 
binds Ubc9 in a 1:1 
stoichiometry. (a) Size-
exclusion chromatography 
of Ubc9, BP2∆FG and both 
proteins at a 1:1 and 2:1 
molar ratio shows that 
Ubc9 and BP2∆FG form a 
1:1 complex. Gel filtration 
traces are shown for all four 
column runs, peak fractions 
of the 2:1 analysis are 
also shown on SDS PAGE 
stained with Coomassie 
blue. (b) Experiments were 
done as in a; for Ubc9 and 
IR1+M, the 2:1 gel filtration 
trace was removed from 
the figure for clarity, but 
behaves analogously to that 
in a. (c) CD spectra of Ubc9, 
BP2∆FG and IR1+M (5.5 µM 
each) demonstrate that 
both BP2∆FG and IR1+M 
are largely unstructured 
proteins whereas Ubc9 
shows characteristic 
hallmarks of a structured protein. The average of eight scans is reported and values are given in terms of ellipticity units 
per mole of peptide residue (ΘR). (d) The measured spectrum of the IR1+M-Ubc9 complex shows very little difference 
to the theoretical noninteracting sum of the individual spectra. For formation of complex between IR1+M and Ubc9, both 
components were mixed  (5.5 µM each) and incubated for 30 min at room temperature before measurement.
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activity. Indeed, IR2 showed some activity at 
very high concentrations, albeit at much reduced 
levels compared to IR1. Notably, M+IR2 worked 
much more efficiently than IR2 alone. The 28-
residue M fragment exerted no effect by itself 
(Fig. 8a), or when added to the isolated IR1 and 
IR2 fragments (data not shown). Taken together, 
these findings demonstrate that the single M 
domain has the potential to enhance catalysis of 
both the N-terminal IR1 and the C-terminal IR2 
fragment. However, IR1 and IR2, and likewise 
IR1+M and M+IR2, clearly differed substantially 
in activity (at least a ten-fold higher concentration 
is required for comparable activity). We therefore 
also addressed whether IR2 and M+IR2 would 
interact with Ubc9 in pull-down assays. Neither 
IR2 nor M+IR2 bound to Ubc9 at detectable levels, 
even under low stringency conditions that allowed 
detection of IR1 binding (Fig. 8b). In addition, 
M+IR2 did not coelute with Ubc9 in gel filtration 
(compare Fig. 2a with Fig. 8c). It is therefore 
conceivable that their reduced activity compared 
to IR1 and IR1+M, respectively, is due at least in 
part to a reduced ability to stably interact with 
Ubc9.  It remains to be determined whether this 
is due to a lower affinity or higher koff. 
BP2∆FG binds Ubc9 with 1:1 stoichiometry
The finding that both IR1 and IR2 are active raised 
the question of whether the larger fragment, 
BP2∆FG, binds to one or more Ubc9 molecules 
simultaneously. To address this, Ubc9 and 
BP2∆FG were mixed at molar ratios of 1:1 and 
2:1, and chromatographed on an analytical gel 
filtration column (Fig. 9a). To ensure saturated 
binding, very high molar concentrations (100 µM) 
were used. As revealed by absorption spectra 
and SDS-PAGE (shown for the 2:1 sample) 
only a 1:1 complex was formed. Similar results 
were obtained with the IR1+M fragment (Fig. 
9b). During size-exclusion chromatography, 
BP2∆FG and IR1+M eluted at positions of high 
apparent molecular mass when compared with 
globular molecular mass standards (Fig. 9 and 
data not shown). To determine the absolute 
molecular mass of individual components and 
of Ubc9 complexes, we used multiangle laser 
light scattering (MALLS), a technique that is 
independent of the shape of molecules30. BP2∆FG, 
IR1+M, Ubc9, and the complexes eluted with 
molecular masses comparable to the calculated 
values for monomeric species and 1:1 complexes, 
respectively (Supplementary Fig. 2 online; for 
example, calculated and determined molecular 
masses for Ubc9-BP2∆FG were 51 and 55 kDa, 
respectively; for Ubc9-IR1+M, they were 29 and 
31 kDa, respectively).  
BP2∆FG is largely unstructured
The aberrant mobility and asymmetric peak 
of elution observed for BP2∆FG and IR1+M 
in size-exclusion chromatography indicate an 
extended conformation. Notably, addition of 
Ubc9 (19 kDa) to IR1+M (10 kDa) did not shift 
the elution volume, but improved the peak to a 
more symmetrical and compact shape (Fig. 9b). 
The elution volume of the complex conforms to 
a globular protein of 30 kDa (corresponding to 
the mass of Ubc9-IR1+M), indicating that IR1+M 
changes from an extended to a more globular 
conformation upon Ubc9 binding. To explore this 
further, we used CD spectroscopy (Fig. 9c). In 
contrast to Ubc9, whose CD spectrum shows 
the expected hallmarks of secondary structure 
elements, the spectra of BP2∆FG and IR1+M 
show very little α-helical or β-sheet content and 
are consistent with largely unstructured proteins. 
Upon incubation of IR1+M with Ubc9 for 30 min 
at room temperature, conditions that lead to 
quantitative complex formation, the CD spectrum 
of the complex was measured.  It showed very 
little difference from the theoretical noninteracting 
sum of the individual spectra (Fig. 9d). Taken 
together, our findings suggest that BP2∆FG and 
IR1+M are largely unfolded proteins that gain 
a more compact conformation upon binding to 
Ubc9. Interaction does not, however, lead to a 
substantial gain of secondary structure elements 
or to substantial changes in Ubc9 structure. 
Discussion
Modular structure of RanBP2s catalytic 
domain
Here we dissected RanBP2’s E3 ligase domain to 
gain insights into its mechanism (for a summary 
of data see Supplementary Fig. 3 online). We 
found that RanBP2 has two minimal ~50-residue 
catalytically active fragments, IR1 and IR2. They 
are 40 % identical to each other, and are highly 
conserved between different vertebrate species 
(Supplementary Fig. 4 online). To be efficient, 
they have to be used at very high concentrations 
(~1 µM). IR1 and IR2 are separated by the M 
domain (25 residues in human RanBP2). This 
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domain markedly enhances the catalytic activity 
when fused to the C terminus of IR1 or the N 
terminus of IR2, but is itself inactive. Consistent 
with the idea that M functions at least in part 
by increasing the affinity to Ubc9, IR1+M and 
M+IR2 work at substantially lower concentrations 
than IR1 or IR2 alone. Despite their structural 
and functional similarities, IR1 and IR2 (IR1+M 
and M+IR2) clearly differ in activity and Ubc9 
binding. An important question for future studies 
is therefore whether both fragments function 
independent of each other in the context of full-
length RanBP2, for example, on different targets, 
or whether the less active IR2 fragment serves, 
for example, an autoregulatory or inhibitory 
function (IR1+M is more active and less specific 
than IR1+2).
RanBP2 wrapping around Ubc9
One simple model, folding around Ubc9, may 
explain how IR1+M and M+IR2 could be 
functional equivalents (Fig. 10). Based on the 
observation that the catalytic domain of RanBP2 
is largely unstructured, the fragment IR1+2 can 
be aligned in two distinct ways, such that the 
M and IR domains in IR1+M and M+IR2 can be 
positioned identically on Ubc9  (assuming an 
extended sheet structure, 36 residues would be 
binding, whereas BP2∆FG would have a substantial 
proportion of unengaged unstructured areas that 
might interfere with certain target binding.
Function without direct target interaction
The SUMO E2 enzyme Ubc9 recognizes many 
targets directly via a defined consensus 
sequence. This is, however, not enough for 
efficient modification. RanGAP1, the only known 
target efficiently modified in the absence of E3 
ligases, has a second binding site for Ubc931. Most 
other targets seem to lack a second interaction 
site, which may explain why stable interactions 
with Ubc9 have not been found (interactions were 
mainly observed in two-hybrid assays).  These 
proteins are SUMOylated efficiently only in the 
presence of E3 ligases. Two distinct mechanisms 
could account for their stimulatory activity: 
first, they may serve as bridging factors, and 
by doing so stabilize the interaction between 
target and SUMO-charged Ubc9. Alternatively, 
they may function by accelerating the SUMO 
transfer time between Ubc9 and its targets such 
that even transient encounters are sufficient for 
modification. This could, for example, be achieved 
by allosterically changing Ubc9’s catalytic cleft. 
Notably, these mechanisms are not mutually 
exclusive, and both have been discussed for 
ubiquitin RING-finger E3 ligases
7
. An allosteric 
effect has, for example, been proposed for Apc11, 
the 84-residue RING-finger component of the APC 
complex32–34. 
Although the bridging mechanism probably applies 
to PIAS E3 ligases, it is not compatible with our 
findings on RanBP2’s catalytic domain. There is 
no evidence for target interactions, and shorter 
RanBP2 fragments stimulate SUMOylation of more 
targets than larger fragments. We therefore favor 
the idea that RanBP2 functions by accelerating 
SUMO transfer, possibly by an allosteric 
mechanism. Alternatively, RanBP2 may function 
by helping to position thioester-bound SUMO for 
efficient transfer. Although we have not addressed 
this experimentally, it is at least conceivable that 
RanBP2 binding influences non-covalent and/or 
covalent Ubc9-SUMO interactions.  
A notable possibility for an allosteric mechanism 
has been raised by recent work by Pickart and 
coworkers: they demonstrated that a strictly 
conserved asparagine present in E2 enzymes 
is essential, for example, for Ubc9- and PIAS-
dependent catalysis of Stat1 SUMOylation, 
and proposed that it serves to stabilize the 
Figure 10 Model for RanBP2-Ubc9 interaction.
sufficient to fully wrap around Ubc9 at its largest 
diameter). In either conformation, one of the 
IR fragments would not engage in binding. Our 
model is consistent with the mobility of IR1+M 
with and without Ubc9 in molecular size-exclusion 
chromatography (extended shape for IR1+M, 
globular shape of the complex). It fits with the 
Ubc9 mutagenesis, which implicates far removed-
residues on Ubc9’s surface in IR1 binding (i.e. Ile4, 
Val25 and Leu57), and it offers an explanation 
for our finding that BP2∆FG shows strong target 
preferences (Sp100 is modified efficiently, p53 is 
not), whereas the equally active IR1+M fragment 
does not (modification of p53 and Sp100). In our 
model, IR1+M would be fully involved in Ubc9 
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oxyanion intermediate formed during lysine 
attack. This would, however, require a change in 
asparagine side chain orientation relative to the 
conformation seen in existing E2 structures29. 
Here we extended their findings to demonstrate 
that RanBP2-dependent SUMOylation of Sp100 
also requires Asn85. One hypothesis is therefore 
that RanBP2 (and perhaps PIAS E3s) accelerates 
catalysis by influencing the orientation of this 
asparagine side chain in Ubc9. A subtle change 
in side chain orientation of Asn5 would not be 
detectable in CD spectra, and high-resolution 
structural analysis will be required to resolve this 
issue. Notably, although Asn5 is also essential 
for E3-independent modification of Stat129 and 
Sp100, Ubc9 N85Q can SUMOylate RanGAP1 
(Supplementary Fig. 1 online). In contrast 
to Stat1 and Sp100, RanGAP1 stably interacts 
with Ubc9. It could therefore be modified even if 
isopeptide bond formation in N85Q Ubc9 were to 
be slowed down substantially. 
In conclusion, the catalytic core domain of 
RanBP2 is distinct from that of any other known 
E3 ligase. It is an extended protein that interacts 
with Ubc9 via largely hydrophobic interactions. 
Stimulation of target SUMOylation seems to be 
catalyzed via enhancing Ubc9’s activity rather 
than by target recruitment. Whether this indeed 
involves allosteric changes in Ubc9 awaits future 
structural analysis. 
Material and methods
Plasmids. Plasmids for GST-BP2∆FG (residues 2553–
23), Ubc9, SUMO1, Aos1, Uba21, GST-IR1+2 (residues 
2633–2761), GST-IR1 (residues 2633–2685), GST-IR2 
(residues 2711–2761), GST-M (residues 2683–2711)25, 
GST-Sp10035, GST-p53 and GST-HDAC419, His-Lef-
12, GST-PIAS136 and wild-type His-Ubc931 have been 
described. GST-M-L (residues 2661–2735) and GST-
M+IR2 (residues 2683–2761) constructs were generated 
by PCR and ligation into the BamHI and EcoRI sites of 
pGEX-2T. Single point mutants were generated by site-
directed mutagenesis. GST-IR1+M (residues 2633– 2711) 
was derived from GST-IR1+2 by introduction of a stop 
codon in position 2712.
Expression and purification of recombinant proteins. 
Purification of SUMO1, Aos1, Uba2, and Ubc9 was done as 
described1. GST-BP2 constructs, GST-p53, GST-HDAC4, 
His-Lef-1 and His-Ubc9 were expressed in E. coli BL21 gold 
(Stratagene); GST-PIAS1 and GST-Sp100 were expressed 
in the E.coli strain Rosetta (Novagen). His- and GST-fusion 
proteins were purified according to standard protocols. 
Tags in GST- BP2∆FG were removed by Factor Xa cleavage 
(Novagen) and subsequent gel filtration; GST-tags in 
other GST-BP2 constructs, GST-PIAS1, and His-Ubc9 were 
removed by cleavage with biotinylated thrombin according 
to manufacture’s instructions (Novagen).
Antibodies. Rabbit anti-GST antibody was provided 
by L. Hengst (Max-Planck Institute for Biochemistry); 
mouse monoclonal anti-SUMO1 was obtained from 
Zymed Laboratories; rabbit anti-His was obtained from 
Santa Cruz Biotechnology; rabbit anti-RanBP2 had been 
described1. Secondary antibodies were obtained from 
Jackson Laboratories.
In vitro SUMOylation. In vitro SUMOylation was done as 
described1. Unless stated otherwise, 250 ng of substrate 
( 196 nM GST-Sp100,  127 nM GST-HDAC4,  278 nM His-
Lef1 or 166 nM GST-p53), ATP, 10 ng Ubc9 (28 nM), 150 
ng E1 (68 nM), 500 ng SUMO1 (2.2 µM) and 20 ng BP2 
fragments (31 nM BP2∆FG, 67 nM IR1+2, 109 nM IR1+M, 
15 nM IR1, 115 nM M-L) or ~1 µg PIAS1 were incubated 
in a total volume of 20 µl transport buffer supplemented 
with protease inhibitors, 1 mM DTT, 0.05% (v/v) Tween 
and 0.2 mg ml–1 ovalbumin Grade VI (SIGMA) at 30°C 
for 30 minutes. Reactions were stopped by addition of 2x 
Laemmli buffer.
Ubc9 interaction studies. For gel filtration, 50 µg of 
indicated recombinant proteins were incubated on ice for 
1 hour before application to gel filtration on Superdex 
75 (Pharmacia). Fractions of 250 µl were collected and 
analyzed by 5–20% (w/v) SDS-PAGE. For Ni2+ pull-down 
assay, His-Ubc9 was bound to ProBound resin (Invitrogen) 
and incubated with indicated proteins in 200 µl transport 
buffer supplemented with protease inhibitors, 1mM DTT, 
0.05% (v/v) Tween and 0.2 mg ml–1 ovalbumin at 4°C 
for 1 hour.  After washing, bound and input samples were 
analyzed by SDS-PAGE. For the GST pull-down assay, 100 
µl of bacterial lysate containing recombinant Ubc9 (0.5 
µg µl–1) was mixed with 50 µl beads containing 5 µg GST-
IR1+2, GST-IR1+M and GST-IR1 in 1ml of PBS plus 0.1% 
(v/v) TritonX100 for 30 min at room temperature. After 
washing three times with PBS plus 0.1% (v/v) TritonX100, 
proteins associated with the beads were analyzed by 5–
20% (w/v) SDS-PAGE. 
Analytical gel filtration. Samples (50 µl) were applied 
to an analytical Superdex 200 PC 3.2/30 gel filtration 
column (Pharmacia) on the SMART system (Pharmacia) at 
room temperature. Individual proteins had concentrations 
of 27 µM Ubc9, 157 µM BP2∆FG, or 526 µM IR1+M. For 
formation of complex, proteins were mixed at a molar ratio 
of 1:1 (100 µM each of BP2∆FG and Ubc9; 12 µM each 
of IR1+M and Ubc9) or 1:2 (74 µM BP2∆FG and 14 µM 
Ubc9; 109 µM IR1+M and 21 µM Ubc9), and incubated 
on ice for one hour  before loading. 
 
Multiangle laser light scattering (MALLS). Proteins 
were applied to an analytical Superdex 200 HR 10/30 gel 
filtration column (Pharmacia) coupled to a miniDAWN light 
scattering detector (Wyatt Technology) and a Dn-1000 
differential refractive index detector (WGE Dr. Bures) at 
4°C. Data analysis was carried out with the program Astra 
2
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using a dn dc–1 value of 0.1530. Protein concentrations 
were comparable to those used for the analytical gel 
filtration experiments, in the mixtures of BP2∆FG-Ubc9 
and IR1+M-Ubc9 a small excess of Ubc9 (~10 %) was 
used.
Circular dichroism. CD spectra were recorded on a 
Jasco J-715 spectropolarimeter provided with a PFD-
350S temperature controller and a thermostatic cell 
compartment. For signal averaging and processing the 
Spectra Manager software J-700 was used. The spectra 
were registered at 30°C in the range 195-260 nm with 
a scanning speed of 50 nm min–1 in 1x PBS, pH 7.5, and 
1mM DTT. Protein concentration (determined by UV) was 
5.5 µM.
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Supplementary Figure 1 Comparison 
of Ubc9 WT and Ubc9 N85Q for Sp100-
RanGAP1 SUMOylation and thioester 
bond formation. (a) Indicated amounts 
of Ubc9 WT or N85Q mutant were ap-
plied to in vitro SUMOylation reactions 
(500 ng SUMO1, 150 ng E1 and ATP) of 
250 ng GST-Sp100 (top) or 1.5 µg Ran-
GAP1 (bottom). Samples were analyzed 
by immunoblotting with anti-GST or anti-
RanGAP1 antibodies, respectively. (b) 
Ubc9 WT and N85Q mutant were com-
pared for thioester bond formation (200 
ng SUMO1, 100 ng Ubc9, 200 ng E1 and 
ATP). Analysis was done by SDS-PAGE in 
the absence or presence of DTT and im-
munoblotting with anti-SUMO1.
Supplementary figure 2 Calculated ver-
sus measured masses of light scattering 
analysis. BP2∆FG, IR1+M, Ubc9 and the 
complexes eluted with molecular masses 
comparable to the calculated values for 
monomeric species and 1:1 complexes, 
respectively.
Supplementary Figure 3 
Results of Ubc9 binding, ‘auto-
modification’, ligase activity 
and specificity for the different 
RanBP2 fragments analyzed 
in this study. N.d.: not de-
tectable, blanks: not tested. 
SUMO1 chain formation was 
clearly shown for the RanBP-
2∆FG fragment. In case of the 
smaller fragments it was not 
distinguished between chain 
formation and SUMOylation 
on different Lysines.
Supplementary Figure 4 Residues re-
quired for RanBP2’s ligase activity are 
highly conserved. Sequence comparison 
between IR1 and IR2 from human (Homo 
sapiens gi|1009337), mouse (Mus muscu-
lus gi|192199), rat (Rattus norvegicus 
gi|31156169, gi|29922782), bovine (Bos 
taurus gi|03901), frog (Xenopus leavis 
gi|17499975, gi|17470945, gi|24034, 
gi|17504982, gi|13486416) and chicken 
(Gallus gallus gi|25536955, gi|25339577, 
gi|27593034, gi|25509215). Sequences 
were obtained by translated BLAST search 
using the IR1+2 protein sequence as a 
query. The sequences for rat, frog and 
chicken were assembled from different 
EST-clones. White circles and squares 
highlight four essential and five important 
residues, respectively, that were identified 
in IR1 and M mutagenesis. 
Protein                     Calculated molecular weight    MALLS molecular weight
Ubc9 19 kDa 23 kDa
BP2∆FG 32 kDa 34 kDa
IR1+M 10 kDa 14 kDa
Ubc9 & BP2∆FG (1:1) 51 kDa 55 kDa
Ubc9 & IR1+M (1:1) 29 kDa 31 kDa
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Posttranslational modification with small ubiquitin-related modifier (SUMO) alters functions 
of many proteins, but the molecular mechanisms and consequences of this modification are 
still poorly defined. During a screen for novel SUMO1 targets, we identified the ubiquitin-
conjugating enzyme E2-25K (Hip2). SUMO attachment severely impairs E2-25K ubiquitin 
thioester and unanchored ubiquitin chain formation in vitro. Crystal structures of E2-25K(1–
155) and of the E2-25K(1–155)–SUMO conjugate (E2-25K*SUMO) indicate that SUMO 
attachment interferes with E1 interaction through its location on the N-terminal helix. The 
SUMO acceptor site in E2-25K, Lys14, does not conform to the consensus site found in most 
SUMO targets (ψKXE), and functions only in the context of an α-helix. In contrast, adjacent 
SUMO consensus sites are only modified when in unstructured peptides. The demonstration 
that secondary structure elements are part of SUMO attachment signals could contribute to 
a better prediction of SUMO targets. 
very few SUMO targets can be modified efficiently 
and at large quantities in vitro. In fact, only one 
SUMO conjugate has been structurally analyzed 
so far5, and this is RanGAP1, the most efficient 
target known to date. Here we describe the 
identification, biochemical and structural analysis 
of a novel SUMO target, the ubiquitin-conjugating 
enzyme E2-25K.
  
Results
Identification of E2-25K as a novel SUMO 
target 
To identify novel SUMO targets from HeLa cells, 
we made use of the observation that addition of 
GST–SUMO1 and ATP to cell extracts results in 
the appearance of GST–SUMO1 conjugates. Upon 
enrichment of modified proteins on GST columns 
and separation on SDS-PAGE, we applied mass 
spectrometry to identify putative targets. A 
protein band migrating at 65 kDa contained 
Introduction
Covalent attachment of ubiquitin and SUMO 
to proteins plays a major role in regulating 
cellular functions. Both modifications depend 
on a similar enzymatic cascade. Ubiquitination 
involves a single E1 ubiquitin-activating enzyme 
(Uba1), one of several E2 ubiquitin-conjugating 
enzymes, and one of many distinct E3 ubiquitin 
ligases. The latter are responsible for target 
selection (reviewed in1,2). Conjugation with SUMO 
requires the E1 heterodimer Aos1–Uba2 and the 
single E2 enzyme Ubc9, which contributes to 
target selection, and is often facilitated by E3 
ligases3,4. Whereas ubiquitination can promote 
protein degradation, SUMOylation largely serves 
to regulate protein interactions. The list of known 
SUMO targets has grown substantially in recent 
years, but the mechanisms of target selection 
and the molecular consequences of modification 
are still poorly understood. Obtaining structural 
insights has been complicated by the fact that 
36
Chapter 3
both GST–SUMO1 and the 25-kDa ubiquitin-
conjugating enzyme E2-25K, suggesting that 
the latter was covalently modified (Fig. 1a). E2-
25K belongs to class II of ubiquitin-conjugating 
enzymes6, and carries a C-terminal UBA domain 
in addition to a catalytic core. Its biological role 
is not yet understood, but different studies point 
to roles in Alzheimer disease7, as a regulator 
of huntingtin, and in antigen processing and 
representation9. In vivo targets and E3 ligases for 
E2-25K-dependent ubiquitination are not known, 
but biochemical studies have revealed E2-25K’s 
ability to catalyze the synthesis of unanchored 
Lys48-linked polyubiquitin chains6. 
To verify that E2-25K is a target for SUMO 
modification, we first tested its modification in 
vitro. E2-25K was efficiently SUMOylated even at 
low concentrations of Aos1–Uba2 and Ubc9 (68 
nM and 2 nM, respectively) in the absence of 
E3 ligases (Fig. 1b). This places E2-25K amongst 
the best in vitro substrates for Ubc9-dependent 
SUMO modification known thus far.
Modification of endogenous E2-25K in vivo could 
also be demonstrated, but only after enrichment 
of SUMOylated proteins using a His-SUMO1-
expressing cell line10 and pull-down assays on Ni2+ 
beads (Fig. 1c). We could not detect SUMOylated 
E2-25K by direct immunoblotting of cell lysates 
with or without SUMO overexpression (data not 
shown). Although we cannot formally rule out 
the possibility that E2-25K is modified upon His-
SUMO1 overexpression in the stable cell line, very 
low levels of steady state modification have been 
observed for many SUMO targets11-13. 
SUMO inhibits ubiquitin - E2-25K thioester 
formation 
To gain insight into the consequences of E2-
25K SUMOylation, we generated modified and 
unmodified E2-25K and tested both for unanchored 
ubiquitin chain formation. SUMOylated E2-25K 
is severely reduced in activity (Fig. 2a). Two 
different steps leading to chain formation could 
be affected by SUMO attachment: transfer of 
ubiquitin from the E1 enzyme to E2-25K (thioester 
bond formation), or transfer of ubiquitin from the 
loaded E2 to an ubiquitin acceptor (isopeptide 
bond formation). SUMO attachment strongly 
impairs ubiquitin thioester bond formation 
(densitometric analysis of several experiments 
indicates a 5-12 fold inhibition)(Fig. 2b). To test 
whether it confers an additional effect on the 
isopeptide bond formation step, we compared 
the formation of di-ubiquitin by similar amounts 
of ubiquitin-charged unmodified and modified E2-
25K (Fig. 2c). Here, SUMO has at best a minimal 
effect (up to 1.5-fold reduction of the transfer 
rate by densitometric analysis). To investigate 
SUMO’s effect on the thioester formation step in 
more detail, we tested the effect of SUMO on E2-
25K in an E1 concentration- (Fig. 2d) and time-
dependent (Fig. 2e) manner. Here, we included 
E2-25K(1–155) lacking the C-terminal UBA 
domain, as we obtained high-quality crystals for 
structure solution only for the truncated protein 
(see below). 
Direct comparison of full-length and truncated 
E2-25K was complicated by the observation that 
E2-25K and E2-25K(1–155) differ substantially in 
their requirement for E1 enzyme (compare top 
and bottom panel of Fig. 2d). As the truncated 
protein requires at least five fold less E1 for 
the same amount of thioester, this suggests an 
inhibitory function for the UBA domain. Notably, 
SUMO inhibited thioester formation for both full 
length (up to 12-fold inhibition) and truncated (up 
to 5-fold inhibition) E2-25K.
Figure 1 E2-25K is SUMOylated in vitro and in vivo. (a) 
Identification of E2-25K as a SUMO1 substrate: proteins 
that stably associated with GST–SUMO1 upon incubation 
in HeLa S3 cytosol were separated on SDS-PAGE. Mass 
spectrometry identified peptides for GST, SUMO1 and E2-
25K in the indicated band. Size given in kDa. (b) E2-25K 
is SUMOylated in vitro: 500 ng E2-25K, 150 ng Aos1–
Uba2, 10 ng Ubc9, and 1.5 µg SUMO1 in 20 µl reaction 
volume were incubated with or without ATP for 30 min at 
30°C. Analysis was done by immunoblotting. (c) E2-25K 
is SUMOylated in vivo. Ni2+ pull-down under denaturing 
conditions from wild-type HeLa cells (left lanes) or 
HeLa cells stably expressing His-SUMO1 (right lanes). 
Immunoblotting was with two different anti-E2-25K and 
anti-SUMO1 antibodies. Size given in kDa.
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A crystal structure of the E2-25K*SUMO 
conjugate 
SUMO may inhibit E2-25K thioester formation by 
interfering with the E1-E2 interaction, by masking 
of the catalytic cysteine, or by inducing a structural 
change in E2-25K. We addressed this question by 
solving and comparing the crystal structures of 
E2-25K(1–155) and the E2-25K(1–155)*SUMO 
conjugate at 1. Å and 2.3 Å, respectively, using 
in vitro purified and modified protein (Fig. 3 
and Table 1). The truncated protein is active in 
unanchored ubiquitin chain formation in contrast 
to a slightly shorter fragment14, that lacks main 
chain interactions and may not have folded 
correctly. The structure of unmodified E2-25K(1–
155) shows the canonical E2-core fold (r.m.s. 
deviation of 1.0 Å for 147 of 155 Cα atoms) 
when compared to its yeast homolog Ubc115. In 
agreement with mass spectrometry analysis the 
structure of modified E2-25K(1–155) (Fig. 3a) 
clearly reveals attachment of the C terminus of 
SUMO to Lys14 (Fig. 3b). SUMO binding buries 
~250 Å2 of the accessible surface area of E2-
25K. In a recently solved NMR structure of the 
RanGAP*SUMO complex5, no interactions were 
observed between SUMO and the target other than 
the isopeptide bond. The E2-25K interface with 
SUMO, however, involves three hydrogen bonds 
and several hydrophobic interactions, primarily 
between exposed side chains of the E2-25K N-
terminal helix and the backbone of the kinked 
SUMO C terminus (Fig. 3c). A kinked C terminus 
is also seen in structures of tetra-ubiquitin16,17 
and in a structure-based model for the ubiquitin 
thioester with yeast Ubc115, but kinking is absent 
in structures of complexes of deconjugating 
enzymes and E11-21. 
Superposition of modified and unmodified E2-
25K(1–155) gives an r.m.s. deviation of 0.70 Å 
(using all Cα atoms), demonstrating that SUMO 
does not cause substantial conformational 
changes as a modifier in its substrate. The only 
substantial difference in secondary structure 
elements is in the N-terminal helix, which is 
somewhat bent outward when SUMO is linked. 
Some changes are also seen in the loops between 
Figure 2 SUMOylation of E2-25K inhibits ubiquitin thioester formation. (a) Ubiquitin (Ub) chain formation. SUMO-
modified (*S) or unmodified E2-25K (1.5 µg; arrows), 8 µg ubiquitin and 100 ng ubiquitin-E1 were incubated for indicated 
times with an ATP regenerating system at 37°C. Analysis was done by Coomassie blue staining. (b) Ubiquitin thioester 
formation. SUMO-modified or unmodified E2-25K (1 µg), 2 µg ubiquitin, 130 ng ubiquitin-E1, and ATP were incubated 
for 1 hour at 30°C. Analysis was done by immunoblotting. Left, nonreducing conditions allow detection of thioester; 
Right, reducing conditions. (c) Ubiquitin transfer. Equal amounts of E2-25K and E2-25K*SUMO ubiquitin thioesters were 
generated by incubating 10 µg E2-25K, 10 µg ubiquitin K48R, and 1.25 µg ubiquitin-E1 with ATP at 37 °C for 12 and 70 
min, respectively. Ubiquitin-E1 was inhibited by EDTA, and wild-type ubiquitin was added to allow di-ubiquitin formation. 
Immunoblotting with anti-E2-25K (top) or anti-ubiquitin (bottom) followed. (d) Ubiquitin thioester formation of full-
length and truncated E2-25K. 1 µg of SUMOylated or unmodified full-length (top) or truncated E2-25K(1–155) (bottom) 
was incubated with ATP, 1 µg ubiquitin and indicated concentrations of ubiquitin-E1 for 30 minutes at 30°C. Analysis 
under nonreducing conditions was by immunoblotting. Asterisk, ATP- independent unspecific band. (e) Experiment was 
done as in d but in a time course using 6 ng E1 for E2-25K(1–155) and 100 ng E1 for full-length E2-25. Asterisk, 
isopeptide linked ubiquitin to E2-25K thioester; #, di-ubiquitin.
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the secondary structure elements, but notably, 
the loop containing the active site cysteine shows 
no substantial shifts upon SUMO modification. 
SUMO itself also does not undergo substantial 
structural changes, as its secondary structure 
is very similar to that of its unconjugated yeast 
homologue SMT3 and to that of ubiquitin16.
Ubc9 and ubiquitin E1 compete for E2-25K 
access
As our structural data clearly reveal that SUMO 
conjugation does not result in major structural 
changes or masking of the catalytic cysteine, 
reduced thioester formation could best be 
explained by steric interference of SUMO with 
the E2-25K–E1 interaction. This interpretation is 
consistent with studies implicating the N terminus 
of conjugating enzymes in E1 interaction21-23. To 
gain further evidence for this model, we mutated 
nine residues in the N-terminal helix of E2-25K 
and tested them for ubiquitin thioester formation 
(Fig. 3d, top). Mutations in two residues, Arg11 
and Phe13, caused strongly reduced thioester 
formation, indicating E1 interactions at these 
sites. Of these, Arg11 is buried upon SUMO 
attachment (Fig. 3b,f), in agreement with the 
idea that SUMO inhibits E1 interaction by steric 
hindrance in vitro. 
Notably, SUMOylation of E2-25K also involves 
Arg11 and Phe13 (Fig. 3d, bottom). These 
results suggest that the ubiquitin E1 and Ubc9 
directly compete for an overlapping surface on 
E2-25K (Fig. 3f). To address this experimentally, 
we allowed for simultaneous ubiquitin thioester 
formation and SUMOylation (Fig. 3e). In the 
first set of experiments we kept Ubc9 constant 
and increased ubiquitin E1 concentrations; in the 
second set we kept E1 constant and increased 
Ubc9 concentrations. These experiments revealed 
clear competition between both reactions, with 
a strong preference for E1-mediated thioester 
formation. This indicates that E2-25K can be 
SUMOylated only in uncharged form and at low 
ubiquitin E1 concentrations. 
A helical SUMO acceptor site 
As shown above, the acceptor lysine for SUMO 
conjugation in E2-25K is Lys14. This was 
rather surprising because Lys14 is not part of 
a consensus motif found in most SUMO targets 
(ψKXE, where ψ is a hydrophobic residue and X 
is any residue). Ubc9 requires both the bulky 
hydrophobic and the acidic side chains of the 
conventional consensus motif to recognize and 
modify its targets24-26. Notably, acidic residues 
are not required for modification of the E2-25K 
Figure 3 Crystal structure of SUMO-modified E2-25K. (a) The E2-25K*SUMO structure showing the covalent linkage 
between E2-25K (cyan) Lys14 and the C terminus of SUMO (pink). The E2-25K catalytic cysteine is yellow. (b) Refined 
electron density map (2mFo-  DFc) at the linker region between E2-25K (cyan) and SUMO (pink). (c) The interface 
between E2-25K and SUMO is small but defined. Hydrogen bonds and interface side chains are shown. (d) Mutation 
analysis of the N-terminal α-helix. Top, thioester bond formation. Wild-type (WT) E2-25K or mutants (500 ng), 150 ng 
ubiquitin E1, 1 µg ubiquitin, and ATP were incubated for 30 min at 30°C. Analysis was done under nonreducing conditions. 
Bottom, SUMOylation. E2-25K wild-type or mutants (250 ng), 150 ng SUMO E1, 500 ng SUMO1, 250 ng Ubc9 and ATP 
were incubated 30 min at 30°C. Asteriks indicates a faster-migrating form that has also been noticed by others3. (e) 
Competition between ubiquitin thioester formation and SUMOylation: 500 ng Ε2-25Κ, 150 ng SUMO Ε1, 1 µg SUMO1, 
1 µg ubiquitin, ATP and indicated amounts of ubiquitin E1 and Ubc9 were incubated 30 min at 30°C. (f) Position of the 
residues individually mutated in E2-25K. Top, residues that affect thioester formation (green). Bottom, residues affecting 
SUMOylation (purple). For both, residues not affecting thioester formation or SUMOylation are cyan. 
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acceptor site; instead, the basic residues Arg, 
Lys10, Arg11 and the aromatic hydrophobic 
residue Phe13 seem to be involved (Fig. 3d,f). 
SUMOylation sites of mutated proteins were 
analyzed by mass spectrometry. Whereas most 
mutants involve Lys14 as major modification site, 
the weakly modified mutant F13A is SUMOylated 
at Lys10 (data not shown). 
Not only the primary sequence, but also the 
secondary structure of the E2-25K acceptor 
site differs substantially from that of previously 
characterized SUMO targets. Whereas Lys14 is 
part of an α-helix, most of the known SUMO target 
sites fall either in unstructured N or C termini 
or in loop regions12,25. We therefore wondered 
whether secondary structure in conjunction 
with a specific primary sequence defines a 
SUMO acceptor site. E2-25K was an ideal model 
substrate for this question, as it contains three 
consensus site lysine residues (Lys10, Lys1 and 
Lys2) in close proximity to Lys14 (Fig. 4a,b 
and Supplementary Fig. 1 online). All four 
lysines are exposed to the solvent in the E2-25K 
structure, and are found in α-helices or β-strands. 
We first analyzed single point mutants in each 
of these lysine residues for their modification in 
vitro (Fig. 4). Notably, only the K14R mutant 
was incompetent for modification, indicating 
that Lys10, Lys18 and Lys28 are not modified in 
the context of properly folded E2-25K. We then 
used WT and mutant peptides comprising the 
N-terminal helix of E2-25K (residues 2–19) to 
analyze the competence of Lys10 and Lys14 for 
modification in the absence of a helical structure 
(Fig. 4c). Circular dichroism was used to confirm 
the lack of helical structure (data not shown). In 
this case the consensus site residue Lys10 was 
strongly preferred over the nonconsensus residue 
Lys14. In summary, we showed that the ψKE 
motif surrounding Lys10 is recognized only as 
part of an extended structure, whereas the helical 
motif surrounding Lys14 is recognized only in the 
context of an α-helix, and requires basic rather 
than acidic residues for recognition.
Discussion
Here we described the ubiquitin-conjugating 
enzyme E2-25K as a novel target for SUMOylation. 
While it is efficiently modified in vitro by Ubc9 
and the SUMO E1 enzyme, we observed very 
low levels of modification in vivo that we could 
only detect upon enrichment from a cell line that 
stably overexpresses His-SUMO1. Because SUMO-
modifying enzymes should have access to E2-25K 
(distributed throughout the cell), this may be due 
to a constant turnover by SUMO isopeptidases, 
or due to strict regulation of the modification. 
In vitro, SUMO interferes with E2-25K ubiquitin 
thioester formation. The physiological relevance 
of E2-25K SUMOylation cannot easily be 
addressed, because no E2-25K-dependent in vivo 
E3 ligases or substrates are available. At least 
two different scenarios are compatible with the 
low steady state levels of E2-25K SUMOylation: 
first, SUMOylation of E2-25K may act as an 
inhibitor of E2-25K-dependent ubiquitination, 
and may be spatially or temporally regulated. 
Alternatively, E2-25K may go through constant 
cycles of modification and demodification, which 
may contribute to assembly and disassembly of 
Figure 4 SUMO target sites are defined by their structural 
context. (a) Position of four lysine residues in the N 
terminus of E2-25K. (b) In the folded protein, Lys14 is 
the preferred substrate. Wild-type (WT) or indicated E2-
25K mutant (500 ng), 1 µg SUMO1, 300 ng Aos1– Uba2, 
500 ng Ubc9 and ATP were incubated for 30 min at 30°C. 
(c) In an unfolded peptide, Lys10 is preferred. Indicated 
peptide (20 µg), 1.5 µg SUMO-E1, 340 ng Ubc9, 15 µg 
SUMO, and ATP were incubated for 0–5 hours. (d) In 
folded E2-25K protein, Lys14 is preferred. Wild-type or 
indicated E2-25K mutant (7.5 µg), 12 µg SUMO-E1, 425 
ng Ubc9, 20 µg SUMO, and ATP were incubated for 0–2 
hours at 37 °C. 
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E1-E2-E3. In this scenario, SUMOylation of E2-
25K may even act as a positive regulator of E2-
25K dependent ubiquitination. Such a model is 
supported by the observation that ubiquitin E2 N 
termini are involved not only in E1 but also in E3 
interaction27. A related model has been proposed 
for one subfamily of ubiquitin E3 ligases, members 
of which are regulated by neddylation, another 
ubiquitin-related modification2,29. 
SUMO modification can have substantial 
consequences for the binding properties of its 
targets, either allowing or prohibiting formation 
of complex with partners. Whether this is due to 
conformational changes in the acceptor protein or 
due to the addition or masking of binding interfaces 
is unclear in most cases. A recent NMR study by 
Macauley et al.5 of the RanGAP1*SUMO1 complex 
indicates that SUMO1 is connected to RanGAP1 like 
‘beads on a string’. The crystal structure analysis 
of SUMO-modified and unmodified E2-25K again 
demonstrates the absence of conformational 
changes in the target. Together these studies lend 
credit to the idea that SUMO generally functions 
by masking and/or providing binding interfaces 
rather than by inducing conformational changes 
to its target. 
Acceptor sites for SUMO frequently fit a ψKXE 
consensus motif. In RanGAP1, this motif is part 
of an extended loop structure that is recognized 
by Ubc925. Some nonconsensus acceptor sites 
have been identified in other proteins, but the 
structural context of these is largely unknown. An 
exception is PCNA, which is SUMOylated on the 
nonconsensus residue Lys164, which is also part 
of a loop structure12. In E2-25K both the primary 
sequence surrounding the acceptor site, Lys14, and 
the secondary structure element (an α-helix) are 
distinct. Although E2-25K has several consensus 
motifs, including one surrounding Lys10, these 
are not modified in the folded protein. Thus, 
the ψKXE motif surrounding Lys10 is recognized 
only as part of an extended structure, whereas 
the helical motif surrounding Lys14 is recognized 
only in the context of an α-helix, and requires a 
phenylalanine upstream of the lysine, and basic 
rather than acidic residues for recognition. These 
findings strongly underscore the importance 
of structural elements in lysine recognition for 
SUMOylation, which is critical for better prediction 
of SUMO targets. The identification and structural 
analysis of other proteins with helical SUMO 
acceptor sites and their interaction with Ubc9 will 
be important for precise definition of this novel 
motif in the future. 
Methods
Plasmids, enzymes and antibodies. GST–SUMO1 
(1–97) and SUMO enzymes have been described30,31. 
GST–E2-25K was a gift from C. Pickart (Johns Hopkins 
University)14. GST–E2-25K(1–155) was cloned in pETM30 
(European Molecular Biology Laboratory). Mutants were 
generated by site directed mutagenesis. For small-
scale experiments, wild-type E2-25K and mutants were 
expressed and purified according to standard protocols, 
and the GST-tag was removed by cleavage with 
biotinylated thrombin (Novagen). Mammalian ubiquitin 
E1 was from Affinity or Boston Biochem. Ubiquitin was 
either obtained from Sigma or recloned from a vector 
kindly provided by N. Dantuma (Karolinska Institute) 
into the pETM30 vector; GST-tag was removed by TEV 
cleavage. Affinity-purified rabbit anti-E2-25K against 
full-length bovine protein was generated as described30. 
A second rabbit anti-E2-25K was provided by C. Pickart 
(Johns Hopkins University)32. Mouse monoclonal anti-
SUMO (anti-GMP1), mouse monoclonal anti-ubiquitin, and 
secondary antibodies were obtained from Zymed, Santa 
Cruz, and Jackson Laboratories, respectively.  
Table 1 Data collection and refinement statistics
                                    E2-25K(1–155) E2-25K(1–155)*SUMO
Data collection 
Space group P212121  P43212 
Cell dimensions (Å)
   a, b, c 38.26, 68.15, 78.26 58.39, 58.39, 162.84
Resolution (Å) 50-1.8 (1.90-1.80) 84 50-2.3 (2.42-2.30)
Rmerge 0.072 (0.548) 0.070 (0.511) 
I / σI 17.8 (3.3) 30.6 (3.8)
Completeness (%) 100 (100) 99.9 (99.9) 
Redundancy  7.1 (7.3) 13.4 (13.0) 
Refinement 
Resolution (Å) 50-1.8 50-2.3 
No. reflections 19,623 13,245 
Rwork / Rfree 16.7/21.9 21.0/27.9 
No. atoms 
   Protein 1,278 1,869 
   Ligand/ion 4 0 
   Water 261 83 
B-factors 
   Protein 30.6 57.9 
   Ligand/ion 42.0 
   Water 39.5 57.2 
R.m.s deviations 
    Bond lengths (Å) 0.017 0.018 
    Bond angles (°) 0.622 0.646 
One crystal was used per data set. Values in parenthesis 
are for highest resolution shell. 
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Identification of SUMOylated E2-25K in HeLa cell 
extracts. HeLa S3 cytosol (40 ml), 200 µg GST-SUMO1, 
2 µg RanBP2∆FG31 and ATP were incubated for 1h at 37°C 
(subsequent analysis showed that RanBP2 had no effect 
on E2-25K SUMOylation in vitro, data not shown). Modified 
proteins were enriched on glutathione beads, washed 
with 50 mM Tris pH .0, 750 mM NaCl, 1% (v/v) NP40, 
eluted with 20 mM glutathione, and separated on a 7% 
(w/v) SDS-PAGE. Coomassie blue-stained protein bands 
were digested by trypsin (Promega, sequencing grade) as 
described33 and desalted using homemade miniaturized 
reversed-phase columns34. 
MALDI-TOF mass spectra were acquired on a Reflex III 
instrument (Bruker Daltonik) in positive ion reflector 
mode. As a matrix, α-cyano-hydroxycinnamic acid was 
used. The E2-25K modification site was identified by online 
reverse-phase nanoscale liquid chromatography tandem 
mass spectrometry using an AB-MDS Sciex QSTAR pulsar 
quadrupole time-of-flight mass spectrometer. 
Detection of endogenous E2-25K*SUMO1 by pull-
down. A HeLa cell line expressing HisSUMO1 was 
provided by R. Hay (University of St. Andrews)10. Cells 
from eight 100 mm2 flasks were lysed under denaturing 
condition using a standard protocol (Qiagen), and His-
SUMO1-modified proteins were enriched on Ni2+ProBond 
resin (Invitrogen). 
In vitro SUMOylation and ubiquitination and 
thioester bond formation. Small-scale in vitro 
SUMOylation assays were done as described31. E2-
25K–ubiquitin thioester and chain formation assays were 
essentially done as described31, using Uba1 and ubiquitin 
instead of Aos1–Uba2 and SUMO1. Chain formation 
involved incubation for up to 16 hours in the presence 
of an ATP regenerating system. Di-ubiquitin formation 
was carried out by initial thioester formation using Uba1, 
E2-25K and ubiquitin K48R. E1 activity was blocked by 
addition of 10 mM EDTA. Equal amounts of thioesters for 
SUMOylated and unmodified E2-25K were used for di-
ubiquitin formation initiated by addition of excess of wild-
type ubiquitin.  
Expression and purification of E2-25K*SUMO1 
conjugates for crystallization. GST–E2-25K(1–155) 
was expressed in Escherichia coli using IPTG induction 
overnight at 15°C. Purification included glutathione 
affinity chromatography and TEV cleavage of the GST–tag 
followed by size-exclusion chromatography (Superdex 75, 
Pharmacia). E2-25K was SUMO-modified on large scale by 
incubating 10 mg E2-25K(1–155) with 100 µg E1, 00 µg 
Ubc9 and 7.5 mg SUMO in the presence of 5 mM ATP and 
5 mM MgCl2 for 4 hours at 37 °C. SUMO-modified E2-25K 
was purified by size-exclusion chromatography (Superdex 
75) followed by anion-exchange chromatography 
(MonoQ).  
Crystallization and data collection. Both SUMO-
modified and unmodified E2-25K(1–155) were stored in 20 
mM Tris pH 8.0, 100 mM NaCl, 5 mM β-mercaptoethanol 
and 0.1 mM PMSF at 5-10 mg ml-1. E2-25K(1–155) crystals 
were grown at room temperature using hanging drops 
against 17% (w/v) PEG MME 5000, 70 mM (NH4)2SO4, 100 
mM Tris pH .5. E2-25K(1– 155)*SUMO crystals grew in 
sitting drops at room temperature against 17% (w/v) PEG 
4000, 10% (v/v) glycerol, 200 mM MgCl2 and 100 mM Tris 
pH 8.5. Cryoprotection was achieved with mother liquor 
supplemented with 20% (v/v) glycerol. Data were collected 
from a single crystal at 100 K on European Synchrotron 
Radiation Facility beam line ID14-2 (λ = 0.933) for E2-
25K and ID14-4 (λ = 0.939) for E2-25K*SUMO. Data were 
processed with Mosflm and Scala35. 
Structure determination and refinement. A 
systematic procedure involving a subset of available E2 
structures (PDB entries 1FXT, 1AYZ, 1AAK, 1QCQ, 1JAT, 
1J7D and 1FZY) provided optimal phasing after molecular 
replacement35, side chain mutation, automated side chain 
fitting in ARP/wARP36
 
and rigid body refinement35. The 
best model (PDB entry 1FZY), which had an Rfactor of 0.32 
and Rfree of 0.44, improved considerably compared with 
molecular replacement (Rfactor=0.41, Rfree=0.49), allowing 
almost complete ARP/wARP autobuilding of E2-25K in 
both crystal forms. SUMO was built manually using O37 in 
the E2-25K*SUMO structure. Rebuilding and refinements 
were done with O37 and Refmac35. Percentages of residues 
in most favored, additionally allowed, generously allowed 
and disallowed regions of the Ramachandran plot for E2-
25K were 90.5, ., 0.7 and 0.0, respectively. For E2-
25K*SUMO they were 91.9, 7.4, 1.5 and 0.0, respectively. 
Crystallographic parameters are summarized in Table 1. 
All structure figures were generated using PyMOL (http://
www.pymol.org).
 
Coordinates. Atomic coordinates and structure factors 
for E2-25K(1-155) and E2-25K(1-155)*SUMOM have 
been deposited in the Protein Data Bank (accession codes 
2BEP and 2BF, respectively). 
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Supplementary Figure 1 Conventional SUMO sites in E2-25K structure (ball-and-stick 
representation), showing how the lysines (green) are exposed but the rest of the se-
quence motifs are buried in the folded protein. Top right panel shows Lys14 (purple), 
the actual site of the SUMO modification, with the amino acids that are involved in the 
sumoylation process according to mutation analysis (Fig. 3d)
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Posttranslational modification with small ubiquitin related modifier SUMO is a widespread 
mechanism for rapid and reversible changes in protein function. Considering the large number 
of known targets, the number of enzymes involved in modification seems surprisingly low: 
a single E1, a single E2, and a few distinct E3 ligases. Here, we show a novel mechanism 
of target discrimination: auto-sumoylation of the E2 conjugating enzyme Ubc9, while not 
altering its activity towards HDAC4 and E2-25K, impairs activity on RanGAP1 and strongly 
enhances activity on the transcriptional regulator Sp100. Enhancement is dependent on 
the presence of a SUMO interacting motif (SIM) in Sp100, in close proximity to its SUMO 
acceptor site. The crystal structure of SUMO modified Ubc9 demonstrates how the newly 
created binding interface can provide the gain in affinity otherwise provided by E3 ligases. 
This reveals a new concept for the central role of Ubc9 in target selection and modification.
via their SUMO consensus motif (ΨKxE/D), 
but this interaction by itself is not sufficient for 
efficient SUMO transfer to the target lysine. 
Target modification therefore often depends on a 
third class of enzymes, the E3 ligases (Hay, 2005; 
Johnson, 2004; Pichler, 2004), which enhance 
SUMO transfer from the E2 to the substrate. 
So far, three different types of SUMO E3 ligases 
have been identified: the Siz/Pias SP-RING family 
(Johnson and Gupta, 2001; Kahyo et al., 2001; 
Kotaja et al., 2002; Sachdev et al., 2001; Schmidt 
and Muller, 2002), the nucleoporin RanBP2/
Nup35 (Pichler et al., 2002; Pichler et al., 2004) 
and Pc2 (polycomb group protein 2) (Kagey et al., 
2005; Kagey et al., 2003). While target recognition 
is mediated in part by the E2 Ubc9, E3 ligases 
contribute to substrate specificity and accelerate 
catalysis, either by stabilizing the interaction 
between a specific substrate and SUMO loaded 
E2 (SP-Ring type), or by positioning the loaded 
E2 for optimal transfer (RanBP2; (Reverter and 
Lima, 2005)). One exceptional target that does 
not require an E3 ligase for efficient modification 
is RanGAP1 (Mahajan et al., 1997; Matunis et 
al., 1996). Here, stabilization of the interaction 
Introduction
Posttranslational modification with SUMO is 
important for maintaining cellular integrity. 
Sumoylation regulates a large number of 
proteins involved in various cellular processes 
like transcriptional regulation (Girdwood et al., 
2003; Seeler and Dejean, 2003; Yang et al., 
2003), nucleo-cytoplasmatic transport (Pichler 
and Melchior, 2002), genome integrity (Muller et 
al., 2004), DNA repair (Hoege et al., 2002; Stelter 
and Ulrich, 2003) and cell cycle progression (Hay, 
2005). This requires SUMO modification to be 
highly specific and tightly regulated. Isopeptide 
bond formation between SUMO and a specific 
lysine on its substrate depends on an energy-
dependent enzymatic cascade analogous to the 
ubiquitination system. In an ATP-dependent 
reaction SUMO is activated by a single specific 
E1 activating enzyme, the heterodimer between 
Aos1 and Uba2 (also referred to as SAE1/SAE2) 
resulting in an E1-SUMO thioester linkage. SUMO 
is then transferred to the E2 conjugating enzyme 
Ubc9, again forming a thioester. The catalytic cleft 
of Ubc9 directly interacts with many substrates 
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with SUMO loaded Ubc9 is mediated via a second 
binding interface between RanGAP1 and Ubc9 
(Bernier-Villamor et al., 2002). 
If one considers the large number of known SUMO 
targets that are modified in a temporally and 
spatially controlled fashion, the number of known 
SUMO E3 ligases seems rather low. One obvious 
possibility to explain this discrepancy is that many 
E3 ligases still await identification. This would 
be in line with the large number of E3 ligases 
known to exist in the ubiquitin field. Alternatively, 
regulation of sumoylation may take place largely 
at the level of individual target proteins. Both 
posttranslational modification and regulated 
localization can determine target accessibility 
to the conjugation machinery. For example, a 
number of proteins, including HSF-1, contain a 
phosphorylation-dependent sumoylation motif 
(PDSM) (Hietakangas et al., 2003; Hietakangas 
et al., 2006). Finally, regulation of the enzymes 
themselves could serve to determine specific 
target recognition. One example is the Siz1 
dependent mitosis specific sumoylation of septins 
at the yeast bud neck (Johnson and Gupta, 
2001). While Siz1 resides in the nucleus during 
interphase it translocates to the bud neck during 
mitosis. Interestingly, SUMO itself seems involved 
in regulating its enzymes, as it was recently 
described that sumoylation of the SUMO E3 ligase 
PIASy enhances Tcf-4 sumoylation (Ihara et al., 
2005).
Modulation of localisation and activity may 
not be restricted to E3 ligases, but could also 
include Ubc9, as this enzyme directly contributes 
to target recognition. While nothing is known 
about regulated Ubc9 localisation and/or 
phosphorylation, posttranslational modification of 
Ubc9 with SUMO has frequently been observed 
in in vitro sumoylation assays ((Bencsath et al., 
2002); this study). More importantly, several 
screens for new SUMO targets from yeast to men 
revealed the existence of sumoylated Ubc9 in cells 
(Hannich et al., 2005; Wohlschlegel et al., 2004; 
Zhao et al., 2004; Zhou et al., 2004); Of note, 
two of these studies expressed tagged SUMO 
from its endogenous promotor, which excludes 
artificial Ubc9 sumoylation due to overexpression. 
Finally, a recent study on mice reported tissue 
specific levels of sumoylated Ubc9, pointing to 
an important role of this modification in Ubc9 
regulation (Nacerddine et al., 2005). 
We previously reported that the ubiquitin E2 
conjugating enzyme E2-25K is sumoylated at a 
non-conventional SUMO acceptor site in its N-
terminus. Modification masked the E1 interaction 
site and thereby resulted in E2-25K inhibition 
(Pichler et al., 2005). Based on these findings, we 
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Figure 1. Ubc9 is SUMO1 
modified at lysine 14. (A) In vitro 
sumoylation of Ubc9: 4 µg Ubc9, 
500 ng Aos1-Uba2 and 3 µg 
SUMO1 were incubated at 37 °C 
in a 10 µl reaction volume without 
and with ATP for the indicated time 
periods. Samples were separated 
on an SDS-PAGE and stained 
with Coomassie. (B) Identification 
of sumoylated lysine-14 in 
Ubc9 by orbitrap tandem mass 
spectrometric analysis. Tryptic 
digestion of the sumoylated protein 
results in a 19mer-peptide remnant 
from the C-terminus of SUMO-
1 (ELGMEEEDVIEVYQEQTGG-) 
conjugated to the targeted lysine. 
This leads to a mass shift of 2169.9 
Da (when methionine is oxidized) 
and a missed tryptic cleavage at 
the modified lysine residue. The 
figure shows the fragmentation 
pattern of the quadruply-charged 
tryptic peptide (14-KAWR17) 
derived from Ubc9 that contain 
the sumoylated K14. The y series 
of ions (C-terminus containing fragments) that are produced due to fragmentation are labeled, as well as those from 
the b ion series (N-terminus containing fragments). The inset shows the intact peptide ion selected for sequencing. (C) 
Sequence alignment of the N-terminal helix of Ubc9 from various species. The SUMO attachment site, marked in blue, is 
highly conserved from yeast to men. 
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Figure 2. Ubc9 sumoylation does not affect its ability to 
form thioester bonds. 25 nM of either Ubc9 or Ubc9*SUMO 
were incubated with 70 nM Aos1-Uba2, 4.4 µM SUMO1 
and ATP at 30 °C. Reactions were stopped at indicated 
time points with a non-reducing buffer and separated on 
a 5-20% SDS gel. Analysis by immunoblotting was either 
with α-Ubc9 raised in goat (upper panel) or with α-SUMO1 
(lower panel).
initially suspected that Ubc9 sumoylation would 
serve a similar negative regulatory mechanism.
Here we report the surprising finding that Ubc9 
sumoylation, while taking place at a similar non-
consensus site in the N-terminal helix of Ubc9, 
instead serves as a modulator of target selection. 
While modification of some targets is not affected 
by Ubc9 sumoylation, Ubc9 modified with SUMO is 
strongly impaired for RanGAP1 modification. Most 
strikingly, sumoylation significantly increases Ubc9 
efficiency in Sp100 modification, to an extent that 
can otherwise only be achieved in the presence of 
E3 ligases. The crystal structure of SUMO*Ubc9 
demonstrates no structural change in Ubc9, but 
reveals a newly created binding interface involving 
Ubc9 and SUMO. In combination with our finding 
that a SUMO interaction motif (SIM) in Sp100 is 
required for the enhanced modification, these 
data demonstrate that Ubc9 sumoylation serves 
to recruit Ubc9 to a subclass of SUMO targets. 
Results and discussion
SUMO is conjugated to lysine 14 in Ubc9
To gain insight in the role of Ubc9 sumoylation, 
we first aimed to identify the SUMO acceptor 
site. Based on our previous experience with E2-
25K sumoylation, where sumoylation did not take 
place on a consensus site motif, we decided to 
employ mass spectrometry to identify the Ubc9 
sumoylation site. For this, we first performed an in 
vitro sumoylation assay by incubating the SUMO 
E1 (Aos1-Uba2), Ubc9 and SUMO1 in the presence 
of ATP (Figure 1A). Although relatively high protein 
concentrations are required to conjugate SUMO 
to Ubc9 compared to other substrates, we can 
clearly see the formation of Ubc9*SUMO in time. 
We excised the Ubc9*SUMO band from the gel 
and after in gel reduction, alkylation and tryptic 
digestion the sample was applied to orbitrap 
tandem mass spectrometric analysis (Olsen et 
al., 2004). The expected remnant 19mer-peptide 
from the SUMO1 C-terminus was conjugated to 
lysine 14 in Ubc9 leading to a mass shift of 2169,9 
Da and disappearance of the peptide 14-KAWR-
17 from Ubc9 (Figure 1B). No other modified 
peptides were found indicating that lysine 14 was 
the only SUMO attachment site.
Despite the presence of a consensus site for 
SUMO attachment at position 65 (FKDD), our 
data clearly demonstrate that the non-consensus 
site surrounding lysine 14 serves as the SUMO 
acceptor site on Ubc9. This site is located on the 
N-terminal α-helix of Ubc9, and it is structurally 
equivalent to the E2-25K sumoylation site. 
Interestingly, the motif surrounding lysine 14 
is distinct from that in E2-25K (see below), 
but conserved in Ubc9 suggesting a general 
importance for this modification (Figure 1C). The 
relatively inefficient modification of Ubc9 in vitro 
is in contrast with the fact that Ubc9 was found 
sumoylated in many in vivo target screens (see 
above), which indicates that Ubc9 sumoylation in 
vivo is most likely regulated by an E3 ligase.
Ubc9 sumoylation does not impair SUMO 
thioester formation
The N-terminus of E2 conjugating enzymes is of 
major importance for E1 interaction and thioester 
formation (Bencsath et al., 2002; Huang et al., 
2005; Tatham et al., 2003). Consistent with this, 
we previously found that E2-25K sumoylation 
interferes with ubiquitin E1 interaction resulting 
in an impaired ability to form ubiquitin thioesters 
(Pichler et al., 2005). As Ubc9 is modified at a 
structurally equivalent lysine on the N-terminal 
α-helix, we tested whether SUMO modification 
of Ubc9 also affected E1 interaction and thioester 
formation. For this, we purified SUMO modified 
and unmodified forms of Ubc9 from an in vitro 
sumoylation reaction and compared their E1 
interaction in a native gel mobility assay. While 
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SUMO modified E2-25K is strongly reduced in E1 
(Uba1) interaction compared to free E2-25K, SUMO 
modification of Ubc9 only has a mild effect on E1 
(Aos1-Ub2) interaction (Supplementary Figure 
1). Furthermore, we show that the Ubc9K14R 
mutant is not affected in E1 interaction in contrast 
to the charge-changing K14E mutation (Bencsath 
et al., 2002). Next, we studied the effect of Ubc9 
sumoylation on thioester formation. Equimolar 
amounts of modified and unmodified Ubc9 were 
incubated with the SUMO E1, SUMO1 and ATP 
under conditions allowing thioester formation 
but not isopeptide bond formation on Ubc9, and 
followed the reaction over time. As shown in 
Figure 2, sumoylation of Ubc9 does not affect 
SUMO thioester formation. The mild effect of Ubc9 
sumoylation on E1 interaction does not impair 
Ubc9*SUMO thioester formation in our assay 
conditions, which is in contrast to sumoylation 
of E2-25K. This indicates a functionally different 
role for SUMO modification on the SUMO E2 Ubc9, 
compared to the ubiquitin E2, E2-25K.
Sumoylation of Ubc9 causes a shift in target 
specificity
Since Ubc9 sumoylation did not affect SUMO 
thioester formation, we went on to test putative 
consequences on target modification. For this, we 
selected four different well-characterized SUMO 
targets, RanGAP1, Sp100, HDAC4 and E2-25K 
that vary in acceptor sites and requirements for 
E3 ligases and examined SUMO modification in a 
multiple turnover assay. First, we tested RanGAP1, 
a target that is efficiently sumoylated in the 
absence of an E3 ligase. Recombinant RanGAP1, 
Aos1-Uba2, SUMO1 and ATP were incubated for 
30 min with increasing concentrations of Ubc9 or 
Ubc9*SUMO, and modification was analysed by 
immunoblotting with α-RanGAP1 (Figure 3A, top 
panel). To rule out that Ubc9 itself is modified 
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Figure 3. Sumoylation of Ubc9 causes target discrimination. (A) 2.2 µM RanGAP1 was incubated with 4.4 µM SUMO1, 70 
nM Aos1-Uba2, ATP and indicated concentrations of either Ubc9 or Ubc9*SUMO at 30 °C for 30 minutes. Samples were 
separated on a 6% and 12% SDS-PAGE and analysed by immunoblotting with α-RanGAP1 and α-Ubc9, respectively. (B) 
In vitro sumoylation assays were performed as in (A) but with 127 nM GST-HDAC4 and 2.2 µM E2-25K. Separation was 
on 7% or 12.5% SDS gels and immunoblotting with α-GST and α-E2-25K, respectively. (C) Sumoylation as in (A) but 
with 200 nM GST-Sp100. Samples were separated on 7% and 12.5% SDS-PAGE and western blotting was performed with 
α-GST or α-Ubc9. (D) Single turnover transfer of SUMO from thioester to RanGAP1 was followed by adding preformed 
thioesters to 12.5 nM RanGAP1 at 4 °C for the indicated time points. (E) As in (D) but at 30 °C and with 595 nM E2-
25K. (F) As in (E) but with 225 nM GST-Sp100. (G) Sumoylation of RanGAP1 in the presence of E3s, assay as in (C) but 
supplemented as indicated with either  nM RanBP2∆FG or 170 nM PIAS1. (H) Model of the switch in target specificity 
via Ubc9 sumoylation.
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Figure 4. Enhanced sumoylation of Sp100 with Ubc9*SUMO depends on SUMO interacting motif (SIM) in Sp100. (A) SIM 
consensus motif aligned with the Sp100 wt and Sp100∆SIM mutant sequences. The SIM is marked in green, mutations in 
SP100 are indicated in red, and acidic residues or potential phosphorylation sites are underlined. (B) In vitro sumoylation 
assay performed as in Figure 3C using each 200 nM GST-Sp100 wt or GST-Sp100∆SIM, 4.4 µM SUMO1, 70 nM Aos1-
Uba2, ATP and indicated amounts of Ubc9 or Ubc9*SUMO. Detection was with α-GST. (C) Apparent association constants 
for Ubc9, Ubc9*SUMO and SUMO towards Sp100 and Sp100∆SIM as determined by surface plasmon resonance. 
during the reaction, the same samples were also 
tested in an immunoblot with α-Ubc9 antibodies 
(Figure 3 A, lower panel). While RanGAP1 could be 
quantitatively modified with either form of Ubc9, 
there was a significant and reproducible difference 
in efficiency: five-fold higher concentrations of 
modified Ubc9 compared to unmodified Ubc9 
were needed to obtain similar levels of RanGAP1 
sumoylation. As Ubc9 is the rate-limiting factor in 
this experimental set up, this suggests a five-fold 
reduction in modification rate. 
Surprisingly, when we then turned to HDAC4 and 
E2-25K, this negative effect of SUMO modification 
on Ubc9 function could not be generalized. As 
shown in Figure 3B, both HDAC4 (top panel) and 
E2-25K (bottom panel) were modified with equal 
efficiency by Ubc9 and Ubc9*SUMO. Of note, E2-
25K and HDAC4 are rather inefficient targets for 
E3 independent modification. Therefore, much 
higher concentrations of Ubc9 were needed, 
compared to RanGAP1 sumoylation shown in 
Figure 3A. 
In parallel, we tested another well-known SUMO 
substrate, Sp100 (Figure 3C). Again, we were 
in for a surprise: in this case Ubc9*SUMO had 
increased activity compared to Ubc9. In fact, Sp100 
modification reached levels usually observed only 
in the presence of an E3 ligase. We therefore 
went on to compare directly Ubc9*SUMO with the 
combinations Ubc9 / RanBP2∆FG and Ubc9 / PIAS1 
(Figure 3D). Indeed, at 250 nM Ubc9*SUMO was 
as efficient in Sp100 sumoylation as RanBP2∆FG, 
and clearly better than the E3 ligase PIAS1. 
We have shown that SUMO modification of Ubc9 
can either decrease, increase, or not affect target 
modification under multiple turnover conditions. 
The fact that thioester formation is not affected 
by Ubc9 modification suggests that the obtained 
changes in target modification take place at the 
final conjugation step, the transfer from the 
SUMO-Ubc9 thioester to the target. To prove 
this hypothesis we tested RanGAP1, E2-25K and 
Sp100 modification with modified and unmodified 
Ubc9 under single turnover conditions (Figure 3E-
G). We preformed Ubc9 or Ubc9*SUMO thioesters 
and stopped the reaction with EDTA to inhibit the 
E1 enzyme and thus Ubc9 reloading. The reaction 
mixture was subsequently incubated with a target 
and the transfer of SUMO to the target was 
measured over time. Consistent with the multiple 
turnover reactions, SUMO modified Ubc9 results 
in an approximately 5 fold reduction in RanGAP1 
modification, E2-25K modification is not affected 
and Sp100 modification is strongly enhanced 
compared to the reactions with unmodified Ubc9. 
Taken together, these findings suggest that 
Ubc9 sumoylation does not alter Ubc9’s catalytic 
activity, but positively or negatively interferes 
with the SUMO transfer to selected substrates, 
and thereby modulates the target choice (Fig 
3H).
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A SIM recruits Ubc9*SUMO to Sp100
Next, we set out to elucidate the mechanism 
behind the enhancement of Sp100 modification 
by Ubc9*SUMO. One  possibility is that SUMO 
attachment adds a new binding interface to Ubc9, 
allowing it to better interact with Sp100, similar to 
its role in RanGAP1 - RanBP2 interaction at nuclear 
pore complexes (Mahajan et al., 1997; Matunis 
et al., 199; Reverter and Lima, 2005). Several 
groups mapped a motif required for non-covalent 
SUMO interaction, the so-called SUMO interaction 
motif or SIM (also referred to as SUMO binding 
motif or SBM) (Hannich et al., 2005; Hecker et 
al., 2006; Minty et al., 2000; Song et al., 2004; 
Song et al., 2005). The minimal motif consists 
of a short hydrophobic stretch (V/I)(V/I)X(V/
I/L), which can bind SUMO in both orientations 
and is flanked in many cases by additional acidic 
residues or potential phosphorylation sites 
(Figure 4A)(Hecker et al., 2006; Song et al., 
2005). Structural studies of SUMO bound to a 
SIM have revealed that the hydrophobic residues 
add a β-strand to a β-sheet of SUMO (Reverter 
and Lima, 2005; Song et al., 2005). Interestingly, 
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Figure 5. Crystal structure of Ubc9*SUMO. (A) The Ubc9*SUMO structure demonstrates the covalent linkage between        
Ubc9 (blue) Lys14 and the C-terminus of SUMO (yellow). The catalytic cysteine of Ubc9 is shown in yellow. (B) The 
interface between Ubc9 and SUMO with hydrogen bonds shown in gray dotted lines and interface side chains shown as 
sticks. (C) Superposition of Ubc9 and E2-25K, both conjugated to SUMO, in cartoon representation with surface area in 
the background. Ubc9*SUMO is blue (Ubc9) and yellow (SUMO), E2-25K*SUMO is cyan (E2-25K) and pink (SUMO). (D) 
Percentage of surface area buried per residue as calculated by PISA (Krissinel and Henrick, 2005) in the interface of E2 
and SUMO, plotted against the sequence of Ubc9 compared to E2-25K. Ubc9 residues are shown in blue, E2-25K residues 
shown in cyan. Secondary structure is depicted on top and bottom. (E) Structural model of the Ubc9∆hairpin mutant. Deleted 
β-hairpin is shown in gray, Ubc9 without the hairpin shown in blue, SUMO shown in yellow. (F) Thioester formation assay 
for Ubc9∆hairpin (670 nM) versus Ubc9∆hairpin*SUMO (670 nM) with 260 nM Aos1-Uba2, 6.7 µM SUMO. Incubation was at 
30°C and reactions were stopped at indicated time points with a non-reducing buffer and separated on a 15% SDS gel. 
Analysis by immunoblotting was with α-Ubc9 raised in goat.
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this binding motif was identified in SUMO targets 
but also in enzymes of the SUMO cascade like 
the SUMO E1 and several SUMO E3s (Hecker et 
al., 2006; Minty et al., 2000; Reverter and Lima, 
2005; Song et al., 2004). 
Sp100 interaction with SUMO was recently 
demonstrated by a yeast two hybrid assay 
(Hecker et al., 2006), suggesting the presence 
of a SIM. Therefore, we analysed the Sp100 
protein sequence for such a motif and indeed 
found a hydrophobic stretch at position 323 to 
326 followed by an acidic region (Figure 4A). We 
mutated the first two hydrophobic amino acids 
of the SIM motif in Sp100 to lysines (I323K, 
I324K), mutations earlier shown to effectively 
disrupt SUMO interaction of such motifs (Song 
et al., 2004). We tested this Sp100 SIM mutant 
(Sp100∆SIM) for sumoylation with unmodified 
and modified Ubc9 (Figure 4B). In the presence 
of unmodified Ubc9, both wt and mutant Sp100 
were sumoylated at similar low levels, indicating 
that mutagenesis did not affect Sp100 folding. 
However, only Sp100 wt was efficiently modified 
by sumoylated Ubc9 in contrast to the Sp100 SIM 
mutant. Mutation of the SIM in Sp100 clearly 
reverses the enhancing effect of Ubc9*SUMO 
compared to Ubc9 alone. To prove that this is 
indeed due to binding of the SIM to SUMO on 
Ubc9 we performed surface plasmon resonance 
(SPR) experiments in a Biacore flow system. GST-
Sp100 wt and GST-Sp100∆SIM were bound to the 
chip via amine coupling and their interaction with 
Ubc9, Ubc9*SUMO as well as with free SUMO was 
measured. The shape of the response curve is 
indicating either a relatively low binding affinity, 
or a high off rate (Fig 4C). By measuring response 
curves at various concentrations we determined 
the affinity for free SUMO and modified and 
unmodified Ubc9 for Sp100 and Sp100∆SIM 
(Figure 4D). The affinity of Ubc9 for the target 
Sp100 (Kd=155 ± 11 µM) presumably reflects the 
affinity of the E2 for the SUMO target site ΨKxE/D. 
The presence of SUMO in Ubc9*SUMO increases 
the affinity for Sp100 five-fold (Kd=27.5 ± 1.7). 
This increase is caused by the presence of the 
SIM on Sp100 since mutation of the SIM reduces 
the affinity of Ubc9*SUMO for Sp100 (Kd = 104 ± 
6) to levels comparable to unmodified Ubc9. The        
increase in affinity for sumoylated Ubc9 is due 
to an additional interface that is solely formed 
by the SUMO moiety since the affinity of Sp100 
for free SUMO (Kd=23.7 ± 1.4) is very similar to     
Ubc9*SUMO and is reduced to the same extent 
by mutation of the SIM (Kd=99 ± 5). However,  
the SIM mutations in Sp100 do not completely 
abolish the interaction between SUMO and the 
SIM since there is still some affinity of the Sp100 
SIM mutant for free SUMO. This also explains 
the fact that the Sp100 SIM mutant has residual 
activity with SUMO modified Ubc9 compared to 
unmodified Ubc9 in Sp100 modification assay (Fig 
4B).
These results show that the affinity of Ubc9*SUMO 
for Sp100 is not higher than the added affinities 
for Ubc9 and SUMO and we conclude that 
there is no cooperativity between the Ubc9 and 
SUMO binding sites on Sp100. Therefore, Ubc9 
sumoylation introduces an additional binding 
interface for selected targets resulting in enhanced 
target modification. 
Crystal structure of Ubc9*SUMO
To study the effect of covalent SUMO modification 
on the Ubc9 conformation we solved the crystal 
structure of Ubc9 modified with SUMO1 (Table 1). 
We used a deletion mutant of SUMO1 lacking the 
flexible N-terminal 20 amino acids (SUMO∆N20) 
for crystallization. As shown in Figure 5A the 
structure of the covalent complex (Ubc9*SUMO) 
confirmed complex is very similar to non-linked 
SUMO, except for the C-terminal tail which 
connects SUMO to Ubc9. The r.m.s. deviation 
with other SUMO crystal structures is between 
0.66 and 0.85 Å for the SUMO core domain (70 
Cα atoms) (Lois and Lima, 2005; Mossessova 
and Lima, 2000; Pichler et al., 2005; Reverter 
and Lima, 2004; Reverter and Lima, 2005). The 
interface between Ubc9 and SUMO is small but 
defined and buries 345 Å2 of solvent-accessible 
surface area on Ubc9 and 353 Å2 on SUMO. It 
comprises 4 direct and several water-mediated 
hydrogen bonds. On the Ubc9 side, the residues 
interacting with SUMO are situated on the N-
terminal helix and on, or close to, the β-hairpin 
between the first and the second β-strand (Figure 
5B). For SUMO, besides the C-terminus, residues 
53-5 of the loop between α-helix 1 and β-strand 
3 play the most important role in the interaction 
with Ubc9, contributing 3 hydrogen bonds to the 
interface (Figure 5B). 
Most important in the interface is the covalent 
bond between SUMO and Ubc9. Since SUMO 
linkage to Ubc9 takes place on the equivalent 
lysine compared to E2-25K and both target 
sites do not conform to classical consensus sites 
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and are situated on a helix, we compared the 
sequence context around the target sites. For 
the E2-25K helical acceptor site, the following 
residues have been shown to be most important 
for sumoylation: Arg, Lys10, Arg11 and Phe13 
(Pichler et al., 2005). Of these residues, only 
Arg is conserved in Ubc9. Clearly, the E2s have 
different needs for the molecular environment of 
their modification sites and further investigation 
is required to show whether there are general 
requirements for sumoylation of helical acceptor 
sites.
Although SUMO is attached to the equivalent site 
in both Ubc9 and E2-25K, it is obvious from the 
structure that the orientation of SUMO relative to 
the E2s is substantially different in Ubc9*SUMO 
compared to the E2-25K*SUMO complex (Pichler 
et al., 2005). Upon superposition of the two 
E2s there is only minimal overlap between the 
conjugated SUMO molecules (Figure 5C). A 
major difference between E2-25K and Ubc9 is 
a β-hairpin which protrudes from the Ubc9 core 
domain into the solvent (Figure 5B and 5D). 
This hairpin consists of a 5 amino acid insertion 
(31-35) that is conserved in Ubc9 orthologs but 
not found in other E2 conjugating enzymes. It 
interacts with SUMO in addition to the interaction 
with the N-terminal helix of Ubc9 (Figure 5D). 
This extra interaction with the Ubc9-specific β-
hairpin could explain the different positioning of 
covalently bound SUMO on Ubc9 compared to E2-
25K, and be the origin of the functional difference 
between these E2s upon sumoylation. To test 
this hypothesis we created a mutant of Ubc9 
that lacks this β-hairpin (Ubc9∆hairpin), in which we 
replace amino acid 30 to 36 with two glycines to 
retain the hairpin character (Figure 5D and 5E). 
If this mutant can no longer stabilize the position 
of SUMO, it should behave like E2-25K*SUMO 
and Ubc9 ∆hairpin*SUMO should show reduced E1 
interaction and thioester formation. Indeed, as 
can be seen in Figure 5F, thioester formation is 
inhibited in this SUMO modified Ubc9∆hairpin and to a 
similar extent as observed for SUMO modified E2-
25K (Pichler et al., 2005). Therefore, we conclude 
that the positioning of SUMO with respect to the 
E2 is important for the functional role of this 
modification.
Does the position of SUMO attached to Ubc9 
give insight how modification affects Ubc9 
target choice? From our structural data we can 
not explain the inhibitory effect on RanGAP1 
sumoylation: Comparison of the Ubc9*SUMO 
structure with the Ubc9-RanGAP1 complex 
(Bernier-Villamor et al., 2002) (Supplementary 
Figure 1) shows that RanGAP1 and SUMO are 
located on different sites of Ubc9 and therefore 
steric hindrance between the target and SUMO is 
unlikely. However, from the structure we cannot 
exclude that the SUMO conjugated to Ubc9 has an 
effect on the positioning of the thioester. Since the 
transfer of SUMO from the thioester to the target 
is known to be extremely efficient for RanGAP1 
specifically, thioester positioning could become 
rate limiting for RanGAP1 and not for the other 
targets. In contrast to RanGAP1, for Sp100, the 
structure does offer an explanation for the change 
in modification with SUMO modified Ubc9. 
The newly created binding interface
In addition to the binding interface of Ubc9 with 
the consensus site of Sp100, SUMO modification 
of Ubc9 creates an additional, high affinity 
binding interface for Sp100. The newly created 
combinatorial binding interface is shown in Figure 
6 and shows the positioning of the catalytic cleft 
and the SIM interaction site on the surface of 
Ubc9*SUMO. This demonstrates that the SIM 
has to be positioned at a defined distance to 
the SUMO attachment site in the substrate. The 
mechanism of creating a second Ubc9 binding 
interface is analogous to the additional Ubc9 
interaction that is found on RanGAP1 or created 
Table 1: Data Collection and Refinement Statistics
Ubc9*SUMO
Data collection
Space group P212121
Cell dimensions: a, b, c (Å) 27.5, 66.6, 122.6
Resolution (Å) 60-2.2 (2.32-2.21)
Rsym 14.4 (43.9)
I/σI 5.2 (1.8)
Completeness (%) 97.3 (81.5)
Redundancy 12.4 (10.0)
Refinement
Resolution (Å) 60-2.2
Number reflections 117850
Rwork/Rfree (%) 18.3 / 25.8
Number of atoms
   Protein 1895
   Water 150
   Ion 3
Rms Deviations
   Bond lengths (Å) 0.015
   Bond angles (°) 1.601
Highest resolution shell is shown in parenthesis.
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by the SP-RING E3 ligases which also stabilise 
the interaction between loaded E2 and the target 
(Figure 6). Notably, each of these mechanisms 
involve a different surface on Ubc9 in addition to 
the catalytic cleft but all function by enhancing 
E2-target interaction (Fig 6). 
In conclusion, this study has shown that 
sumoylation of the SUMO conjugating enzyme 
Ubc9 regulates target discrimination. Modification 
of some substrates is inhibited, others are 
unaffected, and selected substrates are 
enhanced. Enhancement is due to the generation 
of an additional binding interface that recognizes 
targets containing a SIM correctly oriented with 
respect to the SUMO acceptor site. The function 
of Ubc9 modificaton with SUMO is therefore 
comparable to the function of RING E3 ligases. 
Together, these findings emphasize the unique 
role of Ubc9 in target discrimination, and add one 
building block to how target specific sumoylation 
can be accomplished with a limited number of 
enzymes. 
Experimental procedures
Plasmids and antibodies
SUMO(∆N20), Ubc9, RanBP2∆FG, Aos1-Uba2, RanGAP1 
(Pichler et al., 2002; Pichler et al., 2005), GST-Sp100 
(Seeler et al., 2001), GST-HDAC4 (Kirsh et al., 2002), 
GST-Pias1 (Sapetschnig et al., 2002) and GST-E2-25K      
(Haldeman et al., 1997) were described before. GST-Sp100 
mutants were generated by site-directed mutagenesis. 
Mouse α-SUMO1 was obtained from Zymed, mouse α-
Ubc9 used for pull downs was from BD Biosciences, goat 
α-Ubc9, rabbit α-GST, goat α- RanGAP1 and rabbit α-E2-
25K were described before (Pichler et al., 2002; Pichler 
et al., 2005). Secondary antibodies were from Jackson 
Laboratories, Biorad or Biosource. 
Protein expression and purification
Purification of SUMO1, Aos1-Uba2, GST-Sp100, GST-
HDAC4, E2-25K, RanGAP1 RanBP2∆FG and Pias1 was 
performed as described (Pichler et al., 2002; Pichler 
et al., 2005; Pichler et al., 2004). Ubc9 and Ubc9∆hairpin 
were expressed in BL21(DE3) cells using IPTG induction 
overnight at 15 °C. Purification was performed on a 
POROS S column in 20 mM Bis-Tris pH 6.5, 50 mM NaCl, 
0.1 mM PMSF, 1 mM DTT, and eluted with a salt gradient 
between 0.05 to 1 M NaCl. Ubc9 containing fractions were 
Ubc9
SUMO
Ubc9
Target
(Sp100)
SIM
Ubc9
RanGAP1
Ubc9
Target SP-RING
E3
KΨ xD/E
KΨ xD/E
KΨ xD/E
SUMO
SP-RING
E3
Figure 6. Model of Ubc9 target discrimination via gain in affinities. Left panel shows a cartoon of Ubc9-target interactions, 
mediated either through SUMO, target or an E3 ligase . Right panel demonstrates the distinct surfaces in Ubc9 involved in 
these interactions. The catalytic cleft in Ubc9 interacts with its targets via the SUMO consensus motif (light green) which 
usually results in inefficient in vitro sumoylation. Stabilization of this interaction enhances modification achieved by gain 
in affinity via introducing additional binding interfaces (dark green). Sumoylation of Ubc9 increases interaction of targets 
with a SIM in a defined distance as we demonstrated for Sp100 in this study (top panel). RanGAP1 itself contains two 
binding interfaces (Bernier-Villamor et al., 2002)(middle panel) and is an unusually efficient SUMO substrate. Similarly 
the SP-RING E3 ligases can stabilize the interaction between the target and Ubc9 resulting in enhanced modification 
(bottom panel). 
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concentrated, pooled and further purified by gel filtration 
on a Superdex 75 column in 20 mM Tris pH .0, 100 mM 
NaCl, 0.1 mM PMSF, 1 mM DTT. 
Multiple and single turnover in vitro sumoylation 
and thioester bond formation
In vitro modification and thioester bond formation assays 
for Ubc9 and E2-25K were performed as described in 
Pichler et al 2002. Thioester formation assays for the 
Ubc9∆hairpin mutant were performed in buffer containing 
20 mM HEPES pH 7.3, 110 mM potassium acetate, 2 mM 
magnesium acetate, 0.05% Tween 20, 0.2 mM ovalbumin 
and 0.1 mM DTT with 260 nM Aos1-Uba2, 6.7 µM SUMO 
and 670 nM Ubc9∆hairpin or Ubc9∆hairpin*SUMO. Reactions 
were started by addition of 5 mM ATP and time points 
were immunoblotted and analysed with α-Ubc9.
Single turnover assays were performed by generating 
the E2-SUMO thioester at 30°C in buffer containing 20 
mM HEPES pH 7.3, 110 mM potassium acetate, 2 mM 
magnesium acetate, 0.05% Tween 20, 0.2 mM ovalbumin 
and 1 mM DTT. Reaction mix contained 0.9 µM Aos1-Uba2, 
7.2 µM SUMO1, 3.7 µM Ubc9 or Ubc9*SUMO and 5 mM 
ATP and was incubated for 4 minutes. The reaction mixture 
containing the E2-SUMO-thioester was then diluted in 
the same buffer supplemented with 10 mM EDTA (dilution 
buffer) to inactivate the E1. For GST-Sp100 and E2-25K 
thioesters were diluted 15 times after which 225 nM GST-
Sp100 or 595 nM E2-25K was added and time point were 
taken during the incubation at 30°C. Since the RanGAP1 
reaction is extremely fast thioesters needed to be diluted 
250 times with dilution buffer to be able to follow the reaction 
upon addition of 12.5 nM RanGAP1 at 4°C. Samples were 
run on 15 or % SDS gels and bands were visualized by 
immunoblotting against α-GST, α-E2-25K or α-RanGAP1. 
A control blot was analysed with α-Ubc9 (suppl data). 
Surface plasmon resonance
Surface plasmon resonance spectroscopy (SPR) was 
performed at 25°C on a BIAcore T100. Roughly 000 
response units of GST, GST-SP100WT or GST-SP100∆SIM 
were immobilized on different flow cells of a CM5 
sensor chip (Biacore) using amino coupling. Different 
concentrations of Ubc9, Ubc9*SUMO or SUMO in running 
buffer (25 mM HEPES pH 7.3, 100 mM NaCl, 0.5 mM EDTA 
and 0.05% Tween-20) were injected across the chip at 
30 ml/min. Saturation binding values were measured for 
each protein, using the flow cell with GST as reference, 
and plotted as a function of concentration. The apparent 
dissociation constants (Kd) and association constants (Ka) 
for the interactions were determined by fitting the data 
according to a steady state affinity model using the Prism 
4.03 software (GraphPad Software, Inc.).
Ubc9*SUMO purification and crystallization
Ubc9 and Ubc9∆hairpin were modified with SUMO1 (or 
SUMO∆N20) in large scale by incubating 15 mg Ubc9, 1 
mg Aos1-Uba2, 11 mg SUMO1, and 5 mM ATP in 3 ml of 20 
mM Tris .0, 100 mM NaCl, 0.1 mM DTT and 5 mM MgCl2 
for 4 to 6 hours at 37 °C. Ubc9*SUMO and Ubc9 were 
separated by applying the reaction mixture to a MonoQ 
column. The Ubc9 and Ubc9*SUMO containing peaks were 
pooled separately and both were next applied to a MonoS 
column as a final purification step. After concentration 
proteins were stored at -0 °C in a buffer containing 
20 mM Tris .0, 100 mM NaCl, 1 mM DTT and 0,1 mM 
PMSF. Ubc9*SUMO (4.2 mg/ml) was crystallized at room 
temperature using hanging drops against 24% (w/v) 
PEG3350, 200 mM Sodium Formate and 100 mM Bis-Tris 
Propane. Cryoprotection was achieved by increasing the 
concentration of PEG3350 in the mother liquor to 40% 
(w/v). 
Mass spectrometry. 
The protein band containing sumoylated Ubc9 was excised 
from an SDS-PAGE gel and subjected to in-gel reduction, 
alkylation, trypsin digestion and subsequent sample 
desalting and concentration, as previously described 
[Olsen 2004]. The resulting peptide mixture was analyzed 
by nano-HPLC-MS/MS using an Agilent 1100 nanoflow 
system connected to a hybrid linear ion trap orbitrap 
(LTQ-Orbitrap) mass spectrometer (Thermo Electron, 
Germany), equipped with a nanoelectrospray ion source 
(Proxeon Biosystems, Odense, Denmark), essentially as 
described (Olsen et al., 2005).
Data collection and structure determination
Data were collected from a single crystal at 100K using 
a Cu-Kα source, helios optics (Bruker) and a MAR345 
X-ray detector. Processing of the data was performed 
using MOSFLM and SCALA (Collaborative Computational 
Project 4, 1994). The structure was solved by molecular 
replacement with the program Molrep (Collaborative 
Computational Project 4, 1994) using both Ubc9 (Tong 
et al., 1997) and SUMO (Pichler et al., 2005). Rebuilding 
was done with Coot (Emsley and Cowtan, 2004) and 
ARP/wARP (Perrakis et al., 1999) and refinement was 
done with REFMAC (Collaborative Computational Project 
4, 1994). Percentages of residues in the most favoured, 
additionally allowed, generously allowed and disallowed 
regions of the Ramachandran plot were 92.5, 6.5, 1.0 and 
0.0 respectively. The model includes 150 water molecules 
and one formate molecule from the crystallization buffer. 
Crystallographic parameters are summarized in Table 1. 
Buried solvent-accessible surfaces areas between the 
molecules were calculated with the program PISA (Krissinel 
and Henrick, 2005). Besides the described Ubc9-SUMO 
interface around K14 there were two other interfaces 
found by the program, one between two Ubc9 molecules 
and another between Ubc9 and another SUMO molecule in 
the crystal lattice (manuscript in preparation). Multiangle 
laser light scattering and gel filtration experiments showed 
only monomers, indicating that these interactions are not 
present in solution for Ubc9*SUMO. 
All structure figures were generated using Pymol (http://
www.pymol.org). Atomic coordinates and structure 
factors have been deposited to the Protein Data Bank with 
accession code xxxx.
Gel shift assays
Interaction of SUMO E1 with Ubc9 and Ubc9*SUMO was 
determined by a native gel mobility shift assay. Ubc9 or 
Ubc9*SUMO were incubated with increasing amounts 
of E1 for 15 minutes at room temperature. Bound and 
unbound forms were separated on a 4.5 % polyacrylamide 
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gel (acrylamide:bis, 37.5:1) in a Tris-Borate buffer pH .0, 
containing 2% glycerol. Loading and running buffer were 
also buffered with Tris-Borate pH .0. Gels were soaked 
in a 0.1% SDS solution prior to the blotting procedure. 
Analysis was done using α-Ubc9. E2-25K and E2-
25K*SUMO gel shifts were performed identical except that 
the gel contained  % polyacrylamide gel (acrylamide:bis, 
29:1) in a Tris buffer pH .3 and a Tris-glycine running 
buffer was used. Analysis was done using α-E2-25K.
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Supplementary figure 1: 
SUMO modification of Ubc9 
has only minor effect on 
E1 interaction. (A) Ubc9 or 
Ubc9*SUMO (400 nM) were 
incubated with increasing 
amounts of SUMO E1 and 
complex formation was 
visualized by immunoblotting 
on a native gel using an α-
Ubc9 antibody. Free Ubc9 is 
positively charged under these 
conditions and therefore does 
not enter the gel while Ubc9 
in complex with E1 does. (B) 
Same as in (A) but comparing 
Ubc9WT with Ubc9*SUMO. (C) 
Same as in (A) but comparing 
ubiquitin E1 interaction with 
E2-25K and E2-25K*SUMO 
using an α-E2-25K antibody.
Supplementary figure 2: 
Control blot for single turnover 
reactions. Preformed thioesters 
were added to 225 nM Sp100 
at t=0. At the start of the 
reaction about half of the Ubc9 
or Ubc9*SUMO is loaded with 
SUMO, after 30 minutes most 
of the loaded complexes are 
gone and no self-conjugated 
Ubc9 or Ubc9*SUMO has been 
formed.
Supplementary figure 3: 
RanGAP1 interacts with Ubc9 
on the opposite site compared 
to the covalently linked SUMO. 
Superposition of Ubc9 from the 
Ubc9-RanGAP1420-59 structure 
(Bernier-Villamor et al. 2002) 
and the Ubc9*SUMO structure. 
Catalytic cysteine of Ubc9 is 
shown in yellow.
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The ubiquitin related modifier SUMO regulates a wide range of cellular processes by post-
translational modification with one, or a chain of SUMO molecules. Sumoylation is achieved 
by the sequential action of several enzymes in which the E2, Ubc9, transfers SUMO from the 
E1 to the target mostly with the help of an E3 enzyme. In this process Ubc9 forms a thioester 
bond with SUMO, but also interacts with SUMO non-covalently. Here we show that this 
non-covalent interaction promotes the formation of short SUMO chains on targets such as 
Sp100 and HDAC4. We present a crystal structure of the non-covalent Ubc9-SUMO1 complex, 
showing that SUMO is located far from the E2 active site and resembles the non-covalent 
interaction site for ubiquitin on UbcH5c and Mms2. Structural comparison suggests a model 
for poly-sumoylation involving a mechanism analogous to Mms2-Ubc13 mediated ubiquitin 
chain formation.
enzyme and in most cases an E3 ligase such as 
PIAS, Pc2 or RanBP2 (Melchior, 2000; Johnson, 
2004). In the first step a thioester bond is formed 
between the modifier and the catalytic cysteine 
of the E1 enzyme in an ATP-dependent reaction. 
This thioester bond is subsequently transferred to 
the catalytic cysteine of the E2 enzyme, and in 
the last step the modifier is ligated to the ε-amino 
group of a lysine on the substrate with or without 
the help of an E3 ligase. In contrast to ubiquitin 
conjugation the E2 enzyme in sumoylation plays 
an active role in target recognition by interacting 
with a ΨKxE/D consensus site sequence present 
on most, but not all targets (Sampson et al., 
2001). 
There are four vertebrate SUMO isoforms with 
partially overlapping target specificity. SUMO2 
and SUMO3 differ only by three N-terminal 
residues and they share 45% sequence identity 
with SUMO1. The recently identified SUMO4 is 
more similar to SUMO2/3 (7%) than to SUMO1 
(41%). Most of the SUMO1 in cells is found in 
conjugates whereas there is a large pool of 
free cellular SUMO2/3 (Saitoh and Hinchey, 
2000; Tatham et al., 2001; Ayaydin and Dasso, 
Introduction
SUMO is a ubiquitin-related post-translational 
modifier that plays an important role in many 
cellular pathways including transcriptional 
regulation, intracellular transport, DNA repair and 
replication (Pichler and Melchior, 2002; Hoege et 
al., 2002; Yang et al., 2003; Stelter and Ulrich, 
2003; Seeler and Dejean, 2003; Girdwood et 
al., 2003; Muller et al., 2004). Sumoylation of 
substrates generally functions by modulating 
their interaction properties with other proteins. 
Although SUMO has been detected mostly as 
single molecule modification, recent reports show 
that formation of SUMO chains is also observed 
for SUMO1 in vitro (Pichler et al., 2002; Pedrioli 
et al., 2006; Yang et al., 2006) and for SUMO2/3 
in vitro and in vivo (Tatham et al., 2001; Fu et 
al., 2005). 
The process of SUMO modification is chemically 
similar to that of ubiquitin conjugation and the 
enzymes involved are mostly homologous. This 
involves the ligation of the C-terminus of the 
modifier to a lysine residue in the substrate, 
mediated by a highly regulated three-step cascade. 
For SUMO this requires Aos1-Uba2 as the E1 or 
activating enzyme, Ubc9 as the E2 or conjugating 
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2004). Apparently, only SUMO2/3 form chains on 
substrates in vivo, whereas SUMO1 chains have 
only been shown in vitro (Pichler et al., 2002; 
Pedrioli et al., 2006; Yang et al., 2006). The 
SUMO2/3 chains are linked through lysine 11, 
located in a traditional SUMO consensus motif in 
the flexible N-terminus of SUMO2/3 and seem to 
play a role in PML localization (Fu et al., 2005). 
The single yeast SUMO homologue, Smt3, also 
forms chains in vivo, which are important for the 
regulation and assembly of the synaptonemal 
complex during meiosis (Bylebyl et al., 2003; 
Cheng et al., 2006). 
Transient interaction is an important feature of 
the sumoylation process. Ubc9, the E2, takes a 
central place by interacting with the E1, SUMO, 
the E3 and the target at various stages. Structural 
studies have revealed the nature of interaction 
of Ubc9 with a target (Bernier-Villamor et al., 
2002) and with an E3 enzyme (Reverter and 
Lima, 2005). Mutational analysis has indicated 
the interface between Ubc9 and the SUMO E1 to 
be mainly through its N-terminal helix and the 
loop between the first and the second β-strand 
(Bencsath et al., 2002). This would suggest a 
similar interaction as was recently shown for 
another ubiquitin-like molecule, Nedd8, with its 
E1 APPBP1-UBA3 (Huang et al., 2005). 
Ubc9 interacts with SUMO both in the thioester 
intermediate, a complex which has been 
structurally characterized for several ubiquitin E2s 
with ubiquitin (Hamilton et al. 2001; McKenna et 
al., 2003b), as well as in a non-covalent manner. 
This non-covalent Ubc9-SUMO interaction involves 
the N-terminal helix of Ubc9, as well as the loop 
between this helix and the first β-strand, a surface 
that is also partially used for E1 interaction (Liu 
et al., 1999; Bencsath et al., 2002; Tatham et 
al., 2003). As a consequence, SUMO and the 
E1 can compete directly for interaction with the 
E2 (Bencsath et al., 2002). The role of the non-
covalent interaction between SUMO and Ubc9 
is unclear and functional studies have been 
complicated by this shared interaction site. This 
non-covalent binding between E2 and modifier is 
not unique for SUMO, as ubiquitin can also interact 
non-covalently with some of its E2 enzymes. The 
details of this interaction were recently shown for 
ubiquitin bound to UbcH5c (Brzovic et al., 2006) 
and to the E2 variant enzyme Mms2 (Brzovic et 
al., 2006; Lewis et al., 2006). The E2-variant 
Mms2 is thought to position ubiquitin for creation 
of lysine 63 linked chains of ubiquitin by the E2 
Ubc13. The non-covalent interface of UbcH5c is 
also important for chain formation, but this is 
thought to follow a different mechanism. 
Here we show the crystal structure of a non-
covalent complex between SUMO1 and Ubc9. 
SUMO1 interacts through its β-sheet with a 
secutive stretch in Ubc9 connecting the first helix 
and strand. This site is located distant from the 
active site cysteine and resembles the Mms2 
and UbcH5c ubiquitin non-covalent interfaces. 
We show that both SUMO1 and SUMO2 similarly 
interact with Ubc9. The high resolution structure 
enabled us to identify Ubc9 and SUMO mutants 
that specifically inhibit the interaction between the 
two proteins. These mutants were used to show 
that interference with this non-covalent interaction 
does not affect SUMO thioester formation but 
strongly reduces SUMO2 chain formation on 
several targets. A model is presented in which 
the non-covalent interaction between SUMO and 
Ubc9 mediates SUMO chain formation involving a 
mechanism similar to K63-linked ubiquitin chain 
formation by the Mms2-Ubc13 heterodimer.
Results
Crystal structure of non-covalent Ubc9-
SUMO complex
To get insight in the functional importance of the 
non-covalent interaction between Ubc9 and SUMO 
we solved the crystal structure of this complex 
using human Ubc9 and SUMO1 lacking the flexible 
N-terminal 20 amino acids (SUMO∆N20) (Table I). 
Ubc9-SUMO crystals were grown by mixing the 
two components in a hanging drop crystallization 
set-up. The quality of the crystals allowed high 
resolution data collection after which the structure 
was solved by molecular replacement using 
the structures of Ubc9 (Tong et al., 1997) and 
SUMO1 (Pichler et al., 2005) as search models. 
The crystal structure shows that non-covalent 
interaction of SUMO1 with Ubc9 occurs on the 
backside of Ubc9 with respect to the active site 
cysteine (Figure 1A). 
There are no large conformational changes in 
either Ubc9 or SUMO upon complex formation 
with r.m.s. deviations of 0.79 Å for SUMO (using 
the core 77 Cα atoms) and 0.60 Å for Ubc9 
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(using all Cα atoms) compared to previous crystal 
structures. The interface between the two proteins 
buries 727 Å2 of solvent-accessible surface area 
on Ubc9 and 642 Å2 on SUMO. This interface is 
relatively hydrophilic, with 5 salt bridges,  direct 
hydrogen bonds and another 12 hydrogen bonds 
mediated through defined water molecules, but 
there are also many van der Waals interactions. 
On the Ubc9 side, all the residues involved in the 
interaction are situated in one continuous stretch 
of sequence at the end of the N-terminal helix, 
the first β-strand and the intervening loop (Figure 
1B and 1E). This compact region of Ubc9 interacts 
with 3 of the 5 β-strands in SUMOs β-sheet. On 
SUMO most contacts are with β-strand 5, but also 
β-strand 1 and 3 and the loops connecting these 
strands are involved in the interface. (Figure 1B 
and 1F). Details of the interactions are presented 
in Figure 1C and Supplementary Figure 1. 
We compared our Ubc9-SUMO structure with the 
non-covalent complexes of ubiquitin with the E2 
enzyme UbcH5c and the E2-variant Mms2 both 
determined by NMR (Brzovic et al., 2006; Lewis 
et al., 2006). Although UbcH5c and Ubc9 are only 
36% identical they both show the E2 specific α/β-
fold and superimpose with a r.m.s. deviation of 
2.5 Å using 136 Cα atoms. The E2-variant Mms2 
is only 15% identical to Ubc9 and adopts a E2-like 
fold lacking the C-terminal helix. It superimposes 
on Ubc9 with a r.m.s. deviation of 1.9 Å using 
115 Cα atoms. Secondary structures of ubiquitin 
and SUMO bound to the E2(-like) proteins are 
also highly similar even though their sequence is 
only 1% conserved (r.m.s. deviation 1.4 Å using 
75 or 72 Cα atoms for ubiquitin bound to UbcH5c 
and Mms2 respectively). Roughly, the interaction 
sites of ubiquitin on UbcH5c and SUMO1 on Ubc9 
are conserved, both ubiquitin and SUMO1 interact 
with the backside of the E2, at least 20 Å away 
from the active site cysteine, and both use their 
β-sheet for this interaction. Also, the solvent-
accesible surface area buried in the complexes is 
comparable, for Mms2-Ub this is 641 Å2 and 650 
Å2 respectively, and for UbcH5c-Ub it is 567 Å2 
and 556 Å2. Comparison with the Mms2-ubiquitin 
structure shows that the interaction of ubiquitin 
with the E2 variant is more similar to the UbcH5c-
ubiquitin interaction than to that between SUMO 
and Ubc9 (figure 1E). 
If we superpose only the E2s it becomes clear 
that the relative orientations of the modifiers 
are slightly different (Figure 1D, 1E). SUMO1 is 
rotated 2.4 degrees towards the N-terminal helix 
of Ubc9 compared to ubiquitin on UbcH5c. The 
tilting of the ubiquitin in the Mms2 structure is 
27.7° compared to the SUMO, but only 14.4° if we 
compare it with ubiquitin interacting with UbcH5c 
(figure 1E). Although crystal contacts could be 
involved, we did see the same orientation for 
SUMO in a second crystal form (data not shown). 
The difference in the position of the modifiers 
results in a change of interaction surfaces on the 
E2s, where SUMO interacts with Ubc9 mainly N-
terminally, the ubiquitin interaction surface on 
UbcH5c and Mms2 is shifted somewhat towards 
the C-terminus (figure 1E). 
SUMO1 and SUMO2 interact with Ubc9 with 
similar affinities 
Both SUMO1 and SUMO2 bind non-covalently 
to Ubc9 (Tatham et al., 2003) and even though 
they are only 44% identical, the residues in the 
interface with Ubc9 are relatively well conserved (9 
identical, 4 homologous, 3 different ) (Figure 1F). 
Of the three non-conserved residues, Gly 1 (Glu 
77 in SUMO2) only makes main chain contacts, 
and the other two, changing Ile 27 into an alanine 
(Ala 23 in SUMO2) and Val 7 into a threonine 
(Thr 3 in SUMO2) can be accommodated in the 
interface without problems. Therefore we deduce 
that the interaction mode of Ubc9 with SUMO1 
and 2 are likely to be very similar, in agreement 
with NMR studies of this interface (Liu et al., 
1999; Tatham et al., 2003). 
In order to determine the affinity of the interaction 
between Ubc9 and SUMO1 and 2 we used 
isothermal calorimetric analysis. In isothermal 
calorimetry (ITC) the absorbance or release of 
energy of mixing two components that interact 
with each other can be measured as heat changes. 
These changes in heat can be used to determine the 
binding constant and thermodynamic parameters 
of the reaction. A dissociation constant of 250 +/- 
70 nM has been reported for the Ubc9-SUMO1 
interaction using ITC (Tatham et al., 2003). In 
our hands the interaction between Ubc9 and 
SUMO1 was stronger, but with a Kd of 2 +/- 23 
nM still in the same order of magnitude (Figure 
2A). The heat exchange or enthalpy contribution 
to the binding is relatively small (maximally 6 
kcal/mol under these conditions) but high enough 
to calculate the Kd accurately. The only obvious 
differences in Kd measurement between ours and 
Tatham et al. are a small pH difference (pH=.0 
versus 7.5 respectively) and the presence of an 
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N-terminal His-tag on Ubc9 in their experiments. 
Both of these factors could contribute to the 3-
fold difference in Kd. 
When we performed identical ITC measurements 
replacing SUMO1 for SUMO2, we were not able to 
measure any reproducible heat exchange during 
the measurement. Nevertheless, if we collected 
the sample from the flow cell after the experiment 
and run it on an analytical gel filtration column 
we observe complete complex formation between 
SUMO2 and Ubc9 (data not shown). Since the 
heat exchange of the reaction for SUMO1 binding 
was very small it seems likely that for SUMO2 
the enthalpic contribution is even smaller and the 
reaction is mostly entropically driven, so it can 
not be measured by ITC.
For a direct comparison of the affinities of Ubc9 
with SUMO1 and SUMO2 we therefore used 
an analytical gel filtration shift experiment. 
First, we tested the method using high protein 
concentrations by mixing pure samples of Ubc9 
(50 µM) and an excess of SUMO1 or SUMO2 (100 
µM) in 25 µl, incubation at 4 °C for 10 minutes 
prior to running it on a Superdex 75 gel filtration 
column. Both for SUMO1 (Figure 2B, upper panel) 
and for SUMO2 (Figure 2B, lower panel) all of 
the Ubc9 was shifted to the Ubc9-SUMO complex 
peak while the excess of SUMO eluted in a peak 
B
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Figure 1 Structure of non-covalent Ubc9-SUMO1 complex.
(A) Cartoon representation of the Ubc9-SUMO1 crystal structure, Ubc9 in blue and SUMO1 in yellow. The catalytic residue 
is shown in sticks. (B) Details of the interaction site. Residues of Ubc9 (upper panel) and SUMO1 (lower panel) involved 
in the interaction shown in sticks, counterpart shown as surface representation. (C) Close-up of Ubc9-SUMO1 interaction. 
(D) Superposition of the UbcH5c-Ubiquitin complex (purple and green respectively) and the Ubc9-SUMO1 complex. Only 
UbcH5c and Ubc9 were used for the superposition, the angle between ubiquitin and SUMO is indicated. (E) Sequence 
alignment of Ubc9, UbcH5c and Mms2 showing secondary structure elements of Ubc9. Residues that loose at least 20% 
of their solvent accessible surface area upon complex formation with SUMO/ubiquitin are shown on a yellow background. 
(F) Sequence alignment of SUMO1, SUMO2 and ubiquitin with secondary structure elements of SUMO1 on top. Residues 
of SUMO1 involved in Ubc9 interaction (determined as in (E)) are shown on a blue background and identical residues in 
SUMO2 are framed. Residues of ubiquitin involved in UbcH5c or Mms2 interaction have a purple background.
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overlapping with the free SUMO peak. To compare 
affinities we used lower concentrations of Ubc9 
(390 nM) with varying SUMO concentrations, 
followed by gel filtration chromatography  and 
western blotting of the fractions using an anti-
Ubc9 antibody. This allowed visualization of the 
free Ubc9 peak shifting to the SUMO bound peak 
upon increased SUMO concentrations in the 
samples (Figure 2C). Both SUMO1 and SUMO2 are 
able to shift the Ubc9 peak under these conditions 
and the peak shift occurs at similar SUMO1 and 
SUMO2 concentrations indicating similar affinities 
of Ubc9 for SUMO1 and SUMO2.
Ubc9H20D and SUMO1E67R inhibit non-
covalent interaction
Although several groups have reported the non-
covalent interaction between Ubc9 and SUMO, 
the function of this interaction has been subject 
of speculation. Based on mutant analysis it has 
been proposed that the interaction is needed for 
SUMO thioester formation (Tatham et al., 2003). 
However, since the binding sites for SUMO and 
the E1 on Ubc9 partially overlap it was difficult 
to create interface mutants that do not affect E1 
interaction, and consequently, thioester formation. 
Now, based on our high-resolution structure, we 
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Figure 2 SUMO1 and SUMO2 have similar affinity for Ubc9.
(A) Isothermal calorimetry data for non-covalent interaction between Ubc9 and SUMO1. Raw (upper panel) and processed 
(lower panel) data for 7 µM SUMO titrated with 12 µl injections of 70 µM Ubc9. Processed data points were fitted to a 
model describing a single set of binding sites. Thermodynamic parameters for the interaction are ∆H = - 5.96 ± 0.2 kcal/
mol and -T∆S = -3.7 kcal/mol  (B) Chromatograms of analytical gel filtration runs for Ubc9 with SUMO1 (upper panel) 
and Ubc9 with SUMO2 (lower panel). Runs of single proteins contained 60 µM Ubc9 or 300 µM SUMO1/2, complex runs 
contained 50 µM Ubc9 and 100 µM SUMO1/2. (C) Gel-filtration based shift assays visualized by western blot analysis 
using anti-Ubc9. For SUMO2 (left panel) as well as for SUMO1 (right panel) several gel-filtration runs were performed 
with a constant Ubc9 and increasing SUMO concentrations (molar ratio is depicted on the left). 
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Figure 3 Mutants that interrupt 
non-covalent Ubc9-SUMO binding 
but not thioester formation  
(A) Thioester formation followed 
in time for Ubc9 and SUMO1 wild 
type and mutants. Concentrations 
were: 100 nM E1, 900 nM Ubc9 
and 3 µM SUMO1. (B) Thioester 
formation assay comparing 
SUMOWT with SUMOE67R. 
Concentrations were: 200 nM E1, 
1.4 µM Ubc9 and 15 µM SUMO1. 
(C) Thioester formation assay as 
in (B) comparing Ubc9WT with 
Ubc9H20D. (D) Non-covalent 
binding studied using analytical 
gel-filtration for Ubc9H20D 
with SUMO1. Curve indicated 
as ‘Ubc9 + SUMO1’ was 44 µM 
Ubc9H20D and 10 µM SUMO1, 
'Ubc9 + more SUMO1' was 27 µM 
Ubc9H20D and 136 µM SUMO1. 
Free Ubc9H20D and the complex 
between Ubc9WT and SUMO are 
indicated for clarity.
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searched for Ubc9 or SUMO1 mutants that only 
abolish the non-covalent interaction between 
Ubc9 and SUMO.
For SUMO1 we generated the following mutants: 
E67R, G68Y, V87W and E89R. These mutants were 
tested for their ability to interact with Ubc9 non-
covalently, as well as for their activity in E1 and 
Ubc9 thioester formation. As summarized in Table 
II, all of these mutants showed decreased non-
covalent interaction with Ubc9 and SUMOE67R 
as well as SUMOE9R were completely unable to 
interact with Ubc9 in the analytical gel filtration 
assay (Supplementary Figure 2 and data not 
shown). SUMO E9R however was also impaired 
in both E1 and Ubc9 thioester formation and 
was therefore not a good candidate to study 
the function of the Ubc9-SUMO non-covalent 
interaction (Figure 3A and Supplementary Figure 
2). The SUMO E67R mutant only has a minor 
defect in E1 and Ubc9 thioester formation and 
would, from these mutants, be the best candidate 
to study the role of non-covalent Ubc9-SUMO 
interaction (Figure 3B and Supplementary Figure 
2).
For Ubc9 we tested mutations in four residues, 
R17E, H20D, G23R and V25W and V25R (Table 
III). These mutants were tested for SUMO1 
interaction and, in addition, for their ability to 
interact non-covalently with the E1 as well as 
their activity in Ubc9~SUMO thioester formation 
(Figure 3A, Supplementary Figure 2, data not 
shown). Valine 25 is equivalent to serine 22 in 
UbcH5c, mutating this residue inhibited non-
covalent interaction with ubiquitin (Brzovic et al., 
2006). In Ubc9 however, mutation of this residue 
did not affect the non-covalent binding of SUMO 
probably due to the fact that it is less well buried 
in the Ubc9-SUMO interface (Supplementary 
Figure 2). Also, the G23R mutation did not 
abolish Ubc9-SUMO non-covalent interaction. In 
contrast, the E17R and H20D 
mutants do disturb the interface 
and are strongly inhibited in 
Ubc9-SUMO interaction (Figure 
3D, Supplementary Figure 2). 
However, Ubc9E17R was also 
deficient in E1 interaction and 
strongly reduced in Ubc9~SUMO 
thioester formation and was 
therefore excluded from further 
studies. Ubc9H20D was the only 
Ubc9 mutant that abolished the 
non-covalent interaction with 
Table II Summary of SUMO mutant data
SUMO WT E67R G68Y V7W E9R
Ubc9 binding ++ - +/- +/- -
E1 thioester ++ + +/- + -
Ubc9 thioester ++ + - +/- -
Table III Summary of Ubc9 mutant data
Ubc9 WT R17E G23R V25W V25R H20D
SUMO binding ++ - ++ ++ ++ -
E1 interaction ++ - ++ ++ ++ +/-
Ubc9 thioester ++ - nd nd nd ++
SUMO (Figure 3D) without affecting thioester 
formation (Figure 3C) even though it does show 
a reduction in E1 interaction (Supplementary 
Figure 2C). This mutation is therefore suited for 
further analysis of the function of non-covalent 
interaction between Ubc9 and SUMO.
Non-covalent Ubc9-SUMO interaction 
promotes SUMO chain formation
In both Mms2 and in UbcH5c the non-covalent 
interaction with ubiquitin is involved in ubiquitin 
chain formation (VanDemark et al., 2001; 
Brzovic et al., 2006). Therefore, we first tested 
Table I Data Collection and Refinement Statistics
Ubc9-SUMO
Data collection
  Space group P21
  a, b, c (Å) 49.5, 35.0, 72.9
  α, β, γ (°) 90.0, 93.4, 90.0
  Resolution (Å) 50-1.4 (1.48-1.40)
  Rsym (%) 6.0 (22.7)
  I/σI 6.3 (1.6)
  Completeness (%) 99.2 (99.3)
  Redundancy 3.5 (3.1)
Refinement
Resolution (Å) 50-1.4
Number reflections 49557
Rwork/Rfree 14.0 (17.7)
Number of atoms
  Protein 2130
  Ligand/ion 1 Na+
  Water 408
B-factors
  Protein 12.5
  Ligand/ion 24.6
  Water 26.8
Rms Deviations
  Bond lengths (Å) 0.014
  Bond angles (°) 1.554
Highest resolution shell is shown in parenthesis.
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the Ubc9 mutant that interferes with Ubc9-
SUMO non-covalent interaction, for free SUMO 
chain formation. Wild type and mutant Ubc9 
were incubated with SUMO, E1 and ATP at 37 
°C and SUMO chain formation was followed in 
time (Figure 4A). Both SUMO1 and the SUMO2 
K11R mutant were included as controls and, 
as expected, they hardly form SUMO chains as 
has been shown before (Tatham et al., 2001). 
SUMO2WT readily forms chains with Ubc9WT, 
however, the Ubc9H20D mutant is less productive 
in chain formation (Figure 4A). Even though the 
difference is not as pronounced as compared to 
SUMO1, it is very reproducible. Also, there is a 
striking difference in formation of higher order 
Uba2 conjugates occurring as a side effect of 
the reaction. Of note, Uba2 has been picked up 
as a target for sumoylation (Zhao et al., 2004; 
Hannich et al., 2005), and we have confirmed 
the presence of SUMO modified Uba2 by mass 
spectrometry (data not shown).
Next, we tested substrate sumoylation using the 
transcriptional regulator Sp100 as a target. If we 
stop the reaction after one hour we observe mostly 
mono-sumoylation of Sp100 and, importantly, 
this is equally efficient for Ubc9WT compared to 
Ubc9H20D (Figure 4B). However, at the latest 
time point in the Ubc9WT reaction a higher band 
also appears that could potentially correspond 
to Sp100*2xSUMO. To investigate whether this 
indicates SUMO chain formation we performed a 
similar experiment but extended the incubation 
time. At later time points we now observe several 
higher bands using Ubc9WT that do not appear if 
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Figure 4 Non-covalent Ubc9-SUMO interaction promotes SUMO chain formation.
(A) Free SUMO chain formation for SUMO1, SUMO2 and SUMO2K11R with Ubc9WT and Ubc9H20D. Formation of SUMO 
chains is followed in time using SUMO1 or SUMO2 antibodies as indicated. Concentrations were: 100 nM E1, 400 nM Ubc9 
and 20 µM SUMO. (B) Sumoylation of Sp100 with SUMO2 comparing Ubc9WT with Ubc9H20D. Concentrations were: 
30 nM GST-Sp100, 175 nM E1, 400 nM Ubc9 and 20 µM SUMO2 and detection was with anti-GST. (C) SUMO chain 
formation on SP100 with SUMO2, comparing Ubc9WT with Ubc9H20D. Concentrations are identical to (B), formation 
of GST-Sp100*SUMO2 conjugates is followed in time using either a GST antibody (upper panel) or a SUMO2 antibody 
(lower panel). (D) SUMO chain formation on Sp100 comparing several mutant proteins. Concentrations were: 1.3 µM 
GST-Sp100, 10 nM E1, 300 nM Ubc9 and 10 µM SUMO and detection was with anti-GST or anti-SUMO2. (D ) Assay as in 
(C) but using GST-HDAC4 as a target.
70
Chapter 5
we use Ubc9H20D, shown on western blots with 
either GST or SUMO2 antibodies (Figure 4C). 
Even though this SUMO2 antibody appears to 
cross react strongly with GST-Sp100, we do see 
an enhancement of the higher molecular weight 
bands using this antibody. 
In order to check whether the higher molecular 
weight bands are a result of SUMO2 chain 
formation, or mono-sumoylation on multiple 
sites in Sp100, we analyzed the Sp100*SUMO2 
Sp100*2xSUMO2 and Sp100*3xSUMO2 samples 
by mass spectrometry. In all samples one major 
modification site in Sp100 was found, this was 
K297, the lysine that has previously been identified 
as the SUMO modification site (Sternsdorf et 
al., 1997). Also, one minor site was found to 
be modified (K387) for 5% or less compared to 
the major site. This indicates that most of the 
‘poly’-sumoylation is due to chain formation of 
SUMO2. In fact, the mass spectrometric analysis 
primarily identified K11, and to a small extent 
K5, as the acceptor lysines on SUMO2 itself. To 
verify that Sp100 is primarily modified on the in 
vivo relevant lysine (K297) and to confirm chain 
formation at lower enzyme concentrations, we 
performed a similar sumoylation reaction using 
less enzyme, comparing Sp100WT with the 
Sp100 K297R mutant. Under these conditions 
we can still show SUMO2 chain formation on 
Sp100WT while Sp100K297R is hardly modified 
(Figure 4D). Additionally, in a similar assay, the 
SUMO2 K11R mutant is also reduced in SUMO2 
chain formation (Supplementary Figure 3). These 
results demonstrate that SUMO chains are formed 
on Sp100 via the consensus site lysine 297, and 
that SUMO2 uses primarily lysine 11 to make 
these chains. 
To examine the importance of the non-covalent 
interaction between Ubc9 and SUMO2 for the 
formation of these chains we tested the Ubc9H20D 
mutant in the same Sp100 chain formation assay. 
Figure 4D shows that this mutant is impaired in 
SUMO2 chain formation on Sp100. To verify this 
result we also tested the SUMO2D63R mutant, 
which is the equivalent of the SUMO1E67R 
mutation. It inhibits SUMO2-Ubc9 non-covalent 
interaction while it is still competent in Ubc9 
thioester formation (data not shown). This SUMO 
mutant also inhibits poly-sumoylation of Sp100 
(Figure 4D). These data strongly suggest that 
non-covalent interaction between Ubc9 and 
SUMO2 promotes poly-sumoylation of Sp100.
To investigate whether the importance of the 
non-covalent binding site for poly-sumoylation is 
a target specific effect we tested SUMO2 chain 
formation on another well-known SUMO target, 
histone deacetylase 4 (HDAC4). Also with this 
target we see a profound inhibition of SUMO chain 
formation upon disruption of the non-covalent 
interaction site between SUMO and Ubc9 (Figure 
4E).
To gain insight in the mechanism of SUMO chain 
formation and the functional role of the non-
covalent Ubc9-SUMO interaction in this process 
we compared our structure with the structure 
of the Mms2-Ubc13 heterodimer (Eddins et al., 
2006). In this complex, the E2 variant (Mms2) 
can bind an acceptor ubiquitin non-covalently 
and form a heterodimer with a functional E2 
(Ubc13) that is activated with ubiquitin. Modeling 
as well as structural studies have shown that in 
this complex the K63 of the acceptor ubiquitin 
is in close proximity to the activated cysteine of 
Ubc13, providing a mechanism for K63-linked 
ubiquitin chain formation (VanDemark et al., 
2001; McKenna et al., 2003b; Lewis et al., 2006). 
The recently published crystal structure of the 
Ubc13~Ub intermediate in complex with Mms2 
also shows this quaternary complex as it has a 
ubiquitin molecule from a neighboring complex 
bound to the acceptor ubiquitin site on Mms2 
(Figure 5A)(Eddins et al., 2006). 
A complex like this could also be formed between 
two identical E2s, which would require the E2 
to interact with itself. Although Ubc9 is not a 
homodimer in solution, self-interaction has been 
shown in yeast two hybrid systems (Hateboer et 
al., 1996; Kovalenko et al., 1996). If we superpose 
the Ubc9-SUMO complex on Mms2 bound to 
ubiquitin from the Mms2-Ubc13~Ub structure, a 
free Ubc9 on Ubc13, and SUMO on the thioester 
ubiquitin (Eddins et al., 2006), we can create a 
model that resembles the Mms2/Ubc13/ubiquitin 
complex (Figure 5B). In this model we can see 
that, although SUMO does not have a lysine at 
the equivalent position to K63 in ubiquitin, the 
N-terminus of the non-covalently bound SUMO 
is close to the active site of the adjacent Ubc9. 
For SUMO2 there are 14 residues of N-terminal 
tail that are not present in the structure, and the 
K11 and K5 are respectively 4 and 10 residues 
upstream from the last residue in the structure and 
could therefore both easily reach the active site of 
the donor Ubc9. Figure 5 shows the comparison 
of the Mms2-Ubc13-2x ubiquitin structure (Figure 
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5A) with a similar model comprising 2x Ubc9-2x 
SUMO (Figure 5B). This attractive model provides 
a possible explanation why chain formation takes 
place on the N-terminal tail of SUMO2 and why 
the non-covalent interaction between Ubc9 and 
SUMO promotes this chain formation.  
Discussion
We have presented here the crystal structure 
of the non-covalent complex between Ubc9 and 
SUMO1. The resemblance of this structure with 
the non-covalent complex between ubiquitin 
and UbcH5c as well as with the E2 variant Mms2 
and ubiquitin underlines the conservation of 
this interaction between homologous pathways. 
The UEV (ubiquitin conjugating enzyme variant) 
domain of Tsg101 (and VPS23) also interacts 
non-covalently with ubiquitin but this interaction 
is different as it primarily uses a β-tongue motif 
formed by the extended first and second beta-
strands and the loop between them (Sundquist 
et al., 2004). 
NMR studies have been performed on the non-
covalent interface between Ubc9 and SUMO1, 
2 and 3 (Liu et al., 1999; Tatham et al., 2003), 
all indicating that the interaction site on Ubc9 is 
primarily formed by the N-terminal region of Ubc9. 
We have now shown the high resolution details 
Mms2
Ubc9
Ubc13
Ubc9
acceptor SUMO
donor SUMO
acceptor ubiquitin
donor ubiquitinA
B
thioester
K63
E20
thioester
SUMO N-terminus
Figure 5 A model for SUMO chain formation.
(A) K63 ubiquitin chain formation by the Mms2-Ubc13 heterodimer (Eddins et al., 2006)(PDB-code: 2GMI). Close-up 
shows Mms2 K63 in sticks and the Ubc13 thioester active site.  (B) Structural model for SUMO chain formation. The non-
covalent Ubc9-SUMO1 complex was superposed on Mms-Ub and another Ubc9 molecule was superposed on Ubc13 (see 
(A)). Thioester SUMO was modeled by superposition on ubiquitin replacing the C-terminal tail with the one from ubiquitin. 
Close-up shows acceptor SUMO N-terminus and donor SUMO-Ubc9 thioester active site.
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of this interaction and found that SUMO interacts 
with the N-terminal helix, the first β-strand and 
the intervening loop of Ubc9. Recently, a model 
for the interaction between Ubc9 and SUMO3 was 
created by docking approaches in combination 
with NMR interaction data (Ding et al., 2005). In 
this model, the equivalent residues of SUMO3, 
compared to SUMO1 in our structure, interact 
with Ubc9. Since SUMO2 and 3 are completely 
identical in the interacting residues, and since we 
have shown that SUMO1 and SUMO2 interact with 
Ubc9 with similar affinities we can conclude that 
all SUMO isoforms interact with Ubc9 using the 
same interaction site and with similar affinities. 
With a Kd of ~0 nM, the interaction between 
SUMO and Ubc9 is relatively strong compared 
to the interaction between ubiquitin and UbcH5c 
with a Kd of ~300 µM (Brzovic et al 2006), and 
between ubiquitin and Mms2 with a Kd of ~100 
µM (McKenna et al., 2003a). Even though the 
buried surface areas between E2 and modifier 
are comparable in all three structures, there are 
more hydrogen bonds and salt bridges in the 
Ubc9-SUMO interface which might account for the 
difference in affinity.
Two mutations, one in Ubc9 (H20D) and one in 
SUMO (E67R in SUMO1 or D63R in SUMO2), were 
identified that individually interfere with Ubc9-
SUMO non-covalent interaction. These mutants 
enabled us to show that the interaction between 
Ubc9 and SUMO promotes SUMO chain formation 
on both Sp100 and HDAC4. There are several 
possible mechanisms that can explain the role of 
this interaction in chain formation. The simplest 
one would be that one Ubc9 molecule interacts 
with two SUMO molecules and the non-covalently 
bound SUMO acts as a direct acceptor for the 
thioester bound SUMO (donor). This mechanism is 
not likely since the distance from the N-terminus 
of the acceptor SUMO to the active cysteine is too 
long to bridge the distance to the acceptor lysines 
K5 or K11, even if the N-terminal residues adopt 
an extended conformation.
Another possibility is that chain formation 
occurs by a mechanism similar to what has been 
proposed for UbcH5c (Brzovic et al., 2006). There, 
the non-covalent interaction between ubiquitin 
and UbcH5c is promoting large assemblies of 
activated UbcH5c~ubiquitin which are required 
for processive BRCA1-directed ubiquitination. 
However, in our hands the Ubc9~SUMO thioester 
does not form these large assemblies (data not 
shown) and even though we can not completely 
rule out that assembly formation may occur with a 
very low affinity we do not favor this mechanism. 
Our favored hypothesis, however, is that the 
poly-sumoylation that we observe involves a 
mechanism that follows the well-established 
model for ubiquitin chain formation as seen in 
Mms2-Ubc13 dependent K63 poly-ubiquitination. 
We have shown here that the non-covalent site 
on Ubc9 closely resembles the non-covalent 
binding site of ubiquitin on Mms2 and that a 
model involving two Ubc9 molecules and two 
SUMO molecules superimposes well on the Mms2-
Ubc13-ubiquitin structures. In this complex the N-
terminus of SUMO would be exposed to covalent 
modification with a donor SUMO molecule, leading 
to chain formation. This model would explain why 
the non-covalent interface between Ubc9 and 
SUMO is needed for SUMO chain formation and 
why the lysines in the N-terminal tail are used as 
linking sites. 
The chain formation that has been observed for 
SUMO2 (Tatham et al., 2001; Cheng et al., 2006) 
is less processive than that which has been seen 
for ubiquitin. This lower processivity is most likely 
an intrinsic feature of Ubc9 and not due to the 
in vitro reaction conditions since poly-ubiquitin 
chains are easily formed in vitro, whereas the 
SUMO chains remain shorter. However, SUMO 
chains have not been extensively studied in vivo 
and, since the yeast homologue of SUMO, Smt3, 
seems to be able to form long chains in vivo 
(Bylebyl et al., 2003), it would not be unlikely 
that additional factors are required for processive 
SUMO chain formation. Nevertheless, the actual 
mechanism for chain formation seems once again 
surprisingly similar between the ubiquitin and 
SUMO pathways.
Materials and methods
Plasmids and antibodies
Ubc9, SUMO1(∆N20), Aos1-Uba2 (Pichler et al., 2005), 
GST-Sp100 (Seeler et al., 2001) and GST-HDAC4 (Kirsh 
et al., 2002) plasmid construction has been described 
before. Ubc9 and SUMO1 mutants were generated by site-
directed mutagenesis. Mouse α-SUMO1 was obtained from 
Santa Cruz and Zymed, mouse α-SUMO2 from Zymed and 
goat α-GST from Amersham. Goat α-Ubc9 and goat α-
SUMO2 were kindly provided by F. Melchior (Georg-August 
University, Göttingen). Secondary antibodies were from 
Biorad or Biosource.
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Protein expression and purification
Purification of Ubc9, Aos1-Uba2, GST-Sp100, GST-HDAC4 
was performed as described (Pichler et al., 2002; Pichler 
et al., 2005) and SUMO2 were expressed in BL21(DE3) 
cells using IPTG induction overnight at 15 °C. Purification 
was performed on an Superdex 75 column in 20 mM Tris 
pH .0, 100 mM NaCl, 0.1 mM PMSF, 1 mM DTT followed 
by an anion exchange (monoQ) column.
Analytical gel filtration
Protein-protein interaction studies by analytical gel 
filtration were performed on a Superdex 75 column on 
the SMART system (Pharmacia) in a buffer containing 
20 mM Tris pH .0 and 100 mM NaCl. Concentrations as 
indicated in the figure legends were mixed and incubated 
for 10 minutes at 4 °C prior to loading (25-50 µl) on the 
column. Eluted fractions were run on SDS-PAGE and 
either analyzed by coomassie staining, or by western blot 
analysis using an antibody against Ubc9.
Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) experiments were 
performed with the VP-ITC Micro Calorimeter (MicroCal, 
Inc.) at 30°C. Stock solutions of Ubc9 and SUMO were 
prepared by dialysis of the purified proteins against 
a buffer containing 20 mM Tris pH .0 and 5 mM β-
mercaptoethanol at 4°C and were degassed before use. 
The sample cell (1.4 ml) contained SUMO (5-10 µM) which 
was titrated with Ubc9 (50-100 µM) using 12 µl injections. 
The injections after saturation were used to determine the 
background signal. Corrected data were analyzed using 
software supplied by the ITC manufacturer to calculate 
the dissociation constant (Kd,). Parameters were obtained 
for a model describing one set of binding sites, using non-
linear least-squares fitting. 
Native gel shift assays
Interaction of SUMO E1 with Ubc9WT and mutants was 
determined by a native gel mobility shift assay. Ubc9 was 
incubated with increasing amounts of E1 for 15 minutes 
at room temperature. Bound and unbound forms were 
separated on a 4.5 % polyacrylamide gel (acrylamide:
bis, 37.5:1) in a Tris-Borate buffer pH .0, containing 2% 
glycerol (or: on a  % polyacrylamide gel (acrylamide:bis, 
29:1) in a Tris buffer pH .3 and a Tris-glycine running 
buffer). Loading and running buffer were also buffered 
with Tris-Borate pH .0. Bands were visualized with 
coomassie staining. 
E1 thioester formation
E1 thioester formation was performed at  °C in the same 
buffer as the thioester formation. Aos1-Uba2 (3 µM) was 
mixed with SUMO (22 µM) and reactions were started by 
addition of 5 mM ATP. Samples from indicated time points 
were denatured in non-reducing loading buffer, run on 
SDS-PAGE and stained with Coomassie.
In vitro thioester formation and target sumoylation 
assays
Ubc9WT and mutant thioester formation assays were 
performed at 30 °C in buffer containing 20 mM Tris pH .0, 
100 mM NaCl, 5 mM MgCl2 and 0.1 mM DTT. Reactions 
contained Aos1-Uba2, SUMO and Ubc9 in concentrations 
as indicated in the figure legends. Reactions were started 
by addition of 5 mM ATP and at the indicated time points 
samples were denatured in non-reducing loading buffer. 
Samples were run on SDS-PAGE, immunoblotted and 
analyzed with α-Ubc9.
Target sumoylation and free SUMO chain formation assays 
were performed at 37°C in buffer containing 20 mM HEPES 
pH 7.3, 110 mM potassium acetate, 2 mM magnesium 
acetate, 0.05% Tween 20, 0.2 mM ovalbumin and 1 
mM DTT. Reaction mix contained Aos1-Uba2, SUMO1 or 
SUMO2, Ubc9 and either Sp100 or HDAC4 in case of target 
sumoylation, in concentrations as indicated in the figure 
legends. After start of the reaction by the addition of 5 
mM ATP, samples were taken at the indicated time points 
and mixed with denaturing and reducing sample buffer. 
Samples were run on % SDS gels or 4-12% NuPage gels 
(Invitrogen) and bands were visualized by immunoblotting 
against α-GST, α-SUMO1 or α-SUMO2. 
Mass spectrometry 
The protein bands containing GST-SP100 conjugated with 
several SUMO2 molecules were excised from an SDS-
PAGE gel and subjected to in-gel reduction, alkylation, 
trypsin digestion and subsequent sample desalting 
and concentration, as previously described (Olsen et 
al., 2004). The resulting peptide mixture was analyzed 
by nano-HPLC-MS/MS using an Agilent 1100 nanoflow 
system connected to a hybrid linear ion trap orbitrap 
(LTQ-Orbitrap) mass spectrometer (Thermo Electron, 
Germany), equipped with a nanoelectrospray ion source 
(Proxeon Biosystems, Odense, Denmark), essentially as 
described (Olsen et al., 2005).
Crystallization, data collection and structure 
determination
Ubc9-SUMO(∆N20) crystals were grown at 4 °C by 
mixing equimolar amounts of Ubc9WT or Ubc9C93S 
and SUMO(∆N20) (450 µM each) in a hanging drop with 
a mother liquor consisting of 16.5 % (w/v) PEG3350, 
100 mM BisTris pH 5.5 and 15 % (w/v) glycerol. The 
complex crystallized using either Ubc9WT or Ubc9C93S, 
as large plates with a maximum of 400 µM in their largest 
dimension. Cryoprotection was achieved by increasing 
the concentration of glycerol to 25 % (w/v). Data were 
collected on a single Ubc9C93S-SUMO1 crystal in a 
separate high and low resolution dataset at 100 K on 
European Synchrotron Radiation Facility beam line ID14-2 
(λ=0.933). Data were processed with MOSFLM and SCALA 
(Collaborative Computational Project 4, 1994).
The structure was solved by molecular replacement with 
the program Molrep (Collaborative Computational Project 
4, 1994) using both Ubc9 (Tong et al., 1997, PDB code 
1U9A) and SUMO (Pichler et al., 2005, PDB code 2BF). 
Rebuilding was done with ARP/wARP (Perrakis et al., 1999) 
and Coot (Emsley and Cowtan, 2004), and refinement was 
done with REFMAC (Collaborative Computational Project 
4, 1994). Percentages of residues in the most favored, 
additionally allowed, generously allowed and disallowed 
regions of the Ramachandran plot were 93.5, 6.0, 0.5 
and 0.0 % respectively. The model includes 40 water 
molecules and one sodium ion from the protein storage 
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buffer. Crystallographic parameters are summarized in 
Table I. Buried solvent-accessible surfaces areas between 
the molecules were calculated with the program Areaimol 
(Collaborative Computational Project 4, 1994) and 
contacts between Ubc9 and SUMO were analyzed with the 
program NCONT (Collaborative Computational Project 4, 
1994). 
All structure figures were generated using Pymol (http://
www.pymol.org). Atomic coordinates and structure 
factors have been deposited to the Protein Data Bank with 
accession code xxxx.
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Lys 25
Ile 27
Gly 28
Gln 29
Phe 66
Glu 67
Gly 81
Glu 83
Glu 85
Asp 86
Val 87
Glu 89
Val 90
Tyr 91
Arg 13
Trp 16
Arg 17
Lys 18
Asp 19
His 20
Phe 22
Gly 23
Phe 24
Ala 26
hydrogen bonds
water mediated hydrogen bonds
salt bridges
Van der Waals interactions
Supplementary Figure 1 Interactions 
between Ubc9 and SUMO
Diagram showing the details of non-covalent 
interactions in the Ubc9-SUMO structure. 
Hydrophobic interactions, salt bridges and 
hydrogen bonds between indicated residues 
are shown.
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Supplementary Figure 2 Analysis of the 
SUMO and Ubc9 mutants
(A) Non-covalent interaction between Ubc9 and 
SUMO mutants. Chromatograms of analytical 
gel filtration runs for Ubc9WT with SUMO 
mutants (upper panel) and Ubc9 mutants with 
SUMOWT (lower panel). (B) E1 (Aos1-Uba2) 
SUMO thioester formation assay for various 
SUMO1 mutants. (C) Analysis of E1 interaction 
of Ubc9 variants. Ubc9 WT and mutants were 
incubated with increasing amounts of SUMO 
E1 and complex formation was visualized by 
immunoblotting on a native gel using an α-
Ubc9 antibody. Free Ubc9 is positively charged 
under these conditions and therefore does not 
enter the gel while Ubc9 in complex with the 
E1 does. Of note, Ubc9H20D interaction with 
the E1 is reduced but not completely abolished 
since the complex becomes visible at a longer 
exposure times. 
α-GST
SUMO2
Ubc9 WT WT
WT K11R
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Sp100*S2
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Supplementary Figure 3 SUMO2 K11R 
mutant is reduced in chain formation.
SUMO chain formation on Sp100 comparing 
SUMO2WT to SUMO2K11R. Concentrations 
were: 1.3 µM GST-Sp100, 10 nM E1, 200 nM 
Ubc9 and 20 µM SUMO and detection was 
with anti-GST or anti-SUMO2. 
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Discussion
SUMO modification is a special type of post-
translational modification important in many 
biological processes. Sumoylation of target 
proteins is a highly regulated process and 
requires three sequential steps involving an E1, 
E2 and mostly an E3 enzyme. To understand this 
multi-step reaction in detail we need to know the 
enzymes involved in each step, the order in which 
the consecutive steps are taking place, the start 
and end states of these steps and the chemical 
nature of each reaction including intermediate 
states. Moreover, for a full understanding of the 
function of SUMO modification in the cell, we 
also need to know how this process is regulated. 
In this thesis we have presented structural and 
biochemical data concerning the process of SUMO 
modification and its regulation at several steps of 
the enzymatic cascade.
In the process of sumoylation, E2 enzymes or 
SUMO conjugating enzymes, play a central role 
by accepting a SUMO molecule from the E1 
and transferring it, often with the help of an E3 
enzyme, to the target. The E2 is also partially 
involved in target recognition since it interact 
with the SUMO consensus site (ΨKxE/D) present 
on many targets. In chapter 4 and chapter 5 we 
describe how the SUMO protein itself regulates the 
function of the E2 enzyme, Ubc9, in two different 
ways. The first example of Ubc9 regulation 
by SUMO involves a non-covalent interaction 
(chapter 5). This interaction between SUMO 
and Ubc9 takes place at a site different from 
the active site and does not influence the basic 
activity of sumoylation. However, we show that 
it is important for the formation of SUMO chains 
possibly through a mechanism that is also used 
in K63-linked ubiquitin chain formation. In this 
case, the regulation of Ubc9 influences the type 
of SUMO signal generated by the sumoylation 
cascade. In chapter 4 we described how SUMO can 
regulate Ubc9 in a different manner by covalent 
modification (chapter 4). This sumoylation of 
Ubc9 takes place on a lysine situated on the N-
terminal helix of Ubc9, which differs again in 
position from the active site and is also distinct 
from the non-covalent interaction with SUMO. 
Modification of Ubc9 with SUMO causes a shift 
in target specificity, some targets are enhanced 
in SUMO modification while others are inhibited 
in modification. This mechanism enables SUMO 
signaling to discriminate between targets by 
modification of a single target, its own E2. The 
enhancement of sumoylation of specific targets 
is dependent on the interaction of the target 
with SUMO on Ubc9, through a SUMO interaction 
motif (SIM). This SIM-mediated enhancement of 
sumoylation resembles the function that is usually 
achieved by an E3 enzyme, so E3 function can be 
provided by E3 enzymes but also by the SUMO 
modification of the E2 Ubc9.
E3 enzymes, or ligases, can also be considered 
as regulators of SUMO modification as they can 
enhance the sumoylation of specific targets. In 
many cases the details of how they perform their 
function is not known. We have studied one of 
these E3 enzymes, the nucleoporin RanBP2, and 
show that it functions by directly influencing the 
E2 enzyme without interacting with the target 
itself (chapter 2). This is different from another 
group of SUMO E3 ligases, the SP-RING family, 
that seem to function by bringing the E2 and the 
target together.
Once targets are modified by this highly regulated 
sumoylation cascade, the consequence of this 
modification is often not easy to determine. We 
have studied the biochemical effect of sumoylation 
for two targets. The first one is Ubc9 itself, where 
sumoylation leads to target discrimination, as 
has been explained above. We also identified 
the ubiquitin conjugating enzyme E2-25K as a 
target for SUMO modification. Here the effect of 
sumoylation is different since it inhibits the basic 
enzymatic activity of the E2. SUMO modified 
E2-25K shows a reduction in ubiquitin thioester 
formation, which is probably because SUMO 
interferes with E1 interaction. These two SUMO 
targets, Ubc9 and E2-25K, show how different 
the functional effect of sumoylation can be, 
even in homologous proteins. We identified the 
Ubc9 specific region that is responsible for this 
difference.
Although the function of sumoylation of these 
two targets differs, their target site is similar. In 
both Ubc9 and E2-25K SUMO modification takes 
place on a non-consensus site lysine located on 
the N-terminal helix of the protein. For E2-25K 
we have shown that it is only modified when 
the site is present on a helix and not when it is 
unstructured. Secondary structure may therefore 
be an additional determinant for SUMO site 
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specificity.
A different way in which the SUMO pathway can 
be regulated is by the formation of SUMO chains. 
Both for SUMO2 and SUMO3 chain formation 
has been observed in vivo. We have shown that 
the non-covalent interaction of SUMO with Ubc9 
is important for chain formation. Therefore, the 
formation of SUMO chains is, at least partially, 
regulated by the E2 enzyme. However, it is likely 
that specific E3 enzymes are involved in chain 
formation in vivo. 
We have described regulation of E2 and E3 
enzymes in sumoylation, studied the consequence 
of sumoylation for several targets, and studied the 
mechanism of SUMO chain formation. However 
many questions are still to be answered before 
we fully understand the process of sumoylation 
and its regulation.
The mechanism of sumoylation
As for the process of SUMO modification, 
information that is lacking is mainly concerning 
the chemistry of the reactions, the reaction 
intermediates and the specificity determining 
factors. How does the E1 perform its successive 
sub-reactions, how does it transfer SUMO to the 
E2 and what determines the directionality of this 
transfer. How is SUMO transferred from the E2 to 
the target and how do the different E3s catalyze 
this reaction? To answer these and other questions 
in detail, structural and biochemical information 
is needed specifically on intermediate steps in 
the SUMO modification cascade. This is not an 
easy task since many of these intermediates 
are unstable and protein interactions are often 
transient. Smart tricks are needed to stabilize 
these intermediates and protein complexes and it 
remains to be seen whether this will be possible 
in the near future.
SUMO signaling
SUMO is a versatile modifier, it can have various 
effects on the modified protein like a change in 
localization, altered activity, enhanced stability, 
modulation of interaction with other proteins 
or a combination of these. We have studied the 
biochemical consequence of sumoylation of two E2 
conjugating enzymes, E2-25K and Ubc9, but the 
function for many other SUMO targets is unknown. 
Also, the role of the SIM, and the various types of 
SUMO modification in SUMO signaling needs to be 
further investigated. The recently identified SIM is 
found in many proteins including several proteins 
involved in the sumoylation cascade. We have 
described how a SIM present on a SUMO target 
can result in the enhanced sumoylation of that 
target in the presence of SUMO modified Ubc9. 
These studies have all been performed in vitro, 
and currently we are testing this mechanism 
in vivo in collaboration with Frauke Melchior 
(University of Göttingen, Germany) and Andrea 
Pichler (Max F. Perutz Laboratories, Austria). 
In contrast with sumoylation, where only one SIM 
has been identified so far, in ubiquitination a large 
variety of ubiquitin binding domains (UBDs) have 
been identified. The identification of other SUMO 
binding motifs may simply lag behind compared 
to the ubiquitin binding domains, but this could 
also reflect a difference in function between SUMO 
and ubiquitin. SUMO may have a more prominent 
function in, for example, blocking certain binding 
sites or changing the function of a target protein, 
in addition to its function as an interaction site 
modulator. Various examples of SUMO targets 
where sumoylation does not merely change the 
interaction surface but has an other functional 
effect, have been described in chapter 1. 
SUMO signaling is not as simple as only mono-
sumoylating with a single isoform. Four SUMO 
isoforms are present in mammalian cells 
and several studies have recently shown the 
importance of SUMO2 and SUMO3 chains. We 
have studied the mechanism of SUMO chain 
formation in vitro and showed that a the non-
covalent interaction between SUMO and Ubc9 
promotes the formation of chains. It would be 
of interest to test our mechanistic model in vivo, 
using the mutants that inhibit this non-covalent 
interaction.
With chain formation, the complexity of signaling 
in the SUMO pathway is expanding and is 
approaching the level as seen in ubiquitination. 
In the ubiquitin field the existence of so called 
‘mixed chains’, chains combining linkages through 
several lysines, has been suggested which may 
also apply to the SUMO field. Obviously, there is 
possibility for several more layers of complexity 
but it remains to be seen whether they exist in 
vivo.
Regulation of sumoylation
We have presented two examples of how SUMO 
can regulate its own enzymatic cascade, by 
covalent and non-covalent interaction with Ubc9. 
It is unlikely that this is the only way the SUMO 
pathway is regulated. Already several additional 
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regulatory mechanisms are known that can 
affect overall sumoylation. Examples are the 
viral protein Gam1 which is able to inhibit E1 
activity, or reactive oxygen species that induce 
the formation of cross-links between the SUMO 
E1 and E2 and thus inhibit sumoylation. Other 
regulatory mechanisms occur at the substrate 
level, examples of which are the temporally and 
spatially regulation for some targets and the fact 
that modification of some targets depends on 
prior phosphorylation. The cell may have other 
ways to control sumoylation and one could think 
of additional modifications of the enzymes in the 
SUMO pathway. This could be analogous to the 
modification of E3-ligases in ubiquitination, or, 
alternatively it would be possible that additional 
posttranslational modification of targets is 
required as a prerequisite for their sumoylation. 
Finally, much is still to be learnt about the role 
of isopeptidases in regulation. The specificity for 
most of these SUMO deconjugating enzymes is 
not clear yet but it is very likely that they are 
important factors in the regulation of SUMO 
signaling.
SUMO target identification
Since SUMO was discovered a decade ago, 
hundreds of substrates have been identified and 
this list is still growing. We have identified two 
new SUMO targets, Ubc9 and E2-25K, but many 
more are likely to exist. In order to understand 
the full biological impact of sumoylation, we 
need to identify the majority of SUMO targets 
and study the functional consequence of their 
sumoylation. In vivo detection and verification 
of SUMO targets however, is often difficult due 
to two reasons; one is that generally, at a given 
moment, only a small fraction of the total amount 
of a protein is sumoylated, and the second is that 
the SUMO isopeptidases are extremely active and 
remove SUMO from the target as soon as cells 
are broken for analysis. This last issue could 
potentially be solved with specific and efficient 
inhibitors of SUMO deconjugating enzymes, 
preferable working in intact cells, however, these 
are not yet available. The problem of low steady- 
state modification of proteins on the other hand, 
is intrinsic to sumoylation and can not be easily 
circumvented. New, highly sensitive, methods 
for identifying SUMO modified proteins from cells 
may accelerate the search for new SUMO targets. 
Mass spectrometry techniques may at some 
point be sensitive enough to analyze endogenous 
sumoylated proteins which would be of great 
value. An unbiased way of identifying new SUMO 
targets may also shed light on the specificity of 
sumoylation and the importance of the sequence 
surrounding the modified lysine. 
Currently, many targets are identified by actively 
searching for the ΨKxE/D consensus sequence 
and, even though this has lead to the identification 
of many SUMO targets, there are also several 
examples where SUMO modification takes place 
on sites not conforming to this consensus site. 
Therefore, we can not exclude the possibility 
that many additional targets will be identified on 
alternative target sites. We have shown that in 
case of E2-25K and Ubc9 sumoylation takes place 
on a non-consensus site and, in both cases, on 
a site situated on an α-helix. In contrast to the 
traditional consensus sequence which is preferred 
in unstructured regions, helical sites may have a 
different preferred sequence. It would be useful 
to understand the requirements for such a helical 
SUMO consensus site. This is currently subject 
of studies in collaboration with Hans Langedijk 
(Pepscan Systems, The Netherlands). 
The process of sumoylation is complex and subject 
to many levels of regulation. We have provided 
new insights into the function of an E3 enzyme, 
the way SUMO can regulate E2s, the biochemical 
consequence of sumoylation of the two targets, 
and the regulation of SUMO chain formation. 
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Summary
To ensure optimal control of cellular processes 
proteins need to be tightly regulated, which 
is mostly controlled at the level of synthesis, 
degradation or modification. Protein modification 
is a powerful tool, especially in signaling cascades, 
since it can quickly change the properties of a 
protein, for example by literally switching them 
on or off. The modifier can be a small functional 
group, like in phosphorylation, methylation or 
acetylation, but it can also be a protein. 
The best known example of protein modification 
is ubiquitin, which regulates protein degradation 
as well as processes like DNA repair, signal 
transduction and endocytosis. Several ubiquitin 
like modifiers have been identified that share a 
common fold with ubiquitin but have different 
functional roles. The Small Ubiquitin related 
MOdifier SUMO is one of these ubiquitin-like 
molecules and functions in various cellular 
processes like intracellular transport, cell 
cycle regulation, DNA repair and regulation of 
transcription. Both ubiquitin and SUMO are ligated 
to their target proteins using a similar mechanism 
involving three regulated enzymatic steps that 
are catalyzed by an E1, E2 and an E3 enzyme.
Since many crucial cellular processes are regulated 
by SUMO modification, it is evident that the 
SUMO pathway can play a role in disease as well. 
In fact, a role for SUMO modification has been 
implicated in cancer, neurodegenerative diseases 
and viral infection. For a better understanding 
of the mechanism of sumoylation and its role 
in human diseases it is essential to study the 
proteins, and protein complexes, involved in 
great detail. The work in this thesis provides 
insight into the regulation of sumoylation by 
describing biochemical and structural aspects of 
SUMO modification; the catalytic mechanism of 
a SUMO E3 ligase, two distinct examples of the 
structure and function of SUMO modified targets, 
and insights into the mechanism of SUMO chain 
formation.
Although E1 and E2 enzymes are homologous 
between SUMO and ubiquitin conjugation this is 
not the case for all E3 enzymes. Ligases or E3 
enzymes play an important role in sumoylation 
since they are able to enhance the modification of 
specific targets. One particular SUMO E3 ligase, 
the nucleoporin RanBP2, is unrelated to any other 
known E3 ligase. RanBP2 is an elongated protein 
that forms the cytoplasmic fibers of the nuclear 
pore complex (NPC) and its E3 ligase activity 
has been shown to reside in a domain towards 
the C-terminus of the protein. In chapter 2 the 
mechanism of the E3 ligase RanBP2 has been 
studied biochemically and it was shown that 
RanBP2 does not work like HECT E3-ligases, which 
form an intermediate thioester with the modifier, 
and also not like the RING type E3 ligases, which 
act as adapters between target and E2. Instead, 
RanBP2 enhances sumoylation, at least in part, by 
altering the catalytic properties of Ubc9 without 
interacting with the target. Binding of RanBP2 
to Ubc9 changes the properties of RanBP2 from 
being largely unstructured to a more compact 
conformation. A model where RanBP2 wraps 
around Ubc9 and accelerates SUMO transfer by 
an allosteric mechanism was proposed. That the 
principle of this mechanism was correct was later 
confirmed by others in the crystal structure of 
the catalytic fragment of RanBP2 in complex with 
Ubc9 and SUMO modified RanGAP1. This structure 
suggests that RanBP2 positions the Ubc9~SUMO 
thioester in an optimal conformation to accelerate 
SUMO transfer to the target.
Even though hundreds of SUMO targets have 
been identified, the biochemical consequence of 
SUMO modification is in many cases not known 
in detail. However, sumoylation generally leads to 
a change in protein interactions, activity, location 
or stability. In chapter 3, the identification of the 
ubiquitin conjugating enzyme E2-25K as a SUMO 
target has been described. We show that SUMO 
modification of E2-25K affects its enzymatic 
activity, inhibiting its ability to form ubiquitin 
thioesters as well as unanchored ubiquitin chains. 
Structure determination of the sumoylated E2-
25K showed that the non-consensus target lysine 
is situated on the N-terminal helix creating a 
small but defined interface between E2-25K and 
the modifier. The target lysine of E2-25K is only 
recognized when present on a helix, suggesting 
that structural context is important for specific 
target site recognition that could lead to a better 
target site prediction. The inhibition of the 
enzymatic activity of E2-25K upon its sumoylation 
is most likely due to interference with the E1 
interaction.
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In chapter 4 we show that E2-25K is not the 
only conjugating enzyme that is regulated 
by sumoylation, as we found that the SUMO 
conjugating enzyme, Ubc9, itself is subject 
to covalent modification with SUMO. The 
Ubc9*SUMO crystal structure shows that the 
position of SUMO with respect to Ubc9 is different 
compared to SUMO linked to E2-25K, even though 
sumoylation takes place on the equivalent lysine 
situated on the N-terminal helix. This difference 
is mediated by the interaction of SUMO with 
a β-hairpin of Ubc9, a feature unique for the 
SUMO E2 not present on any ubiquitin E2. As a 
result of this specific interaction and orientation 
of the modifier, sumoylation of Ubc9 functions 
completely different compared with E2-25K. 
SUMO ligated to Ubc9 does not inhibit its ability 
to form SUMO thioesters, but results in an altered 
substrate specificity; it inhibits the modification of 
certain targets and enhances the modification of 
others. The enhancement of Sp100 modification 
by SUMO modified Ubc9 is dependent on the 
presence of a SUMO interaction motif (SIM) on 
Sp100. The crystal structure of SUMO modified 
Ubc9 demonstrates how the newly created 
binary binding interface can provide the gain 
in affinity leading to enhanced modification of 
certain targets, thereby providing a unique way 
of regulating sumoylation.
A third example of regulation by SUMO differs 
from the previous ones since it does not involve a 
covalent attachment of SUMO but a non-covalent 
interaction between SUMO and Ubc9 and is 
described in chapter 5. Here we have shown that 
the non-covalent interaction between Ubc9 and 
SUMO promotes the formation of SUMO chains, 
a phenomenon that has been shown to occur 
for SUMO isoforms 2 and 3 in vivo. The crystal 
structure of Ubc9 bound to SUMO non-covalently 
shows that this interaction takes place at a site 
distinct from the catalytic site at the back of the 
Ubc9 molecule. Disruption of this interaction 
strongly reduces the formation of SUMO chains 
on several targets. Similar interactions between 
ubiquitin(-like) proteins and ubiquitin were shown 
for UbcH5c and Mms2, and we propose a model 
in which SUMO2 chain formation occurs through 
a mechanism similar to ubiquitin chain formation 
by the Mms2-Ubc13 heterodimer.
In this thesis we describe various aspects of 
both regulation by sumoylation as well as the 
regulation of the process of sumoylation itself. We 
found several ways in which SUMO can regulate 
the process of sumoylation and determined the 
function of sumoylation of two distinct targets. 
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Samenvatting
Eiwitten behoren tot de belangrijkste bestanddelen 
van levende organismen aangezien bijna alle 
cellulaire processen afhankelijk zijn van een of 
meerdere eiwitten. De bouwstenen van eiwitten 
zijn de aminozuren die ketens vormen in een 
volgorde gebaseerd op de basenvolgorde van ons 
DNA. Er zijn dus nagenoeg evenveel verschillende 
eiwitten als er genen zijn. De aminozuurvolgorde 
samen met de drie-dimensionele vouwing 
geven ieder van deze eiwitten een specifieke 
structuur en functie. Alle processen in de cel 
waarbij eiwitten betrokken zijn dienen op een 
gecontroleerde manier te verlopen. Daarom 
bestaan er verschillende mechanismen om 
eiwitten te reguleren. Dit gebeurt meestal op 
het niveau van eiwit-synthese, -afbraak of -
modificatie. Post-translationele modificatie 
van eiwitten is een belangrijk mechanisme in 
bijvoorbeeld signaal transductie, aangezien het 
een snelle, doch omkeerbare, verandering in 
functie kan veroorzaken. In dit proces worden 
eiwitten covalent gemodificeerd. In veel gevallen, 
zoals bij fosforylering, methylering of acetylering, 
wordt er een kleine functionele groep aan het eiwit 
gekoppeld, er bestaan echter ook modificaties 
bestaand uit hele eiwitten.
Het meest bekende voorbeeld van deze laatste 
modificaties is de ubiquitinering, dit is een 
modificatie met het 76 aminozuren tellende eiwit 
ubiquitine. Modificatie van substraateiwitten 
met ubiquitine kan resulteren in verschillende 
effecten waarvan de afbraak van het substraat 
het bekendste voorbeeld is. Echter, ubiquitinering 
speelt ook een rol bij reparatie van DNA schade, 
endocytose en vele andere cellulaire processen. 
Naast ubiquitine bestaan er ook een aantal 
modificerende eiwitten die qua structuur gelijkenis 
vertonen met ubiquitine, maar een andere rol in 
de cel vervullen. SUMO is een van deze ubiquitine-
achtige eiwitten en functioneert in cellulaire 
processen zoals intracellulair transport, regulatie 
van de celcyclus en DNA transcriptie. SUMO wordt 
covalent aan substraten gekoppeld door middel 
van een serie enzymatische reacties gelijkend op 
die in ubiquitinering, waarbij achtereenvolgens 
drie enzymen betrokken zijn. In de eerste stap 
activeert het E1 enzym SUMO door de vorming 
van een thioester binding tussen het actieve 
cysteïne residu van het enzyme en de C-terminus 
van SUMO. Vervolgens wordt SUMO overgedragen 
aan een E2 enzym waarbij het karakter van de 
binding behouden blijft, een thioester, maar nu 
tussen SUMO en het actieve cysteïne residu van 
het E2 enzyme. Tenslotte wordt SUMO, meestal 
met behulp van een E3 enzyme, overgezet naar 
het substraat waarbij een isopeptide binding 
wordt gevormd tussen de C-terminus van SUMO 
en een lysine van het substraat.
Aangezien vele biologische processen gereguleerd 
worden door middel van SUMO modificatie is 
het niet verwonderlijk dat sumoylering ook een 
rol speelt bij bepaalde ziektes. Er zijn sterke 
aanwijzingen dat SUMO een rol kan spelen in 
virale infecties, kanker en neurondegeneratieve 
aandoeningen zoals de ziekte van Alzheimer, 
Parkinson en Huntington. Om het mechanisme 
van sumoylering en de rol van SUMO in deze 
aandoeningen beter te begrijpen is het belangrijk 
om de eiwitten en eiwitcomplexen die hierbij 
betrokken zijn tot in detail te analyseren. 
Het werk beschreven in dit proefschrift biedt 
nieuwe inzichten in de regulatie van sumoylering 
door het bestuderen van biochemische en 
structurele aspecten van SUMO modificatie. Het 
beschrijft het katalytisch mechanisme van een 
SUMO E3 enzym, de structuur en functie van 
twee gesumoyleerde substraten en het geeft 
nieuwe inzichten in het mechanisme van SUMO 
ketenvorming.
Van de drie enzymen betrokken bij SUMO 
modificatie zijn de E1 en E2 homoloog aan hun 
equivalenten in ubiquitinering, dit is echter niet het 
geval voor alle E3 enzymen of ligases. Doordat ze 
in staat zijn de modificatie vele malen efficiënter 
te laten verlopen, spelen E3’s een belangrijke 
rol in sumoylering. Een van deze E3 enzymen, 
RanBP2, vormt een onderdeel van een groot 
eiwit complex dat betrokken is bij transport van 
cytosolaire eiwitten naar de celkern, het nuclear 
pore complex (NPC). RanBP2 is een langgerekt 
eiwit dat het cytosol insteekt en waarvan het C-
terminale gedeelte actief is als SUMO E3 ligase. 
Het vertoont echter geen enkele gelijkenis met 
andere bekende SUMO of ubiquitine ligases. In 
hoofdstuk 2 beschrijven we de biochemische 
karakterisatie van dit SUMO E3 enzym. We tonen 
aan dat RanBP2 geen thioester met SUMO vormt 
als tussenproduct en daarom niet verwant is aan 
de HECT-type ubiquitine E3 ligases. Vervolgens 
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laten we zien dat RanBP2 niet fungeert als adapter 
tussen de E2 en het substraat en daarom ook niet 
lijkt op de RING-type E3-ligases. RanBP2 is echter 
in staat de sumoylering te versnellen zonder een 
directe interactie aan te gaan met het substraat. 
De data gepresenteerd in hoofdstuk 2 leiden tot 
een model waarbij de interactie van RanBP2 met 
de E2, Ubc9, in staat is de reactie te beïnvloeden 
via een allosteer mechanisme. Het principe van dit 
model is later bevestigd door een andere groep, 
met de opheldering van de kristalstructuur van 
het katalytische gedeelte van RanBP2 in complex 
met Ubc9 en een gesumoyleerd substraat. Deze 
structuur laat zien dat RanBP2 waarschijnlijk 
verantwoordelijk is voor het optimaal positioneren 
van de Ubc9~SUMO thioester voor snelle 
overdracht van SUMO naar het substraat.
Al zijn er honderden SUMO substraten 
geïdentificeerd, de biochemische consequentie 
van hun modificatie is in veel gevallen niet tot in 
detail bekend. Echter, over het algemeen heeft 
sumoylering een verandering in eiwit interacties, 
activiteit, locatie of stabiliteit tot gevolg. In 
hoofdstuk 3 beschrijven we de identificatie 
van een nieuw SUMO substraat, het ubiquitine 
conjugerende enzym E2-25K. We tonen aan dat de 
sumoylering van dit enzym resulteert in een afname 
van enzymatische activiteit. De kristalstructuur 
van het SUMO geconjugeerde E2-25K, tevens 
de eerste substraat*SUMO kristalstructuur die 
bepaald is, laat zien dat SUMO gekoppeld wordt 
aan een lysine in de N-teminale helix van E2-
25K. Naast deze covalente binding is er een 
klein maar goed gedefinieerd bindingsoppervlak 
tussen beide eiwitten. Het feit dat de sumoylering 
plaatsvindt op een lysine gesitueerd in een α-helix 
is bijzonder aangezien de meeste SUMO sites zich 
bevinden in ongestructureerde delen van een 
eiwit. In het geval van E2-25K is deze secundaire 
structuur echter cruciaal voor de herkenning 
van deze lysine voor sumoylering. De observatie 
dat secundaire structuur van belang is voor de 
herkenning van een SUMO site kan leiden tot een 
betere voorspelling van nieuwe SUMO modificatie 
sites.
In hoofdstuk 4 laten we zien dat E2-25K niet 
het enige E2 enzym is dat gereguleerd wordt 
door sumoylering door aan te tonen dan het 
SUMO conjugerende enzym Ubc9 zelf ook 
covalent gemodificeerd kan worden met SUMO. 
De kristalstructuur van Ubc9 gemodificeerd met 
SUMO demonstreert dat de positie van SUMO 
ten opzichte van Ubc9 verschilt van SUMO ten 
opzichte van E2-25K. Dit was een onverwacht 
resultaat aangezien Ubc9 en E2-25K op elkaar 
lijken qua structuur en in beide gevallen SUMO 
gekoppeld is aan een equivalente lysine in de 
N-terminale helix van de E2’s. Het verschil in 
de positie van SUMO kan verklaard worden door 
een extra interactie van SUMO met een Ubc9-
specifieke β-hairpin die afwezig is in ubiquitine 
E2’s als E2-25K. Wellicht mede door het verschil 
in oriëntatie van SUMO, heeft de sumoylering van 
Ubc9 een compleet ander effect dan sumoylering 
van E2-25K. SUMO modificatie van Ubc9 
reduceert niet de activiteit van het enzym maar 
heeft een verandering in substraat specificiteit tot 
gevolg. De modificatie van sommige substraten 
wordt geremd en van anderen juist versneld. 
Een specifiek substraat waarvan de sumoylering 
versneld wordt als Ubc9 zelf gemodificeerd is met 
SUMO, is de transciptionele regulator Sp100. In 
dit geval is de verhoogde sumoylering afhankelijk 
van de aanwezigheid van een SUMO interactie 
motief (SIM) op Sp100. De kristalstructuur van 
gesumoyleerd Ubc9 laat zien hoe de interactie van 
SUMO gekoppeld aan Ubc9 met de SIM op Sp100 
kan leiden tot een tweedelig bindingsoppervlak. 
Dit resulteert in een efficiëntere binding tussen E2 
en substraat en daardoor een versnelde reactie. 
Hiermee presenteren we een unieke manier van 
regulatie van sumoylering.
Het derde voorbeeld van regulatie door SUMO is 
beschreven in hoofdstuk 5 en verschilt van de 
voorgaande aangezien er geen sprake is van een 
covalente verbinding maar een niet-covalente. 
We laten hier zien dat de niet-covalente interactie 
tussen Ubc9 en SUMO de vorming van SUMO 
ketens bevordert. De details van deze interactie 
demonstreren we in de kristalstructuur van 
het niet-covalente Ubc9-SUMO complex. Deze 
structuur laat zien dat de binding plaatsvindt ver 
van het katalytische cysteïne residu en tevens niet 
overlapt met de covalente bindingsplaats. Kennis 
van de structuur heeft het mogelijk gemaakt 
mutaties te vinden die de niet-covalente binding 
verbreken maar geen invloed hebben op de eerste 
twee stappen in het sumoyleringsproces. Met 
behulp van deze mutaties tonen we aan dat het 
verstoren van de interactie tussen SUMO en Ubc9 
de vorming van SUMO ketens op verschillende 
substraten remt. Vergelijkbare interacties zijn 
ook gevonden tussen ubiquitine en zowel de 
ubiquitine E2 UbcH5c als het E2-achtige eiwit 
Mms2. Vergelijking met deze structuren leidt tot 
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een model waarin het mechanisme van SUMO 
ketenvorming gelijkenis vertoont met de vorming 
van ubiquitineketens door de Mms2-Ubc13 
heterodimeer.
 
In dit proefschrift worden verscheidene aspecten 
van zowel regulatie door sumoylering als regulatie 
van het proces van sumoylering zelf beschreven. We 
hebben verschillende manieren gevonden waarop 
SUMO het proces van sumoylering kan reguleren 
en de functie beschreven van sumoylering van 
twee specifieke SUMO substraten.
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very welcome distraction.
Valerie, door je betrokkenheid op het lab maar 
zeker ook daarbuiten hoor jij natuurlijk op een 
prominente plek in deze lijst. Ik denk dat we hier 
wel een cliché aan kunnen spenderen, jarenlang 
hebben we lief en leed gedeeld! Niet alleen 
hebben we ontzettend veel lol gehad maar ik heb 
ook veel van je geleerd, want voor iedereen die 
het nog niet gelooft, onze gesprekken gingen echt 
wel eens over wetenschap. Leone, met z’n drieën 
hebben we aardig wat hoogte- en dieptepunten 
meegemaakt, die tijd zal ik niet snel vergeten. 
Bedankt dat je altijd voor me klaar stond!
De mensen uit de begin periode zijn inmiddels 
grotendeels gevlogen maar verdienen zeker nog 
wat aandacht in dit hoofdstuk. Meindert, wat 
hebben we ontzettend veel gelachen, al denk ik 
er nog steeds over om je aan te klagen wegens 
permanente geestelijke en lichamelijke schade. 
Hoe is het met de brommers in SF? Katjusa, my 
first years in the lab were never dull because of 
you. We spend many hours in coffee-breaks, the 
gym or running in Vondelpark together, thanks 
for all the fun. En natuurlijk zijn er  vele anderen 
die bijgedragen hebben aan een onvergetelijke 
tijd in het lab. Herrie, nooit de beroerdste om 
een botte opmerking te maken, maar helaas 
komen die maar zelden hard aan, je bent een 
te grote goeierd. Joyce, er zijn eigenlijk geen 
dingen waarmee ik bij jou niet terecht kan maar 
behalve voor je luisterend oor heb ik ook grote 
waardering voor je eindeloze enthousiasme voor 
proeven en aanverwante zaken. Sari, jij bekijkt 
de dingen altijd van de praktische kant, krijg ik 
‘de wekelijkse tip van Sari’ ook in Boston? Patrick, 
over onze synchrotron trips zouden we nog eens 
een boek kunnen schrijven maar met jou verliep 
het altijd heerlijk georganiseerd en rustig. Ganesh, 
it was great having you around, I wish you all 
the best in Grenoble. Gretel, your willingness to 
help has no boundaries, I have really appreciated 
that, thanks! Mark, toen je kwam was het al snel 
duidelijk dat je een goede aanwinst was voor het 
lab, gezellig en nooit te beroerd om iets voor een 
ander te doen. Val en ik zeiden niet voor niks bijna 
dagelijks: ‘waren alle mannen maar zoals Mark!’. 
Dokter Ulens, of zal ik je voor deze gelegenheid 
eens tutoyeren? Je was een welkome afwisseling 
in het lab, met niemand te vergelijken en zeer 
verfrissend om de dingen eens van een andere 
kant te bekijken. Bovendien nam jij mijn vragen 
altijd serieus en werden ze nooit met half werk 
afgedaan, iets dat ik enorm heb gewaardeerd 
(naast natuurlijk de broodnodige uitbreiding van 
mijn vocabulaire). Alex, het gaat vast en zeker 
lukken met die grote complexen! Sasha, thanks 
so much for being persistent with the Biacore 
experiments, you are a great colleague! Annet, 
aan die bench gaat het zeker lukken. Francesca 
and Rick, the latest members of the group, I would 
have loved to have you both around earlier! 
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Dankwoord
I hope I have had enough time to teach you some 
of the ‘basics’ for survival in this lab.
One of the highlights of course was the arrival 
of the Perrakis-lab, now we were not the (only) 
weirdoes anymore. Oli, you have been a great 
help in many biochemical questions but other 
than that also a very nice person to have around! 
Serge, we met right at the start of my PhD at a 
crystallography course in Hamburg, thanks for all 
your help with the crystallography, it was great 
to have you around! Rebecca, you always had an 
answer to the most detailed biochemical question 
and, at least as important, I want to thank you 
for the numerous times you cooked me the best 
diners! Mark, je was er niet zo lang maar lang 
genoeg om een zeer gewaardeerde collega te 
worden. Ik kom je paleisje in Nijmegen nog wel 
eens bekijken!. Also I would like to thank Kostas, 
Valeria, Vangelis, Suzanne, Angelina, Marouane, 
Diederick, Krista, Mobien, Koen and Mattheos for 
their help, advice and fun over the past years.
Aan de andere kant van de onzichtbare lijn op 
H2, zijn ook een hoop mensen geweest die mijn 
tijd op het NKI tot enigszins draagbaar hebben 
gemaakt. René natuurlijk, bedankt voor alles, 
niet in de laatste plaats voor het selecteren van je 
OIO’s. Piet, Sebas en Menno, goed voor de nodige 
uurtjes bij de koffiemachine of borrels. Jasper 
en Armida, altijd gezellig met jullie, alleen een 
beetje rustig aan voor tien uur ’s morgens graag. 
Annette, wanneer gaan we weer karaoke? Linda, 
vanmiddag koffietje doen? Mariëlle, Katrien, 
Roderik, Roderick en Mandy, bedankt voor 
jarenlange gezelligheid. Daarnaast ook veel dank 
aan Marlijn en Suellen voor de vele regel-dingen 
en niet te vergeten Roelof, voor al die sequenties 
en de nodige droge humor bij de koffie.
Buiten H2 maar (ooit) binnen de muren van het 
NKI zijn er nog een aantal mensen die ik graag 
wil bedanken voor koffie-breaks, roddel-uurtjes, 
etentjes en ontzettend veel lol: Arne, Anja, Floris, 
Henri, Gerben, Barbara, Marcel (doen we een 
colaatje in Boston?), het was super!. Daarnaast 
heb ik jarenlang met veel plezier gehockeyd in 
het NKI-AvL team, iedereen bedankt!
Hoewel de verhoudingen van dit dankwoord 
het niet zouden vermoeden zijn er ook buiten 
het NKI een hoop mensen geweest die mij op 
belangrijke wijze hebben bijgestaan, namelijk 
door voor afleiding te zorgen. Eefje, Wieneke en 
Josine, ik weet niet waar ik moet beginnen, de 
hoogtepunten zijn inmiddels ontelbaar geworden, 
ik heb nu al zin in de volgende! Pim, Mirjam, 
Wopke, Bas, Rienk, Melle en Evelien, ooit zagen 
we elkaar iedere dag, nu mag dat misschien 
wat minder zijn maar onze uitjes zijn nog altijd 
verzekerd van een grote dosis idioterie, vertier, 
gezelligheid en sporadisch een serieus gesprek. 
Voor de Wageningse nostalgie en alle andere 
dolle activiteiten veel dank aan Martijn en Inge 
(China gaat ongetwijfeld onder het kopje ‘dolle 
activiteiten’ vallen Inge!). Marjon, bijkletsen met 
als dekmantel schaatsen was super! Cecile, als je 
naar Boston komt neem je dan het toetje mee? 
Ook veel dank aan mijn huisgenoten, Mijntje, 
Harald, Gerben, Jeroen en Finn, ik zal jullie en de 
Vosmaerstraat missen!
Als er iets was dat mij alle proeven-ellende kon 
doen vergeten dan was het wel zeilen. Dat was 
maar tot op zekere hoogte de bezigheid zelf, 
echter voornamelijk het omringd zijn door een 
groep losgeslagen randdebielen van het NSG-
zeilkamp. Ik vrees dat het een invloed op mij 
gehad heeft die ik nooit meer kwijtraak, iets 
waar ik alle betrokkenen voor wil bedanken! 
Met stip natuurlijk de Amsterdamse tak van het 
zeilkamp, Janneke en Femke. Jan, super dat je 
mijn paranimf wil zijn, en bedankt voor al je goeie 
zorgen de afgelopen tijd!
Pap en mam, voor alle randvoorwaarden voor een 
succesvolle promotie kon ik bij jullie terecht, af en 
toe uitrusten, vitaminen bijtanken, uitwaaien aan 
de Maas, maar vooral altijd heel veel belangstelling 
en gezelligheid, bedankt! Ondanks jullie eigen 
drukke leven word ik hoe langer hoe meer verwend 
door jullie, ik geloof dat ik in de laatste jaren van 
mijn promotie meer voedselpaketten mee naar 
Amsterdam heb gekregen dan tijdens mijn hele 
studie. Lonneke, jij natuurlijk ook ontzettend 
bedankt voor je steun en belangstelling al die 
jaren. Ik zal die bos bloemen die ik midden in de 
nacht op mijn tafel vond niet snel vergeten!
Lieve Thijn, de manier waarop jij wetenschap 
benadert was een openbaring voor mij en heeft 
zeker bijgedragen aan de goede afloop van mijn 
promotie. Daarnaast zijn er nog vele andere 
redenen om je op deze plek te bedanken maar 
daar zal ik de rest niet mee vermoeien….
Het was super!
Puck
